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ABSTRACT 
 
NMR-BASED AND AUTOMATED DOCKING CHARACTERIZATION OF 
PROTEIN STRUCTURE, DYNAMICS, AND LIGAND BINDING 
 
 
 
Andrew L. Olson 
 
Marquette University, 2010 
 
 
 
 
 
 NMR-based methods used in conjunction with a technique called docking are 
used to characterize ligand binding to proteins.  Standard NMR methods were used to 
study the backbone dynamics of substrate binding to phosphomevalonate kinase (PMK) 
and it was observed that ligand binding caused PMK to undergo large conformational 
changes.  These changes were reflected by the appearance of many chemical shift 
changes upon binding of the natural substrates of PMK (both the binary and ternary 
complexes) in 1H-15N HSQC NMR titration experiments.  The same process was used to 
characterize the effect ligand binding has on the many arginines in the active site (and 
distal to the active site) to determine the effect of long-range coulombic interactions on 
ligand binding.  While studying the backbone dynamics of PMK it was discovered that 
the N-terminal tail of PMK consisting of 10 residues was very disordered which is unlike 
every other monphosphate kinase.  The function of this N-terminal tail was investigated 
by attempting to find other proteins in human liver cells that bind this peptide, monitored 
by ESI mass spectrometry.   
 The thioredoxin system of Mycobacterium Tuberculosis consists of a thioredoxin 
reductase and three thioredoxins.  To help facilitate the understanding of this mechanism 
the solution structures of the oxidized and the reduced forms of thioredoxin C (TrxC) 
were solved by NMR and modeled with the crystal structure of the thioredoxin reductase 
complex.  The two redox states of TrxC are very similar to each other with most of the 
differences coming from subtle changes in the active site of TrxC.   
 Automated docking is the process of computationally determining how a ligand 
binds to a protein and the correct orientation.  A large scale docking study, termed virtual 
screening, was carried out by docking 10,590 compounds into three proteins to find 
inhibitors for each protein, and those predicted to bind best were tested experimentally.  
For each protein there were 3 compounds found to bind with reasonable affinity.  
 When ligands bind to a protein they can undergo dynamic changes.  To explore 
this phenomenon, 15N labeled NAD+ cofactor (and other derivatives) was synthesized 
and bound to oxidoreductases.  Relevant binding motions were monitored using CPMG 
relaxation NMR experiments. 
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CHAPTER I. Introduction to the Methods Used to Characterize Protein Structure, 
Function, and Ligand Binding.   
2 
1.1 Introduction 
To study a protein and its interactions with substrates can be a difficult task since 
one needs knowledge of the protein structure as well as how the protein behaves upon 
binding its specific ligand.  To help facilitate this task we employ standard NMR methods 
to study the protein structure and the dynamical properties associated with ligand 
binding.  NMR is special in this way because we can observe ligand binding and residual 
dynamics information site specifically, since 15N-labeled protein gives us information 
about each amino acid residue (amide bond) in the protein (except prolines) in the 1H-15N 
HSQC (Heteronuclear Single Quantum Correlation) experiment (Figure 1).  After we 
have a structure and relevant dynamical information we can begin to assess how ligands 
bind to the protein, not only its natural substrates but also inhibitors, and other proteins.   
This can be done computationally, using a method called automated docking.    
 
 
 
 
 
 
 
 
 
Figure 1.1. Heteronuclear single quantum correlation experiment (1H-15N HSQC) of 
Thioredoxin C protein with amide (N-H) crosspeaks labeled with amino acid residue 
numbers.   
3 
1.1.2 Protein Structure Determination using NMR 
 Protein structures, due to their size, can be difficult to solve.  The two common 
methods for this are x-ray crystallography and NMR.  The advantage of using NMR is 
that the protein is in its native state (being in solution) and not packed into a solid crystal.  
There are limitations however, mostly due to the size of the protein, in that for proteins > 
25 kDa crosspeak overlap is an issue.  To solve protein solution structures using NMR, 
an extensive set of experiments are acquired on 13C-15N-(2D) labeled protein (Scheme 
1.1).  The backbone amides of the 1H-15N HSQC are generally assigned first using 6 3-D 
NMR experiments, which are 1) HNCO and HN(CA)CO, 2) CBCA(CO)NH and 
HNCACB, 3) HNCA and HN(CO)CA.  Briefly, magnetization starts on the amide proton 
and transfers to the nitrogen, which then transfers to the following atoms in the sequence 
(for example, to Cα and Cβ carbons, in the HNCACB experiment), which are described 
in the title of the experiment.  These experiments are run in the pairs stated above, in 
which one experiment’s chemical shifts will align themselves in the exact same chemical 
shift as its partner experiment, allowing for that chemical shift to be assigned (Figure 
1.2).  This is done until every chemical shift in the 1H-15N HSQC is assigned. 
 The backbone assignments are then used to aid in the assignment of the sidechain 
protons and carbons of all the residues that appear in the 1H-15N HSQC (Figure 1.1).  We 
do this with the 3-D experiments CBCA(CO)NH and CC(CO)NH which are used to 
assign the carbons of the side chains, HBHA(CO)NH and HCC(CO)NH which are used 
to assign all the protons in the side chains, and with HCCH-TOCSY which correlates all 
protons and carbons together.  Getting as many assignments made as possible is very 
important as this will lead to more distance constraints for structure generation.  These 
4 
constraints come from 13C-NOESY (aromatic and aliphatic) and 15N-NOESY spectra.  
These experiments are also 3-D experiments that have the heteroatom chemical shift as 
the third dimensions, and are directly used in structure calcuation.  The NOESY 
experiments are based on the Nuclear Overhauser Effect in which cross peaks arise if 
there are protons in proximity of each other (< 5 Å).  Since there are many residues in a 
protein, all whose protons “see” other protons through the NOE (cross peak), it is 
common to have up to 5000-6000 cross peaks for a (~12 kDa protein) amongst the three 
NOESY spectra.  These cross peaks are used to determine the structure of the protein 
since they all provide distance restraints, which the program CYANA1, 2 uses to calculate 
an ensemble of protein structures based on torsion angle dynamics, a molecular dynamics 
simulation that uses only torsion angles of the backbone as degrees of freedom instead of 
Cartesian coordinates.  CYANA only calculates the proper folding of the protein based 
on these NOE-derived, TALOS (chemical shifts)3, and covalent bonding (connectivity) 
constraints.  To get the correct geometry of the side chains with full consideration of 
inter-atom energetic effects (ex. H-bonds and Van der Waals interactions), the calculated 
structure undergoes water refinement which is a simulated annealing protocol using the 
AMBER molecular force field where the protein is heated rapidly to overcome any local 
minima barriers, it is then allowed to explore higher energy states, and is then cooled 
slowly so that it finds its lowest energy minima.  This is done repeatedly (ex. 100 times) 
to generate an “ensemble” of structures that are consistent with all constraints.  Precision 
of the calculated structures is quantified using a RMSD (root mean squared deviation) for 
atoms in the protein backbone and again for all heavy atoms.   
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Scheme 1.1. Flow chart detailing the steps to solving protein structure using NMR.
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Figure 1.2. Illustration of sequential assignment process using 3D HNCACB and 
CBCA(CO)NH spectra. Residues are i (amino acid of interest), i-1 (amino acid 
proeceeding i), and i+1 (amino acid after i).  Shown are pairs of strips from 1H-13C planes 
at a particular 15N chemical shift.  Typically, there would be one such pair of strips (15N 
planes) per amino acid, in a protein (except for prolines and the N-terminus) 
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Figure 1.3.  Representation of a A) random secondary structure, B) random secondary 
structure with all the restraints from the 13C and 15N NOESY experiments applied, and C) 
the experimental restraints turned into distance restraints in CYANA calculations, used to 
define the secondary and tertiary structure.  Figures taken from NMRFAM Workshop. 
 
 
 
A)	   	   	   	   	   B)	  
C)	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1.1.3 Relaxation Dynamics Studies of Protein Backbone N-H’s 
Protein motions are critical for various biological functions and occur over a wide 
range of timescales.  There is a strong correlation between structural dynamics and 
molecular function, and studying these dynamic processes can give site-specific 
information on motions that span timescales from psec to msec4.  We can characterize 
these dynamic processes by use of NMR with 15N-labelled protein and relaxation 
experiments (measure longitudinal relaxation rate R1 (1/T1), transverse relaxation rate R2 
(1/T2), and the heteronuclear NOE for the amide N-H bond) in conjunction with a 
Modelfree analysis. The Modelfree analysis utilizes the R1, R2, and NOE values obtained 
from the relaxation dynamics experiments, and the spectral density equations: 
R1= 1/4 d2[3J(ωN) + 7J(ωh) + c2J(ωN)                         Eq. 1.1 
R2= 1/8 d2[4J(0) + 3J(ωN) + 13J(ωh)] + 1/6c2[4J(0) + 3J(ωN)]            Eq. 1.2    
NOE = 1 + ¼ T1d2(γH/γN)[5J(ωh)]                Eq. 1.3 
J(ω) = 2/5[(S2τm/1+ (ωτm)2) + ((Sf 2 − S2)τ/1+ (ωτm)2                     Eq. 1.4 
 
in which the spectral density equations are fitted at each Larmor frequency ω (nitrogen 
and proton) and at given field strength using experimentally measured values of 
relaxation parameters (R1, R2, and NOE ) to find S2 and τm.  In the above equations, c 
and d are both constants; γ is the gyromagnetic ratio for nitrogen or proton; S2 is the 
generalized order parameter for movement of the N-H bond vector; Sf is the generalized 
order parameter on the sub-nsec timescale; τm is the isotropic rotational correlation time 
for the whole protein, and τ = τm τe / (τe + τm) where τe is the effective correlation time for 
internal motions within the protein (ex. Loop motions)5-8.  This allows us to quantify any 
changes to the fast timescale motion (psec-nsec) of the protein backbone, especially for 
9 
catalytically relevant regions, by solving to find the generalized order parameter S2 (S2 =1 
means completely restricted and immobile, S2 =0 means no restriction and completely 
mobile).  The Modelfree analysis can also provide insight into the state of the overall 
conformational motions of the protein, and how they change upon substrate addition, by 
measuring the correlation time (τm) for each complex (high τm means the protein tumbles 
slower and behaves like a larger protein; low τm means the protein tumbles faster and 
behaves like a smaller protein).8 
 
1.1.4 Automated Docking and Virtual Screening 
 Docking is the process of positioning a ligand into the binding site of a protein, by 
computationally exploring different translations, orientations, and conformations until a 
lowest energy structure and “pose” orientation is found.  There are many programs that 
are fully capable of virtual screening such as DOCK9, FlexX10, Glide11, and AutoDock12.  
AutoDock is currently the docking program that is in use for virtual screening at 
Marquette University.  AutoDock uses a genetic algorithm (GA) to sample multiple 
conformations of a ligand when binding to a protein.  AutoDock will use those 
coordinates and make derivations to the ligand structure based on the “fitness” level of 
the previous generation of ligands, meaning if a certain ligand binds poorly the 
coordinates of that ligand will not be used for further “generations.” However, if a ligand 
binds well, AutoDock will keep those coordinates and then optimize the binding by 
sampling other torsions of the ligand.  “Fitness” is calculated using a target function that 
is similar to a forcefield equation that describes energy of interactions between the 
10 
protein and ligand.  The GA optimizes the ligands pose to obtain the lowest energy 
function. 
 To quantitatively assess how well a ligand binds, AutoDock employs an 
“expanded” version of the free energy equation shown below, 
 
ΔG = ΔGvdw + ΔGhbond + ΔGelec + ΔGconform + ΔGtor + ΔGsol                                                         Eq. 1.5 
 
Where the first four terms are for the free energy terms for Van der Waals forces, 
hydrogen bonding, electrostatics, and deviations from covalent geometry and are typical 
for molecular mechanics free energy equations.  The latter two terms are the expanded 
portion of the equation and are the free energy terms for rotation of internal torsions 
(internatl entropy) and desolvation upon  binding (modeling hydrophobic effects and 
solvent entropic changes upon binding)12.   
 The experimental information that AutoDock provides is written out at the end of 
the docking session in a docking log file (dlg file).  After the docking is finished and the 
50 poses are generated (Figure 1.4), AutoDock then puts them through a clustering 
analysis to define which poses are similar enough to each other to cluster them together 
(within an RMSD of 2 Å).  Clustering offers an additional verification of the likelihood 
that a certain pose is the correct pose for the ligand binding to the protein.  Figure 1.5 
shows examples of this clustering analysis where A) had a very low energy of binding 
compound at (-10.11 kcal/mol) but there are many different clusters with few poses in 
each cluster.  In practice, this indicates a low probability of binding.  Figure 1.5B shows a 
cluster histogram for a compound with a slightly higher binding energy, but the 
11 
probability of this being an accurate pose is higher since there are fewer number of 
sparsely populated clusters, yet in the lowest energy cluster there are nearly half the 
number of poses clustered together.  In general, an accurate pose (and prediction that a 
compound binds to a protein) is more likely if there is one populated cluster.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  A docking experiment where AutoDock generated 50 poses (all 50 are 
shown) of a structure in the active site of phosphomevalonate kinase.  An example 
structure clustering is shown in the circle.  
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Figure 1.5. Clustering histograms from docking program AutoDock used to detail 
similarites between docked poses.  Panel A is an example of poor clustering and B is an 
example of good clustering. 
 
 
 
 
 
A)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  B)	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1.1.5 Protein Binding Analysis using Chemical Shift Perturbations  
 In NMR analysis, a change of chemical environment will cause the chemical shift 
(any nuclei used to detect NMR signal) of some compound or molecule to change or 
perturb, either upfield or downfield depending on the nature of the new environment.  For 
example, when a protein binds a ligand, those residues that are involved in binding (or 
are causing a structural change in the protein such as domain movement) are perturbed as 
shown in Figure 1.6.   
 These changes in chemical shift can be monitored as a function of ligand 
concentration to give information about ligand binding, such as the affinity of the ligand 
(i.e. inhibitor or substrate) for the protein.  This technique is also useful for screening of 
compounds that are thought to inhibit a certain protein.  Multiple compounds can be 
screened at a time to determine if any of the compounds bind to the protein, by 
monitoring any chemical shift changes that arise in the 1H-15N HSQC.  NMR-based 
titrations are usually complemented with a secondary assay for binding, to detect protein 
inhibition (or activation).  For example, an enzyme kinetic assay can be executed 
utilizing fluorescence or UV spectroscopy, for detection of enzyme reaction at various 
inhibitor concentrations.  
14 
 
Figure 1.6.  Overlay of 1H-15N HSQC titration experiments where Mg-ATP is being 
titrated onto phosphomevalonate kinase.  Chemical shift changes are shown with the 
color change from red (free PMK) to blue (Mg-ATP saturated PMK).  Note that the large 
number of chemical shift changes is an indication of domain reorientation to accept the 
new ligand, since the number of cross peaks (amino acid residues) that are perturbed is 
greater than those in the active site.  
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CHAPTER II. Substrate Induced Structural and Dynamics Changes in Human 
Phosphomevalonate Kinase and Implications for Mechanism  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
2.1      Introduction 
2.1.1 Phosphomevalonate Kinase and Rationale for Dynamics Study 
Protein motions are critical for various biological functions and occur over a wide 
range of timescales.  There is a strong correlation between structural dynamics and 
molecular function, and studying these dynamic processes can give site-specific 
information on motions that span timescales from psec to msec4.  One class of enzymes 
that undergoes large structural and associated motional changes is the kinases.  These 
changes occur due to the binding of their two ligands (substrates) and the need for 
reactive groups to move into close proximity for catalysis.  A model kinase in this regard 
is adenylate kinase, which consists of two domains that adjust to bring their phosphate 
donor and acceptor ligands into proximity for reaction to occur13.   
To better understand the molecular mechanism of enzymatic catalysis, structural 
characterizations of protein-ligand complexes are required.  Of particular interest are 
conformational and dynamic changes that are needed to bring the two highly charged 
substrates of PMK in proximity to react. To facilitate these studies (at the time of the 
study there was no crystal structure), a homology model for human phosphomevalonate 
kinase (PMK) had been generated using the PHYRE homology model method (≈24% 
overall sequence identity between PMK model and template), because there is no 
experimental structure yet available for this protein14.  Our recent NMR chemical shift 
assignments and subsequent secondary structure analysis has largely validated this 
model, based on chemical shift index values that match helical and sheet regions in the 
model. But, the presence of disordered regions and loops has made it impossible to 
pursue a complete structure determination. Currently, 77% of the backbone atoms have 
17 
been assigned, excluding two unassigned gaps that may be disordered regions (residues 
56–72 and 99–111). As such, studies herein refer to the homology model. This model 
consists of two domains. The larger ATP (adenosine triphosphate)-binding domain is 
comprised of a five-stranded parallel β-sheet interweaved with three α-helices.  The 
smaller M5P (mevalonate 5-phosphate) domain is comprised of loop regions and two α-
helices. In the model, two hinge regions, analogous to adenylate kinase, tether the ATP 
and M5P domains together. These may be involved in opening and closing motions to 
permit binding and release of substrates15.  Also, recent site-directed mutagenesis studies 
have identified a ‘‘Walker A’’ ATP binding motif (K17, R18, K19, and K22)16.  
Mutagenesis of some of these residues can decrease catalysis up to 10,000-fold14, 17, 
suggesting this as the active site location for catalysis of phosphoryl transfer.  ‘‘Walker-
A’’ loop residues that are most important for catalysis include K22 and R18. Outside the 
‘‘Walker-A’’ catalytic loop, R110 is also important14, 17.   The reaction catalyzed by PMK 
is shown in scheme 2.1.   
To characterize the effects of substrate addition on protein dynamics, we have 
used NMR relaxation experiments in conjunction with a Modelfree analysis8 to quantify 
any changes to the fast timescale motion (psec-nsec) of the protein backbone, especially 
for catalytically relevant regions. We also report on the conformational effects of 
substrate addition by comparing chemical shift changes and backbone 15N relaxation data 
for various complexes of PMK: (a) Apo-PMK, (b) the binary complex with Mg-ADP 
(adenosine diphosphate), (c) the binary complex with M5P, and (d) the ternary complex 
with Mg-ADP and M5P. 
18 
 
 
Scheme 2.1: Mevalonate Pathway with PMK catalyzed reaction shown in black box.  P 
represents phosphate (-PO32-) and E.C. is “Enzyme Commission.” 
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2.2       Materials and Methods 
2.2.1 Docking of M5P and ATP into Human PMK Homology Model 
 
 The homology model used in our studies was that which was previously prepared 
and reported by Herdendorf and Miziorko14. The binding orientation of ligands in this 
PMK (human) homology model was determined using Autodock412. Gasteiger charges 
and hydrogens were added using AutoDock Tools (ADT).  The docking grids were also 
prepared using ADT, with a grid size of 60 x 60 x 60 Å and a spacing of 0.375 Å.  These 
grids were centered on the ligands (AMP and GMP) of the homology model template, 
bacteriophage T4 deoxynucleotide kinase18.  The homology model and template were 
superimposed on each other, in order to obtain coordinates for the grid box used to dock 
the ligands. The overlay was done using Sybyl 5.8 (Tripos Inc., St Louis, MO, USA).  
Default docking parameters were used, except that 50 genetic algorithm runs were used 
with 2,500,000 as the maximum number of evaluations.  The docking of both ligands was 
done separately, due to inter-ligand repulsion from the negative charges on M5P and the 
ATP triphosphate, even after neutralization of two charges (as would be the case with 
bound Mg2+). This repulsive interaction was recognized based on earlier docking 
attempts to form the ternary complex, which produced erroneously distorted structures 
with the phosphate groups on the two ligands as far apart as possible in the docking box. 
This led us to do independent docking of ATP and M5P to produce the separate binary 
complexes, and these pdb coordinate files were then merged to create the ternary 
complex. This approach positioned the phosphate groups on ATP and M5P in close 
proximity, as required for the phosphate transfer reaction, and therefore provides strong 
validation for the docking poses that were generated. 
20 
2.2.2  Protein Expression and Purification 
 
PMK is normally a 192 residue 22.0 kDa protein, although it was expressed with 
an N-terminal histidine tag and additional linker residues, giving a total molecular weight 
of 24.2 kDa. Uniformly 15N labeled PMK samples were prepared using 15NH4Cl as the 
sole source of nitrogen in minimal media and protein was expressed and purified as 
described previously14, 17.  Briefly, E. coli BL21-(DE3) Rosetta cells were transformed 
with a pET15b(+) expression construct which encoded human PMK with  an N-terminal 
His6 affinity tag.  The transformed cells were plated onto LB (Luria Bertani) agar 
containing ampicillin (amp) and chloramphenicol (chl) antibiotics.  Plates were incubated 
overnight at 37 °C, and a single colony was picked to inoculate 2 mL of media, and 
grown to A600 ~ 0.3.  This culture was then used to inoculate 20 LB-amp-chl plates.  The 
plates were incubated overnight at 37 °C, and resulting bacterial lawns were used to 
inoculate 500 mL of LB-amp-chl to give A600 ~ 1.0.  The liquid culture was then 
incubated at 30°C for 1 h prior to induction with 1 mM IPTG.  The culture was harvested 
4 h post induction at A600 ~2.0.  Bacterial pellets were resuspended in 100 mL of a 50 
mM KPi (potassium phosphate) buffer containing 100 mM KCl, 5 mM imidazole, and 0.5 
mM DTT at pH 7.8.  Lysis was accomplished by passage through a microfluidizer at ~17 
kpsi.  The lysate was clarified by centrifugation at ~100,000 g and the supernatant was 
loaded onto ~0.5-1.0 mL of Ni-Sepharose Fast Flow resin.  The column was washed with 
lysis buffer until A280 < 0.005, and the protein was eluted with lysis buffer supplemented 
with 300 mM imidazole.  The fractions containing PMK were pooled and the 
concentration was determined spectrophotometrically using an extinction coefficient of 
€280 = 32,290 M-1 cm-1. 
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 2.2.3   NMR Sample Preparation 
 
All protein samples were buffer exchanged, using ultrafiltration with an Amicon 
(YM10) membrane, into 5 mM DTT, 20 mM KH2PO4, 10% D2O, and 0.02% NaN2, and 
concentrated to 400-600 µM.  ADP was complexed with Mg2+ by adding a 1:1 ratio of 
MgCl2.  Mg-ADP and M5P were both concentrated to 50 mM prior to titration, with pH’s 
of 5.0 for ADP and 7.0 for M5P.  All experiments were performed at pH 6.5.  
 
 
2.2.4   NMR Spectroscopy 
 
All NMR experiments were performed on a 600 MHz Varian NMR System at 
599.515 MHz using a triple resonance cryoprobe with z-axis gradients at 25 °C.  
Titrations were performed using 100 µM increments for both ligands, until saturation was 
achieved based on 1H-15N HSQC chemical shift changes (1 mM for M5P and 2 mM for 
MgADP).  There were two sets of titrations performed, first starting with M5P then 
adding Mg-ADP.  To assess binding order and synergy, the second titration started with 
Mg-ADP followed by M5P.  15N relaxation experiments were performed on free PMK, 
PMK saturated with M5P (2 mM), PMK saturated with Mg-ADP (20 mM; higher 
concentration was needed due to slow hydrolysis of ADP), and then the ternary complex 
(using the same saturation concentrations).  15N-T1, 15N-T2, and {1H}-15N NOE 
experiments were all performed using the BioPack pulse sequences from Varian, Inc 
(Palo Alto, CA).  Delay times for the T1 experiment were 10.8, 108.3, 215.8, 379.2, 
541.7, 758.4, 1083.4, 1515.8, and 2165.8 ms and 4.31, 8.62, 12.9, 17.2, 21.6, 30.2, 38.8, 
47.4, 55.1 ms for T2.  T1 experiments employed the standard inversion-recovery pulse 
sequence19, while T2 experiments employed the CPMG (Carr-Purcell-Meiboom-Gill) 
sequence, as implemented previously20, 21. NOE’s were obtained by measuring HSQC 
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spectra with and without 1H saturation for a time of 3 s (same for both), with an interscan 
delay of 1 sec.  An interleaved approach was used for the T1 and T2 experiments, to 
average out any potential instability over time22, 23.   
 
2.2.5   NMR Spectroscopy Data Analysis 
 
NMR data were processed using NMRPipe/NMRDraw24, and analyzed using 
NMRView.25  For all experiments, 1H-15N spectra were processed using a 90° shifted sine 
function in the 1H and 15N dimensions.  For 15N-T1 and 15N-T2 experiments, the spectra 
with the shortest relaxation delay were peak picked using NMRView.  For {1H}-15N 
NOE measurements only one spectrum was peak picked, and for each subsequent 
spectrum the peak ellipses were manually adjusted to fit each peak.   
The R1 and R2 relaxation rates were determined by fitting the T1 and T2 curves to 
Equation 1:                                      
                               It= Io*e(-Rt)                                                                               Eq.2.1 
 
where It is the peak intensity after time t, Io is the intensity at time t=0, and R is either R1 
or R2. Fitting was done using the Rate Analysis package included in NMRView.  NOE 
values were obtained by taking the ratio of the intensity versus the control.  This was 
done with two sets of experiments in order to obtain an error for the analysis. T1 and T2 
values were measured for PMK at various concentrations and used to calculate τm values, 
to demonstrate that PMK remains monomeric under the conditions of our NMR studies 
(previous analytical gel filtration studies also established that PMK is monomeric).14   
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Dissociation constants were obtained by measuring the chemical shift changes in 
going from free to various bound states, monitoring peaks in fast exchange in both 1H and 
15N dimensions.  These changes were then combined using Equation 2: 
 
     Δshiftobs = [(1H shift)2+(15N shift/5.51)2](1/2)                       Eq. 2.2 
                 
The chemical shift change (Δshiftobs) as a function of the concentration of the ligand, at 
fixed concentration [Po] were fitted to a quadratic equation, to determine the dissociation 
constant Kd: 
 
Δshiftobs = (Δshiftmax/(2[Po]))*{([Lo] + [Po] + Kd) –{([Lo] + [Po] + Kd)2 – 4[Lo][Po]}1/2}      Eq. 2.3 
 
 using Sigmaplot8, where Lo is the total ligand concentration at a particular titration point, 
Po is the total protein concentration, and Δshiftmax is the maximum chemical shift change 
observed for the particular peak in question. Fitting to the quadratic equation was 
required because [Po] > Kd. Standard deviations resulted from the non-linear least squares 
fitting process (note: as Kd gets very small relative to [Po], errors will become larger 
because Kd become less well-defined in the fitting process).    
 
 
2.2.6   Modelfree Analysis 
 
The parameters of internal motion were determined from the NMR relaxation data 
according to the model-free formalism established by Lipari and Szabo5-7 using 
Modelfree4 software (version 4.20, A. G. Palmer, Columbia University).  The residues 
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were optimized with an isotropic diffusion model using an initial estimate derived from 
the R2R1_diffusion program (A. G. Palmer, Columbia University).  Backbone dynamics 
calculations were performed with 300 Monte Carlo simulations per run using an 
internuclear distance rNH of 1.02 Å and a chemical shift anisotropy (CSA) for the 15N 
nucleus of -172 ppm.  Five models were used to fit our experimental data and were 
iteratively tested in order of increasing complexity (M1= S2; M2= S2, τe; M3= S2, Rex; 
M4= S2, Rex, τe; M5= S2f, S2s, τe) until an acceptable fit was achieved.  S2 is the 
generalized order parameter, τe is the internal correlation time, Rex is the exchange 
contribution term, and S2f  and S2s are for sub-nanosecond and nanosecond motions 
respectively.  These models were tested until they could reproduce the experimental 
relaxation data within 90% confidence limits using appropriate χ2 and F-tests8, and this 
was done for each crosspeak (amino acid).  
 
2.3      Results and Discussion 
 
2.3.1   Docking of M5P and ATP to Human PMK 
 
The docking of M5P and ATP (Fig. 2.1) seems reasonable based on the proximity 
of the reactive phosphate groups to each other, and also their location within 4.0 Å of the 
“Walker A” catalytic loop (which is a peptide motif found in proteins known to bind 
nucleotides, such as ATP), which includes Lys17, Arg18, Lys19, and Lys22 as well as 
other basic residues, especially Arg110. It is striking that the independent docking of 
M5P into PMK positioned its phosphate group within 2.7 Å of the ATP γ-phosphate and 
2.8 Å from Arg110 and Arg138.  
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Figure 2.1. Ternary complex structure of docked ligands ADP and M5P in the active site, 
near the “Walker A” loop, of PMK.  Catalytically important amino acids are labeled, 
including Lys’s 17, 19, and 22, as well as Arg’s 18, 138, and 110. 
 
 
  
In our docked complex of human PMK with M5P and ATP (Fig. 2.1), the key 
catalytic residues identified by Herdendorf and Miziorko14, 17 (Arg18, Lys22, and 
Arg110) are all reasonably well positioned for catalysis.  The only possible exception is 
Lys22, which is in the active site but is pointed away from the phosphate; while this may 
reflect an inaccuracy of the homology model, it is noteworthy that a simple side chain 
rearrangement could easily position its ε-amino group near the ATP γ-phosphate. Arg18, 
Lys22, and Arg110, along with the other basic residues in Fig. 2.1, may be important for 
forming the ternary complex by neutralizing the negative charges on the two substrates, 
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so that their phosphate groups can move into proximity for phosphoryl transfer. 
Additional charge stabilization (from Lys22?) may also be needed to stabilize the 
transition state if it goes by an associative-type mechanism, which would place added 
charge density on the γ-phosphate. An important feature of the model in Fig. 2.1 is that 
the γ-phosphate of ATP is ideally positioned for nucleophilic attack by the M5P 
phosphate (separated by only 2.7 Å). This provides further validation that this structural 
model of the ternary complex is reasonably accurate. 
 
 
2.3.2  Chemical Shift Perturbation Studies to Make the Binary and Ternary 
Complexes 
 
To determine how different ligands affect the residues of the protein, titrations of 
the ligand to the protein can be performed by monitoring 1H-15N HSQC NMR spectra.  
The HSQC experiment monitors the magnetization transfer from the proton to the 
nitrogen on the amide group of the backbone of the protein.  The spectra show crosspeaks 
for all the amide groups in the protein, one for each residue, except for proline.  Addition 
of specific ligands that bind to protein can cause these amide groups to change their 
chemical shift due to environmental changes, giving rise to chemical shift perturbations.  
For chemical shift perturbation studies, a dead-end (i.e. non-reactive) complex with PMK 
was created, to ensure that there would be no catalytic turnover during the NMR 
measurements.  AMP-PNP (Fig. 2.2 and 2.3b) is often used to create such dead-end 
complexes in kinases, but it binds only weakly to PMK and causes few structural changes 
in PMK compared to ATP (Fig. 2.3a) or ADP (Fig. 2.3c).  As a result, ADP was used to 
make the dead end complex (Fig. 2.3c) in our studies.  
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Figure 2.2.  Structures of adenine nucleotides ATP, AMP-PNP, and ADP with 
corresponding Kd values. 
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Figure 2.3. Chemical shift perturbations due to binding of nucleotides a) Mg-ATP titrated to 
saturation onto Apo-PMK, b) Mg-AMP-PNP titrated to saturation onto Apo-PMK, and c) Mg-
ADP titrated to saturation onto Apo-PMK.  All experiments begin at the red cross-peaks, with 
additions in 100 µM increments to saturation, which is indicated by the transition to the blue 
cross-peaks.  The corresponding chemical shift changes are mapped on to the human PMK 
homology model, where the red indicates a large chemical shift change (>0.09 ppm) and pink 
indicates a medium chemical shift change (0.05-0.09 ppm), while blue indicates a small or no 
chemical shift change (or no data). 
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To justify the use of ADP as a suitable replacement for ATP, an ATP titration 
experiment was carried out and is shown in Fig. 2.3a.  Comparing these spectra, it is clear 
that they show the same chemical shift changes for the same residues, which infers that 
the two protein-ligand complexes undergo very similar structural changes.  From the 
HSQC spectra for the Mg-ADP titration (Fig. 2.3c), a pronounced conformational change 
is observed upon substrate addition, due to multiple residues that are affected when the 
complex is formed.  Fig. 2.4a shows the chemical shift perturbations due to Mg-ADP 
binding mapped onto the PMK model, and is consistent with Mg-ADP causing the 
protein to undergo a gross conformational change; that is, the whole protein appears to 
adjust structurally in order to accommodate the addition of Mg-ADP.  Notable changes 
are observed in the loops near the substrate phosphate groups, as well as the region where 
the two ATP-domain helices contact each other.  The Mg-ADP addition was then 
followed by further titration with M5P to form the ternary complex (Fig. 2.4b). To 
determine if there is a preferred sequence for binding, due to synergy, M5P was then 
titrated first to Apo-PMK (Fig. 2.4c).  
Based on the chemical shift perturbations that occurred during titration to form 
binary and ternary complexes, it can be seen that the largest changes occur in forming the 
binary complex, whether it is ADP or M5P that binds first (Fig. 2.4). The chemical shift 
changes include residues outside the binding site, such as hinge regions between 
domains, suggesting that a conformational change has occurred.  
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Figure 2.4. Chemical shift perturbations due to: a) Mg-ADP added to saturation to Apo-PMK b) 
M5P added to saturation to Mg-ADP/PMK c) M5P added to saturation to Apo-PMK and d) Mg-
ADP added to saturation to PMK/M5P.  All experiments begin with the red cross-peaks and 
titrations occur at 100 µM increments to saturation, which is indicated by transition to the blue 
cross-peaks.  The corresponding chemical shift changes are mapped on to the human PMK 
homology model, where the red indicates a large chemical shift change (>0.09 ppm) and pink 
indicates a medium chemical shift change (0.05-0.09 ppm) while blue indicates small or no 
chemical shift change (or no data). Note: Gly21 is visible in panel (a) at a lower threshold. 
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In terms of adenine nucleotide binding, it is interesting that while the γ-phosphate 
of ATP seems to not be important for binding or inducing structural changes, based on 
comparisons of ATP and ADP (Figs. 2.2 and 2.3), the situation is actually more 
complicated - because simple O=>NH substitution of the bridging heteroatom between 
the β and γ phosphates has a dramatic effect on binding.  This suggests there may be 
important interactions with the β-γ bridging heteroatom, which might be important for 
stabilizing this leaving group during phosphate transfer. It is also noteworthy that ADP 
(and ATP) binding causes chemical shift perturbations in the Walker A loop (ex. Arg18) 
and the lid that covers the Walker A loop, as well as the hinge residue for the lid (D163). 
Opening of this lid should only produce a modest change in size of the protein, and so 
would not be expected to produce a change in correlation time. In contrast, domain 
movement between ATP and M5P binding domains would be expected to produce a 
much larger change in size and correlation time, as had been observed in adenylate 
kinase, and appears to also occur in human PMK (vide infra).  
 
2.3.3  Binding Affinity and Synergy  
To quantitatively assess binding affinity and binding synergy, if any, cross-peak 
perturbations (Figs. 2.3 and 2.4) were fitted to obtain Kd values for each binding event.  
Monitoring chemical shift changes and fitting to the quadratic equation (Eq. 2.3) 
permitted determination of dissociation constants (Kd) for the various nucleotides (Fig. 
2.2) and for all four complexes (Fig. 2.5).  The Kd for the Mg-ADP titration to Apo-PMK 
is 19 ± 9  µM and <20 µM for subsequent M5P binding to form the ternary complex.  For 
the titration of M5P to Apo-PMK the Kd is 6 ± 3 µM and 56 ± 16 µM for the subsequent 
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Mg-ADP addition to form the ternary complex.  These values are consistent with the 
previously reported Km values of 47 ± 5 µM for ADP and 34 ± 3 µM for M5P,26 keeping 
in mind that Km values can often deviate from Kd values due to kinetic effects.   
 
 
 
Figure 2.5. Thermodynamic box for the formation of the dead-end ternary complex of 
human PMK with corresponding Kd and τm values for each complex.  Cartoon 
representations of each complex are shown, with the circles representing M5P and the 
squares representing ADP. 
 
 
 
Based on chemical shift perturbations, it appears that binding of either M5P or 
ADP to apo PMK can induce a large conformational change.  Kd values obtained from 
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fitting spectral changes are consistent with their being no preferred binding sequence or 
synergy for the ligands.  This is in contrast to the report of an ordered sequential 
mechanism (M5P binding first and ADP released last) for the pig liver PMK enzyme,26 
but is consistent with recently reported steady state kinetics on human PMK, where 
competitive inhibition was observed using mevalonate 5-diphosphate as a product 
inhibitor versus M5P.17 If anything, our data suggest there is a modest (~3-fold) anti-
synergy, such that affinity for the second ligand is weakened due to presence of the first, 
which could be due to the charge/charge repulsion by the phosphate groups on both 
ligands.  But, this anti-synergy could be unique to our dead-end complex (MgADP/M5P), 
and does not necessarily reflect the situation for the catalytically competent Michaelis 
complex (MgATP/M5P).27 
 
2.3.4  Relaxation Dynamics  
To obtain dynamic information on the psec-nsec time scale motions, longitudinal (R1) 
and transverse (R2) relaxation rates as well as {1H}-15N NOE values were obtained, and 
are summarized in Fig. 2.6 for Apo-PMK, Mg-ADP bound PMK, M5P bound PMK, and 
the ternary (Mg-ADP/M5P) complex.  All of the complexes have relatively rigid 
structures (high S2), indicative of a well-ordered protein backbone on the psec-nsec 
timescale (Fig. 2.6).  Trends in R1 and R2 values in Table 2.1 can best be explained based 
on changes in the overall correlation time of the protein in the different complexes. It 
should again be noted that PMK remains in a monomeric state in our NMR studies (Fig. 
2.7), so changes in correlation time are not associated with aggregation effects.  
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Figure 2.6. NMR dynamics data including R1, R2, NOE, and S2 values, where blue is the 
Apo-PMK complex, red is the M5P saturated complex, yellow is the Mg-ADP saturated 
complex, and green is the ternary complex.   
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Figure 2.7: Representative 1-D spectra from T2 relaxation measurement at A) 500 µM, 
B) 250 µM, and C) 125 µM PMK. The rotational correlation time τm for A) is 12.9 ± 1.2 
ns, B) is 13.5 ± 0.9 ns, and C) is 12.0 ± 0.6 ns.   
 
 
 
           
Table 2.1.  Summarization of relaxation dynamics parameters of apo and ligand induced 
states of PMK.  
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          The changes in PMK correlation time were verified and quantified in the 
Modelfree analysis, where it was found that relaxation data could not be properly fitted 
for the different PMK complexes using the same correlation time. The correlation times 
obtained from the Modelfree analysis of each complex are summarized in Fig. 2.5. These 
correlation time changes are consistent with there being a ligand-induced change in 
overall shape of PMK in the different complexes, as had been previously observed in 
analogous NMR studies of adenylate kinase.   
Based on Modelfree analysis of NMR dynamics parameters (Fig. 2.6), 
generalized order parameters were obtained. These clearly indicate that PMK adopts a 
fairly rigid structure (S2 values >0.8) for all the binary and ternary complexes.  
Furthermore, the average S2 values remain largely unchanged upon formation of the 
binary complex with either ADP or M5P, indicating that the local dynamics for all the 
complexes are virtually the same (Table 2.1) on the psec-nsec timescale.  The large S2 
values, which are consistent with a rigid, highly ordered backbone, are not unexpected 
given the well-structured core of the protein, which includes a 5 stranded parallel β-sheet. 
One might have expected some ordering in the M5P domain upon ligand binding, given 
the high content of extended and loop regions, but this does not appear to be occurring.   
 
2.3.5    Inter-domain and loop motion: ligand binding domains, lid and “Walker A” 
catalytic loop  
Although the protein core may be largely rigid, it is possible that there is some 
motion of domains relative to each other, and of other defined regions. Indeed, chemical 
shift perturbation studies suggested there was a large substrate-induced conformational 
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change (Fig. 2.4). In fact, there were a small number of residues with small or negative 
NOE’s that gave rise to small S2 values (H55, R93, and D163), and these are located in 
loop and potential hinge regions in the homology model (vide infra). Interestingly, the 
“Walker A” ATP binding loop shows the same S2 values as the rest of the protein (i.e. it 
is rigid), indicating that if there is any catalytically relevant change in dynamics, it might 
only occur during turnover with the actual Michaelis complex,27 rather than with the 
“dead-end” complex used in our studies.  One important exception is Gly21, which is 
adjacent to Lys22, the catalytically most important residue in PMK.14 Gly21 undergoes 
an increase in S2 in going from the apo (blue) to the M5P (red) complex, indicating it 
becomes less mobile in the binary complex (Fig. 2.6), perhaps as Lys22 moves into 
position for catalysis (note: Lys22 was not assigned, so changes to its dynamic state are 
not known). Interestingly, Gly21 exchange broadens in the ternary complex, suggesting it 
undergoes msec timescale motion. But, in the conversion of apo PMK to the PMK-M5P 
binary complex, one can see a slow exchange process for Arg18, and a fast exchange 
process for Gly21 (Fig. 2.4c, and expansions in Fig. 2.8).  
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Figure 2.8: Expansions of HSQC spectra, showing crosspeak changes used to calculate 
exchange rates.  R18 is in slow exchange between two states, while G21 is in fast 
exchange between two states.  Crosspeak seperation, in sec-1, therefore defines the 
exchange rate between these two states, for the loop containing R18 and G21. 
 
 
 
Assuming the same motion occurs for these two “Walker A” loop residues, this 
timescale flanking permits an estimation of the rate constant for the “Walker A” catalytic 
loop exchanging between the two states associated with M5P binding as kex = 100-600 
sec-1 (see Fig. 2.8). This is likely to be due to a lid opening/closing motion, which would 
be coupled to “Walker A” loop motion, based on analogy to adenylate kinase where a 
flexible lid caps the catalytic “Walker A” loop. 28-31 
It should be noted that while there doesn’t appear to be significant motion of 
“Walker A” catalytic loop residues on the psec-nsec timescale (besides Gly21), there 
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does appear to be motion on slower (ex. msec) timescales. For example, in the ADP 
binary and ternary complexes, most crosspeaks for residues in the loop were no longer 
visible, due to exchange broadening (Fig. 2.4). For this reason, S2 for ADP complexes 
could not be measured. Accordingly, it is simply not known in these complexes what 
motion might be occurring on the psec-nsec timescale.   
Overall, the psec-nsec timescale dynamics data indicate that M5P binding drives 
the immobilization of catalytic residues (with Gly21 as our “Walker A” reporter), but 
there still appears to be msec timescale motion, especially when ADP is bound.  This 
motion might be important for catalysis, but could also be unique to the particular dead-
end inhibitory complex used in our study.  There is certainly literature precedent for 
kinase active site loop dynamics being very sensitive to the nature of the inhibitory 
complex.  For example, residual dipolar coupling and 15N relaxation measurements of 
various ABL kinase complexes indicated that inhibitors differed significantly in their 
ability to immobilize the catalytic/activation loop.32 
 
2.3.6    Ligand-induced changes to protein size: inter-domain conformational 
change? 
The chemical shift perturbation studies indicated that binding of either ADP or 
M5P may cause a large conformational change (Fig. 2.4), but the above analysis of S2 
values indicated this did not correspond to any significant changes in dynamics within the 
two ligand binding domains, other than some changes to the “Walker A” catalytic loop, 
and the lid that covers it. What about inter-domain motion? The Modelfree analysis 
provided some insights in this regard. As mentioned in the Methods section, relaxation 
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data fitting was optimized for each complex to find the rotational correlation time τm for 
that complex, since it was not possible to fit all complexes using a single τm. Changes to 
fitted τm values for all the complexes (Fig. 2.5) reveal that the ADP binary complex has 
the largest τm of 17.6 nsec while the M5P binary complex has the smallest, with a τm of 
13.5 nsec. The Apo-PMK and the ternary complex fall in between these two extremes, 
with similar τm values of ~15.7 nsec (Fig. 2.5). This suggests that both ADP and M5P 
binding induce conformational changes, but in opposite directions. That is, M5P causes a 
compression of the structure (so PMK tumbles faster), while ADP causes an opening up 
of the structure (so PMK tumbles slower). Such changes would be consistent with a 
movement of the two ligand binding domains relative to each other, as occurs in the 
nucleoside monophosphate kinases. 28-3133 
Why ADP binding causes the structure to open up is not clear. Since the product 
of the PMK reaction is ADP, it could be that the open conformation reflects the protein 
trying to release ADP.  However, the chemical shift perturbation study with ATP (Fig. 
2.3a) shows the same chemical shift perturbations as with ADP, arguing against there 
being a dramatically different conformation in the ATP vs. ADP binary complexes.  The 
changes in τm for the various complexes indicates that protein closure occurs upon 
binding to M5P, with or without ADP present. This tightening/closure of the structure 
induced by M5P binding might be associated with domain movement around a 
His55/Arg93 hinge (Figs. 2.4 and 2.6).  The chemical shift perturbation studies of PMK 
bound to M5P, with subsequent addition of Mg-ADP, demonstrate that the protein may 
open back up to bind ADP/ATP for catalysis.   
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2.3.7     Hinge regions for lid and domain movement 
     The previous discussion presented data in support of ligand-induced structural 
changes, which may be related to inter-domain (ATP/M5P) motion as well as to motion 
of the “Walker A” catalytic loop and the lid that covers it. Regarding movement of the 
lid, it is noteworthy that data on adenylate kinase indicates lid movement occurs on the 
same timescale as catalysis. This is consistent with the lid controlling access to the active 
site, as well as its packing up against the catalytic “Walker A” loop. In adenylate kinase, 
a key catalytic residue in the ATP binding site is Lys21, 33 which twists into an 
unfavorable double gauche rotamer in order to interact with the ATP phosphate, just as 
Lys22 would in the human PMK homology model (Fig. 2.1) if its sidechain were 
adjusted to permit interaction with the ATP phosphate.  This lysine may cycle into a 
catalytically useful orientation in the transition state to stabilize the increasing negative 
charge on the γ-phosphate, which would be created in the associative mechanism that is 
thought to be operative for nucleoside monophosphate kinases.33  Such a mechanism 
would permit selective stabilization of the transition state, and would require motion of 
the “Walker A” loop as the transition state is approached. So, lid motion is potentially 
relevant to catalysis. How does lid motion occur in PMK? 
As noted earlier, a number of potential hinge residues had unusually small S2 
values (H55, R93, and D163), which indicates they are mobile on the psec-nsec timescale 
(note: often, fast timescale motion occurs along with msec timescale motion, which 
would be more relevant for a hinge region). Specifically, residues H55 and R93 are 
positioned (Fig. 2.4) such that they could operate as hinge residues that allow movement 
between the core ATP domain and the M5P domain, possibly for enabling an opening 
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and closing motion upon substrate binding3.  Likewise, Asp163 is located in a potential 
hinge region for the “lid” loop region that is analogous to the “lid” that is present in the 
nucleoside monophosphate kinases. 28-3133, 34 This lid caps the catalytic “Walker A” loop 
in the PMK model.  The potential hinge residue, Asp163, also underwent dramatic 
chemical shift changes upon ligand binding (Fig. 2.4), as would be expected if there were 
motion around this hinge region induced by ligand binding. Motion around this hinge 
region would permit movement of the “Walker A” catalytic loop, which could be coupled 
to lid motion, as in adenylate kinase. The full extent to which catalytic loop and lid 
motions are coupled, and what role this motion might have in catalysis in human PMK, is 
not known, and will be the topic of future studies. But, extensive NMR studies on 
nucleoside monophosphate kinases,33 and especially adenylate kinase as a prototype, 28-
3134 provide a rich literature that describes coupled motions between these loops, and their 
role in catalysis. These studies have also identified ligand-induced changes in protein 
correlation times (due to inter-domain movement; opening/closing), as we have now 
observed in human PMK. It will be interesting to see if human PMK follows the example 
of the adenylate kinase prototype, or whether it will provide unique and new insights into 
the role of such loop and domain motions in kinase-mediated phosphate transfer 
reactions. The studies reported herein provide a foundation for such future studies. 
 
2.4      Conclusion 
PMK is a very dynamic protein with large structural changes that occur upon 
ligand addition, especially the first ligand addition.  However, as shown from the 
Modelfree analysis, we see that the protein conformation changes with different ligands 
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being added upon M5P binding, the protein goes to a closed conformation (τm of 13.5 
nsec) and upon ATP/ADP binding, the protein opens up (τm of 17.6 nsec).  The 
Modelfree analysis has also identified a few potential hinge regions, specifically R93 and 
H55, which may be involved in moving of the M5P binding domain to permit closure of 
the protein.  This analysis has also indicated that D163 may be involved in the lid region 
movement.  This lid caps the “Walker A” ATP binding site, like many other 
monophosphate kinases.  Finally the Kd’s determined from chemical shift perturbation 
studies were very similar to the Km’s previously reported4, and we have determined that 
all ligands bind with similar dissociation constants: 6 +/- 3 µM for M5P binding to free 
PMK and 56 +/- 16 uM for subsequent ADP binding; 19 +/- 9 µM for ADP binding to 
free PMK and <20 µM for subsequent binding of M5P.   
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CHAPTER III.  NMR Dynamics Investigation of Ligand-Induced Changes of Main 
and Side Chain Arginine N-H’s in Human Phosphomevalonate Kinase 
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3.1 Introduction 
3.1.2  Phosphomevalonate Kinase and Arginine Dynamics 
 Studies of the dynamical properties of proteins using NMR spectroscopy is an 
emerging field that has largely been limited to backbone N−H or side-chain methyl 
motions. It is often but not always true that changes to the dynamic state of the backbone 
reflect changes in the side chains. The NMR techniques for quantifying fast-time-scale 
motion involve measuring the longitudinal (R1) and transverse (R2) relaxation rates as 
well as the heteronuclear nuclear Overhauser effect (NOE) for each amino acid backbone 
N−H (or side-chain C−H) bond vector in the protein.4, 7, 8, 35 These values can then be 
used to calculate the generalized order parameter (S2), which is a measure of protein 
flexibility on the psec to nsec timescale. 
We have recently reported on the ligand-induced structural and dynamical 
changes of human phosphomevalonate kinase (PMK).(4) PMK is the fifth enzyme in the 
mevalonate pathway in humans and is involved in steroid biosynthesis.26, 36  PMK 
catalyzes phosphoryl transfer from adenosine triphosphate (ATP) to mevalonate 5-
phosphate (M5P) to form adenosine diphosphate (ADP) and mevalonate 5-diphosphate. 
To permit phosphoryl transfer, the substrates are brought close together, resulting in a 
significant and repulsive buildup of negative charge. To facilitate this difficult task, PMK 
contains 17 arginines (Figure 3.1) and eight lysines, many of them in the active site to 
help neutralize the negative charge on the phosphates.  
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Figure 3.1. Ternary complex of human PMK, with M5P and ATP docked independently 
into the apo crystal structure (3CH4).9  After docking, structure was optimized using 
molecular dynamics (50 ps at 300 K). All arginines are shown, and those known to be 
important for substrate binding or catalysis are labeled.  Inter-phosphate distance is 7 Å, 
so phosphate transfer will require additional domain movement. 
 
 
 
The most important arginines, on the basis of site-directed mutagenesis studies, are R18, 
R48, R73, R84, R110, R111, and R141.14, 17  Here we describe the use of NMR dynamics 
methods to characterize changes in the mobility of arginine side chains upon ligand 
binding. NMR dynamics methods, which have recently been applied to arginine side 
chains,35, 37, 38 allow study of the role that arginine side chains play in ligand binding and 
catalysis. Our studies provide surprising insights into ligand effects on arginine side 
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chains that are remote from the active site, perhaps due to long-range Coulombic 
attractions. 
 
3.2 Methods and Materials 
3.2.1 Docking of M5P and ATP into the Human PMK Crystal Structure 
The binding orientation of ligands in the PMK (human) crystal structure (3CH4) was 
calculated using Autodock4.12  Gasteiger charges and hydrogens were added using 
AutoDock Tools (ADT).  The docking grids were also prepared using ADT, with a grid 
size of 60 x 60 x 60 Å and a spacing of 0.375 Å.  These grids were centered on the 
ligands (AMP and GMP) of the homologous protein, bacteriophage T4 deoxynucleotide 
kinase.18  The PMK crystal structure (apo) and template were superimposed on each 
other, to determine coordinates for the grid box used to dock ligands.  Default docking 
parameters were used, except 50 genetic algorithm runs were used with 2,500,000 for 
maximum number of evaluations.  The docking of both ligands was done separately, due 
to inter-ligand repulsion from the negative charges on M5P and the ATP triphosphate, 
even after neutralization of two ATP charges (as would be the case with bound Mg2+). 
This repulsive interaction was recognized based on earlier docking attempts to form the 
ternary complex, which produced distorted structures with the phosphate groups on the 
two ligands as far apart as possible. This led us to do independent docking of ATP and 
M5P to produce the separate binary complexes, and these pdb coordinate files were then 
merged to create the ternary complex.  The crystal structure of PMK has the R141 
positioned in the proposed binding site of ATP, so that docking of ATP into that site 
caused the ATP to adopt a highly strained conformation with a steric clash involving 
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R141.  So to achieve a proper docking, with minimal perturbation to the crystal structure, 
R141 was temporality changed to glycine.  This allowed a proper docking of ATP into 
the active site.  Then the R141 sidechain was added back and, as expected, there was still 
a steric clash with the R141 sidechain and ATP.  This merged ATP/PMK pdb file was 
then minimized using Amber 99, as implemented by HyperChem 7.5 (Gainesville, FL).  
The minimized structure was then further refined by performing a brief molecular 
dynamics (MD) run (again using the Amber 99 force field, as implemented in 
HyperChem 7.5) to determine any lid motion that may be required to permit ATP 
binding.  MD was performed using a 1 fsec step size, with a heating time of 10 ps and a 
production time at 300K of 50 ps. At the end of the dynamics run, the structure was again 
minimized to produce the final ATP/PMK complex.  During the MD, motion was only 
permitted for residues 120 to 160, which included the lid that contains R141.  This 
approach to docking, with subsequent MD-based refinement, positioned ATP and M5P in 
their respective binding sites, is positions that are consistent with previous binding 
studies.  In the end, there were no dramatic changes to the lid. Rather, there was mostly 
just an adjustment in the orientation of R141 sidechain, with modest lid rearanegement. 
 
3.2.2 Protein Expression and Purification 
 
PMK is normally a 192 residue 22.0 kDa protein, but it was expressed herein with 
an N-terminal histidine tag and additional linker residues, giving a total molecular weight 
of 24.2 kDa.  Mutated PMK constructs (R84M, R111M, R130M, and R141M) were 
described previously.14, 17  Briefly, E. coli BL21-(DE3) Rosetta cells were transformed 
with a pET15b(+) expression construct of wild type and mutant PMK.  The transformed 
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cells were plated onto LB (Luria Bertani) agar plates containing ampicillin (amp) and 
chloramphenicol (chl).  Plates were incubated overnight at 37 °C, and a single colony 
was picked to inoculate 2 mL of media, which was then grown to A600 ~ 0.3.  This culture 
was then used to inoculate 20 LB-amp-chl plates.  The plates were incubated overnight at 
37 °C, and resulting bacterial lawns were used to inoculate 500 mL of M9 minimal 
media-amp-chl with 14NH4Cl and 13C-glucose, as the sole sources of nitrogen and carbon, 
except media was supplemented with .25g/L [13C6, 15N4]-L-Arginine (Isotec Inc.), to give 
A600 ~ 1.0.  The liquid culture was then incubated at 30°C for 1 h prior to induction with 
1 mM IPTG.  The culture was harvested 4 h post induction at A600 ~2.0.  Bacterial pellets 
were resuspended in 100 mL of a 50 mM KPi (potassium phosphate) buffer containing 
100 mM KCl, 5 mM imidazole, and 0.5 mM DTT at pH 7.8.  Lysis was accomplished by 
passage through a microfluidizer at ~17 kpsi.  The lysate was clarified by centrifugation 
at ~100,000 g and the supernatant was loaded onto ~0.5-1.0 mL of Ni-Sepharose Fast 
Flow resin.  The column was washed with lysis buffer until A280 < 0.005, and the protein 
was eluted with lysis buffer (stated above) supplemented with 300 mM imidazole.  The 
fractions containing PMK were pooled and the concentration was determined 
spectrophotometrically using an extinction coefficient of €280 = 32,290 M-1 cm-1. 
 
3.2.3 NMR Sample Preparation 
All protein samples were buffer exchanged, using ultrafiltration with an Amicon 
(YM10) membrane, into 5 mM DTT, 20 mM KH2PO4, 10% D2O, 10% d6-glycerol, and 
0.02% NaN3, and concentrated to 400-600 µM.  All experiments were performed at pH 
6.5 and 298 K.  
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3.2.4 NMR Spectroscopy 
All NMR experiments were performed on a 600 MHz Varian NMR System at 
599.515 MHz using a triple resonance cryoprobe with z-axis gradients at 25 °C.  
Titrations were performed using 100 µM increments for M5P addition, until saturation 
was achieved based on 1H-15N HSQC chemical shift changes (1 mM for M5P).  15N-T1, 
15N-T2, and {1H}-15N NOE experiments were all performed using the BioPack pulse 
sequences from Varian, Inc (Palo Alto, CA).  Delay times for the T1 experiments were 
10.8, 108.3, 215.8, 379.2, 541.7, 758.4, 1083.4, 1515.8, and 2165.8 ms, and delay times 
for the T2 experiments were 4.31, 8.62, 12.9, 17.2, 21.6, 30.2, 38.8, 47.4, 55.1 ms.  T1 
experiments employed the standard inversion-recovery pulse sequence,34 while T2 
experiments employed the CPMG sequence, as implemented previously.32, 33  NOE’s 
were obtained by measuring HSQC spectra with and without 1H saturation for a time of 3 
s (same for both), with an inter-scan delay of 1 sec.  An interleaved approach was used 
for the T1 and T2 measurements, to decrease effects of field instability over long 
experiment times.21 
  The 3D HNCO spectrum was acquired on the same 600 MHz instrument, using 
16 transients, with 24 13C and 16 15N increments, using 13C and 15N spectral widths of 
2250 and 1200 Hz, respectively.  In addition to HNCO, we attempted CC(CO)NH and 
related TOCSY experiments, in an effort to obtain sidechain assignments, but very little 
TOCSY transfer was observed due to relaxation.  A 3D HNCA was acquired using 16 
transients, and 13 13C and 16 15N increments, with 13C and 15N spectral widths of 2100 
and 1200 Hz, respectively. Processing of the 2D planes was performed using 90° shifted 
sine bell window functions in 1H and 15N dimensions.  In an another attempt to assign 
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sidechain NH’s to backbone NH’s, 3D 15N-NOESY experiment were also acquired on 
apo-PMK with mixing times of 80 and 150ms using 16 transients, with 70 13C and 79 15N 
increments.  
 
3.2.5 NMR Data Analysis 
NMR data were processed using NMRPipe/NMRDraw,24 and analyzed using 
NMRView.25  For all experiments, 1H-15N spectra were processed using a 90° shifted sine 
function in the 1H and 15N dimensions.  For 15N-T1 and 15N-T2 experiments, the spectra 
with the shortest relaxation delay were peak picked using NMRView.  For {1H}-15N 
NOE measurements only one spectrum was peak picked, and for each subsequent 
spectrum the peak ellipses were manually adjusted to fit each peak.   
 The R1 and R2 relaxation rates were determined by fitting the T1 (1/R1) and T2 
(1/R2) curves to Equation 3.1:                                        
                                                       It= Io*e(-Rt)                                Eq. 3.1 
where It is the peak intensity after time t, Io is the peak intensity at time t=0, and R is 
either R1 or R2. Fitting was done using the Rate Analysis package included in NMRView.  
NOE values were obtained by taking the ratio of the intensity versus the control.  This 
was done with two sets of experiments in order to obtain an error for the analysis.  
 
3.2.6 Modelfree Analysis 
The parameters of internal motion were determined from the NMR relaxation data 
according to the model-free formalism established by Lipari and Szab5-7o using 
Modelfree4 software (version 4.20, A. G. Palmer, Columbia University).  R2/R1 values 
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were calculated for each complex for those assigned main chain residues and were used 
as the starting point for optimization of τc values.  The optimized τc values (Table 3.1) 
were then fixed for each model afterward.  Main chain and side chain dynamics 
calculations were performed with 300 Monte Carlo simulations per run using an 
internuclear N-H distance rNH of 1.02 Å and a chemical shift anisotropy (CSA) for the 
15N nucleus of -172 ppm for backbone and -114 ppm for sidechain38.  Five models were 
used to fit our experimental data and were iteratively tested in order of increasing 
complexity (M1= S2; M2= S2, τe; M3= S2, Rex; M4= S2, Rex, τe; M5= S2f, S2s, τe) until an 
acceptable fit was achieved.  S2 is the generalized order parameter, τe is the internal 
correlation time, Rex is the exchange contribution term, and S2f  and S2s are for sub-
nanosecond and nanosecond motions respectively.  These models were tested until they 
could reproduce the experimental relaxation data within 90% confidence limits using 
appropriate χ2 and F-tests.  Sidechain N-H’s predominantly fit to model 5 for apo-PMK, 
while the three ligand bound complexes fit best to model 4 in most cases.   
To address the concern of anisotropic rotation affecting the transverse relaxation 
of sidechain residues, we used our data from a previous dynamical study performed on 
the backbone residues of PMK.  In this study, we assessed ligand binding and dynamic 
properties of PMK and at the time there was no structure (axial-anisotropic model needs a 
structure to optimize Dratio for correlation time, which is the reason we could not use it in 
the current study of arginines as they are unassigned) so we could only use an isotropic 
model to assess correlation times of rotation (ns).  Using the isotropic model and average 
R2/R1 as an initial estimate of τc, the correlation times were estimated for each complex 
(Table 3.1). 
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Table 3.1. 
 Apo-PMK M5P MgADP M5P/MgADP 
τc (ns) 15.6 13.5 17.6 15.8 
 
To test whether anisotropic rotation affects the correlation times of the previous study, we 
will rely on the crystal structure of human PMK and use the axial model of diffusion, 
which relies on the structure of the protein in which a global axially symmetric diffusion 
tensor is used for all spins.  From the structure we have the calculated Dratio for human 
PMK (0.88), giving it somewhat of a disc shape.  This input as well as the data from the 
previous study gives us new estimated correlation times based on the anisotropic rotation 
of PMK (Table 3.2). 
 
Table 3.2. 
 Apo-PMK M5P MgADP M5P/MgADP 
τc (ns) 15.4 13.9 19.1 17.0 
 
The S2 values from these data are nearly the same as the reported values of the previous 
study, validating that the use of the isotropic model in calculating the dynamic properties 
of PMK.   
 
3.3 Results and Discussion 
3.3.1 Arginine Assignment and Chemical Shift Perturbation 
Since PMK is a rather large protein (24 kDa), in terms of NMR studies, samples 
were prepared with only arginines having the 15N label (Figure 3.2A). This allowed us to 
make sure that every arginine backbone residue was considered, without concern for 
signal overlap, along with the ε-N−H’s of the side chain. Other arginine side-chain 
N−H’s, though labeled, exchange too rapidly to be observed. Because PMK has 
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significant resonance overlap in the backbone N−H region and also because of significant 
relaxation that precluded side-chain assignments via TOCSY experiments, only half of 
the arginine residues could be assigned. The assigned arginines are labeled accordingly 
on the spectra, and the rest of the arginine backbone N−H’s are labeled R-A through R-I. 
The ε-N−H’s of the arginine side chains are shown at the top of Figure 3.2A and 
expanded in Figure 3.2B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. 1H-15N HSQC spectra of (A) 15N-Arg-PMK with backbone residues labeled 
and (B) expansion of arginine sidechain region with cross-peaks labeled and spectra of 
mutational assignments (boxes).   Spectra were of 500 µM PMK (20 mM potassium 
phosphate, 5 mM DTT, 10% D2O, 10% d6-glycerol) acquired at 298K on a 600 MHz 
Varian NMR System. 
Many attempts were made to assign the arginine ε-N−H’s to their respective 
backbone amides using various NMR spectroscopy experiments including HNCO, 
HNCA, HNCACB, CC(CO)NH, and 15N-NOESY.  Displayed in Figure 3.3 is the HNCA 
experiment of 15N/13C-Arg and U-13C PMK to assign the CHd of the arginine side chain.   
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Figure 3.3. HNCA of  15N/13C-Arg and U-13C PMK. Spectra are of PMK that is 
uniformly 13C labeled, and has 15N label present only in arginines. Spectra are 2D 1H-13C 
(top) and 1H-15N (bottom) planes from the 3D HNCA experiment.  
 
 
 
These spectra provide confirmation for arginine specific labeling, versus metabolic 
scrambling of label into other amino acids. Sidechain crosspeaks show connection of the 
NHe proton to the CHd of the sidechain.  Partnering experiments HNCACB and 
CC(CO)NH to assign the CHd of the side chain with the b and g protons as well as the 
amide N-H gave little signal; not enough to resolve assignments. Spectra in panels (A) 
and (B) of Figure 3.4 are standard 1H-15N HSQC spectra, of backbone and sidechain 
regions of 15N-Arg labeled PMK, and are provided for comparison with HNCO 2D 
planes (panels (C) and (D)). The 1H-15N plane from the 3D HNCO spectrum (panel (C)) 
shows crosspeaks for arginine backbone 15NH’s, adjacent to 13C=O carbonyls, but also 
for arginine sidechain 15NHe’s, adjacent to 13C=NH2 iminos, of the guanidinium groups. 
Panel (D) shows the corresponding 1H-13C HNCO plane, that correlates proton shift of 
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the arginine backbone or sidechain epsilon 15NH with 13C chemical shift of the adjacent 
carbonyl or imino carbon. Imino 13Cz shifts are identified with red lines. In panel (C), the 
R150 backbone and all NHe sidechain crosspeaks are folded, as are the sidechain 13Cz 
crosspeaks in panel (D).  
The last attempt to assign the arginines using NMR was to use a 15N-NOESY 
experiment in which magnetization starts on the backbone amide and transfers to any 
proton within 5 Å, including the ε-N-H of the arginine side chain allowing for 
assignment.  This experiment was run with two isotropic mixing times of 80 and 150 ms 
with both experiments giving good signal to noise for the backbone amides however the 
signal on the ε-N-H of the arginines are very weak (Figure 3.5).  This is likely due to the 
fact that magnetization, when on the ε-NH, was transferred rapidly to water and was 
subsequently destroyed with water suppression, which led to a decrease in signal 
intensity (red box in Figure 3.5) as compared to backbone NH intensity.   Attempts to 
solve this issue using various forms of water suppression proved unsuccessful. 
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Figure 3.4. HNCO and HSQC spectra of  15N/13C-Arg and U-13C PMK. Spectra are of 
PMK that is uniformly 13C labeled, and has 15N label present only in arginines. 
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Figure 3.5.  15N-1H plane from a 15N-NOESY experiment of 500 uM apo-PMK in 20 
mM potassium phosphate at pH 5.5. 15N-NOESY was run with a mixing time of 150 ms, 
ε-NH signal was weak (shown in red box) compared to backbone NH’s, due to increased 
exchange with water. These data are shown, to demonstrate the infeasibility of arginine 
sidechain assignment using the NOESY experiment. Similar problems were encountered 
with TOCSY experiments as well. 
 
 
We had to then resort to assigning these arginines using point mutations.  The 
mutants R18M (arginine # 18 mutated to a methionine), R84M, R110M, R111M, 
R130M, and R141M proteins were all expressed in 15N minimal media so that these 
mutated arginine side chains could be identified in 1H-15N HSQC based on perturbed 
chemical shifts.  Figure 3.6 shows four of the mutant PMK 1H-15N HSQC spectra (R84M, 
R111M, R141M, and R130M) with the black spectra being native apo-PMK chemical 
shifts and red being the corresponding mutant PMK.  In the R84M and R111M panels, 
notice that mutation causes the 3 crosspeaks on the left to be perturbed, broadening or 
shifting, suggesting that these arginine sidechains are likely to be in some proximity to 
each other.  This is consistent with the titration of M5P onto apo-PMK (Figure 3.7), that 
showed these same 3 cross peaks broaden upon binding.  The R141M mutant causes 
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some cross peaks to change slightly, however one crosspeak (SC-12) clearly disappears, 
suggesting it is most likely from the ε-NH of R141.  As with the R141M mutant, the 
R130M mutant causes cross peaks to change slightly, however SC-5 completely 
disappears, implying this is probably the ε-NH of R130.   
 
To monitor arginine involvement in the binding of PMK’s substrates, chemical-
shift titration experiments were performed (Figure 3.7).  Increasing amounts of M5P and 
MgADP were added to PMK, and the arginine backbone and side chains were monitored 
using 1H−15N HSQC spectra. The majority of the arginine N−H’s showed very small 
chemical shift changes, indicating little change in chemical environment for residues 
labeled SC-2 and SC-5−13. For residues labeled SC-1, -2, and -4, the chemical shifts 
were exchange-broadened, indicating some change in environment and motion due to 
binding of M5P (Figure 3.7C). This experiment was duplicated using MgADP (Figure 
3.7D), monitoring chemical shift changes as before. Only SC-1, -2, and -4 showed large 
chemical shift changes, suggesting that they are involved in binding. 
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Figure 3.5.  Assignment by site-directed mutagenesis.  Overlaid 1H-15N HSQC spectra of 
the arginine ε-NH region where black indicates apo-PMK arginine chemical shifts, and 
red is for mutant (R84M, R141M, R111M, and R130M) PMK chemical shifts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. (A) 1H-15N HSQC spectrum showing Arg-PMK chemical shifts, including side chains 
(top) and backbone (bottom). (B) Expanded region of side chain chemical shifts. (C) Chemical 
shift titration showing effect of increasing amounts (100 uM increments) of M5P added to apo-
PMK (red) to saturation (1 mM) shown in gray.  (D) Chemical shift titration of increasing 
amounts of MgADP added to apo-PMK (red) to saturation (1 mM), shown in gray.  (E) Chemical 
shift titration of increasing amounts of M5P added to the  MgADP/PMK complex (red), forming 
the ternary complex (1 mM) shown in gray.  Backbone and sidechain 15N-H atoms, monitored in 
the spectra, are identified on the arginine structure (blue) shown in the inset in panel A, although 
the ε-N-H is the only observable sidechain NH, since it is the least acidic (least prone to exchange 
with solvent).  Spectra were taken at 600 MHz at 298 K.  Arginine backbone assignments are 
indicated, when available.  SC-1 to SC-13 are unassigned arginine side chain N-H’s (no side 
chains have been assigned).  R-A to R-I are unassigned arginine backbone N-H’s. 
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3.3.2 Arginine Dynamics 
Dynamics experiments were performed as before, where we showed that 
substrate-induced domain movement occurs in PMK.39  The longitudinal relaxation rates 
(R1) were generally the same for the backbone and side chains for each particular 
complex and agreed with previous results39 (Figure 3.8 and Table 3.3). The transverse 
relaxation rates (R2) of the backbone N−H’s also correlated with our previous studies.39  
The side chains, however, showed a decrease in transverse relaxation rates relative to the 
backbone. This difference in R2 values for the apo-PMK arginine side chains was 
significant (half relative to backbone) while the difference in R2 between backbone and 
sidechain was small for the M5P/PMK complex, with the other two complexes showing 
an intermediate decrease (Figure 3.8). The 1H−15N NOE values for the side chains varied 
from residue to residue, but this variability was consistent between complexes. 
 
 
 Free M5P MgADP MgADP/M5P 
R1 (s-1) 0.78 ± 0.06 1.1 ± 0.13 0.89 ± 0.07 0.82 ± 0.09 
R2 (s-1) 14.0 ± 1.3 15.6 ± 1.5 15.6 ± 2.1 15.2 ± 1.9 
1H-15N NOE 0.30 ± 0.11 0.15 ± 0.08 0.28 ± 0.10 0.23 ± 0.11 
S2 0.47 ± 0.04 0.67 ± 0.09 0.64 ± 0.04 0.75 ± 0.06 
τc (ns) 20.1 15.5 22.0 18.4 
 
 
Table 3.3.  Average dynamic parameters for the ε-NH’s of arginine sidechains, with the 
correlation time (τc) of the backbone arginine residues used for calculating S2 values of 
the arginine sidechain N-H’s.  Note: These are only averaged in those cases where all 
four complexes have data for a particular sidechain residue.   
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Figure 3.8.  NMR dynamics data including R1, R2, and 1H-15N NOE values, where blue 
is apo-PMK, red is the M5P/PMK binary complex, yellow is the MgADP/PMK binary 
complex, and green is the M5P/MgADP/PMK ternary complex.  The sections are divided 
into assigned backbone N-H’s, unassigned backbone N-H’s and side chain guanido N-
H’s. These are the data that were used to calculate order parameters in Figure 3.9. 
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As in previous studies,39 a model-free analysis(2) was used to generate the 
generalized order parameter, S2. The S2 value is a measure of rigidity (where S2 = 1.0 
indicates complete rigidity and S2 = 0.0 complete fluidity) on the nanosecond-to-
picosecond time scale for the bond of interest,(1, 2) in our case the arginine backbone and 
side-chain N−H bond vectors. Model-free analysis can also differentiate between global 
and local motions. In our previous work on PMK, we showed that domain movement 
(global motion) was affected by ligand binding, with little attenuation of local motions. In 
the side-chain studies presented herein, it was observed that ligand binding causes the 
arginine ε-N−H’s to increase S2 on average from 0.47 in apo-PMK to 0.64−0.75 in the 
binary and ternary complexes (Figure 3.9 and Table 3.3).  As a control to test whether it 
is coulombic attraction that is causing these arginines to rigidify upon ligand binding, the 
same dynamics experiments were repeated as before except in 100 mM KCl buffer 
(Figure 3.10). Addition of KCl into the buffer causes the R2 values the MgADP bound 
PMK to decrease on average from 15 sec-1 to 10 sec-1 which subsequently seems to cause 
the S2 values to decrease in every arginine NH (except SC-12/R141).  
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Figure 3.9. Generalized order parameters (S2 values) for all assigned and unassigned 
arginine backbone and sidechain ε-N-H’s, where blue is apo PMK, red is M5P/PMK 
complex, yellow is MgADP/PMK complex, and green is the M5P/MgADP/PMK ternary 
complex.  Using mutant forms of PMK, we have identified SC-3 and 4 belonging to 
either R84 and R111, and SC-12 as probably belonging to R141.    Nearly all arginine 
sidechain residues undergo a significant increase in S2 (i.e. rigidification) upon binding 
either ligand. 
 
 
Distance to Nearest 
Neg. Charge (ε-NH) 
S2 Values of PMK Complexes Residue 
Number 
Tentative 
Assignment 
Distance Atom Apo M5P ADP Ternary 
SC-3 R84 3.0 Å Carboxyl 
of M5P 
0.588 ----- 0.875 0.648 
SC-4 R111 2.6 Å Carboxyl 
of M5P 
0.593 ----- ----- ----- 
SC-5 R130 14 Å γ-
phosphate 
of ATP 
0.417 0.618 0.730 0.734 
SC-12 R141 14 Å α- 
phosphate 
of ATP 
0.418 0.597 0.667 0.802 
 
Table 3.4.  Distance from arginine sidechain NH (for those that were tentatively assigned 
using site-directed mutagenesis) to the nearest negatively charged atom on either 
substrate. Also shown are changes in order parameter, when available. Note that while 
R141 is close to substrate, it is still distal from any charged atom on the substrate.  
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Figure 3.10. Effect of adding 100 mM KCl. NMR dynamics data of arginine side chain 
ε-NH’s of PMK including the R1and R2 relaxation rates, 1H-15N NOE, and the 
generalized order parameter (S2), where blue is Apo PMK, red is Apo PMK in NMR 
buffer including 100 mM KCl, yellow is MgADP bound PMK, and green is MgADP 
bound PMK in NMR buffer including 100 mM KCl. 
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It should be noted that MgADP bound PMK without salt was able to fit to model 
4 while addition of salt seemed to cause the dynamical changes to fit only model 5.  It 
should also be noted that the backbone NH’s of MgADP bound PMK with in high salt 
behaved the same way as with regular NMR buffer (in terms of S2 values), suggesting 
that only the ε-NH’s are affected by the high salt.  This leads to the conclusion that ligand 
binding causes arginine side chains to rigidify throughout the protein, even distal to the 
binding site, perhaps as a result of long-range Coulombic interactions with the substrates. 
The S2 values for the arginine backbones corresponded to our previous results39 on fully 
15N labeled PMK, where we reported changes in τc due to domain motion, analogous to 
those in adenylate kinase where the differences are attributed to different buffer 
conditions. Surprisingly, the backbone dynamics changes were minimal, in stark contrast 
to the side-chain effects. 
 
3.4 Conclusion 
It has been noted in studies of side-chain methyl groups that changes in the 
dynamic state of side chains may not be well-reflected in changes observed in the 
backbone.40, 41  We also have observed quite large differences between the backbone and 
side-chain responses to substrate binding. Whether such dramatic differences between 
side-chain and backbone dynamics changes are common in arginines (vs aliphatic side 
chains) and/or in interactions with highly charged substrates (multiple phosphate groups) 
cannot be concluded until more arginine side-chain dynamics studies on other proteins 
are reported. 
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While it is possible that substrate binding simply causes a global rigidification of 
side chains in PMK, this seems unlikely. We propose that side chains rigidify because of 
Coulombic attraction from the highly charged substrate(s); in support of this hypothesis, 
the ADP-induced S2 effect is abolished in high salt (Figure 3.10). This must be a long-
range effect, since only four arginines are within 4 Å and only six arginines are within 8 
Å, even though 10 arginine side chains rigidify (Figure 3.9). 
In summary, we have shown that substrate binding to PMK causes arginine side 
chains to undergo a transition from a flexible to a rigid state. The magnitude and global 
nature of this effect is significant. Besides providing mechanistic insights, such studies 
will facilitate computational docking by identifying flexible side chains that can be 
allowed to sample conformational space during the docking calculations. 
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CHAPTER IV. Proteomic Investigation of the N- Teriminal Disordered Region of 
Unknown Function in Human Phosphomevalonate Kinase 
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4.1 Introduction 
 
4.1.1 N-terminal Peptide of PMK and Aims to Discover Function 
 
The most noticeable feature of the order parameter profile (Figure 4.1) of 
backbone amides in PMK is in the N-terminal region, which has no homology to 
adenylate kinase or to the T4 deoxynucleotide kinase template, upon which the homology 
model was based.  But, there is a dramatic and sharp change in S2 from a disordered state 
(S2≈ 0.4) to an ordered state (S2 > 0.8), occurring immediately after Arg9 where the 
homology model starts. The fact that these nine residues are completely disordered in apo 
Phosphomevalonate Kinase (PMK), and all binary and ternary complexes, combined with 
the fact that organisms such as C. elegans lack this N-terminal segment entirely, suggests 
it is not an integral part of the PMK structure.14  Indeed, inspection of the homology 
model reveals no potential structural role for these nine N-terminal residues.  This led us 
to speculate that these residues may be part of a signal or regulatory peptide, which might 
be cleaved off by an as-yet unidentified protease (note: this region shows no homology to 
membrane-binding peptides, and there are no data suggesting PMK is membrane bound).   
To determine the function, if any, of this N-terminal region, we mixed human 
liver proteins with 15N-PMK to determine if any proteins in liver tissue bind to or cleave 
PMK.  We also attempt to identify those proteins that do bind by purifying them using an 
affinity column with just the N-terminal disordered region (synthesized peptide) 
covalently attached to a column.  Proteins that bind to the affinity column, and are eluted 
by free peptide, will be identified by mass spectrometry (MS).  Finally, to ensure that 
those proteins that are identified do actually bind to the peptide, saturation transfer 
71 
difference STD NMR binding studies are performed with the liver proteins and the PMK-
derived peptide. 
 
 
Figure 4.1: S2 values of the backbone amide N-H’s of human PMK with the hinge 
regions and domains labeled.  Note the 9-residue signal peptide S2 values at amino acid 
number 1-9.   
 
 
 
4.2 Methods and Materials 
 
4.2.1 Instruments and Materials 
All NMR experiments were performed on a 600 MHz Varian NMR System 
instrument equipped with a triple resonance cryoprobe and z-axis gradients.  Peptides 
were synthesized at the Medical College of Wisconsin where they were prepared with the 
N-terminus acetylated.  All NuPage and Novex products used for SDS-PAGE 
experiments were purchased from Invitrogen.  All other chemical reagents, including 
activated CH Sepharose 4B, as well as human liver proteins (cytoplasmic) were 
purchased from Sigma Aldrich.   
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4.2.2  15N-1H HSQC Spectra of PMK with Human Liver Proteins Added 
 
 15N-PMK was exchanged into a buffer containing 20 mM potassium phosphate 
and 5 mM DTT at pH of 5.5.  Liver proteins and 500 uM PMK was combined into equal 
volumes in an NMR tube to attain 400 uL total volume.  HSQC spectra were acquired 
after liver protein addition, at 6 hours, and at 24 hours to assess if any changes in 
chemical shifts occur with time.  HSQC spectra were then processed using NMRPipe and 
NMRDraw using a 90° shifted sine bell function in 1H and 15N dimension.   
 
   
4.2.3 Peptide Affinity Column Preparation and Purification of Liver Proteins 
 
  Both peptides were prepared for coupling to the column resin the same way.  One 
gram of CH Sepharose was added to 200 mL of 1 mM HCl solution and the resin was 
allowed to swell for 15 minutes.  This solution was then filtered into a column and 
washed with 500 mL of 1 mM HCl.  The resin swelled to a volume of around 3 mL.  To 
couple the ligand to the resin, 10 mg of ligand (1.7 mM) was dissolved into 3 mL of 
coupling buffer that consisted of 0.1 M NaHCO3 and 0.5 M NaCl at pH 8.0.  The 3 mL of 
peptide ligand solution was added to the resin in the column and shaken at room 
temperature for 2 hours, to permit chemical coupling by reaction of ligand amino groups 
with the N-hydrosuccinamide groups on the resin.  After two hours, the residual ligand 
was washed with 30 mL of coupling buffer.  The remaining active groups of the resin 
were blocked with 0.1 M Tris buffer at pH 8.0 by washing the resin with buffer and 
letting the resin incubate in the buffer for 1 hour.  The resin was washed with alternating 
washes of 0.1 M acetic acid with 0.5 M NaCl at pH 4.0, then with 0.1 Tris-HCl with 0.5 
M NaCl at pH 8.0.  This was done to ensure that no free peptide ligand remained bound 
via ionic interactions.  The column was then packed using a Pharmacia LKB peristaltic 
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pump with 50 mM phosphate buffer with the same pH as the human liver proteins, pH at 
7.4.  It was packed until the bed volume stabilized.  100 uL of human liver proteins were 
then added to 100 uL of phosphate buffer, and then added to the top of the resin.  The 
resin was then washed with the phosphate buffer, and fractions were monitored by UV-
Vis until A280< 0.005, indicating that there was no more protein being eluted from the 
column.  Competitive elution was used to elute any bound protein from the column: 20 
mg of peptide (control or N-terminus) was dissolved into 5 mL of phosphate buffer with 
0.5 M NaCl at pH 5.0 to give a 2 mM peptide solution, and all 5 mL of the peptide 
solution was added to the resin and phosphate/salt buffer was added to the column after 
the 5 mL went through, and all eluent was collected in a single fraction.  The eluent was 
then filtered using a Millipore Amicon-4 Centrifugal Filter with a 10,000-dalton cutoff.  
This solution was concentrated down to approximately 100-200 uL and a SDS-PAGE gel 
was used to determine the molecular weights of the eluted proteins (Figure 4.4).  To get a 
more precise MW value, the log value of all the MW marker proteins vs. the Rf values of 
protein bands was plotted and fitted.  This gave a fitted equation of y=-1.815x + 2.444, 
where y is the log of MW and x is the Rf of the unknown protein in the eluent.  The 
samples were then sent to the Medical College of Wisconsin Protein and Nucleic Acid 
Facility for tandem MS (ESI) based identification, based on sequencing of tryptic 
peptides from the eluted protiens.  The trypsin digested peptides derived from the whole 
proteins were searched against a database of human protein mass spectra fingerprints to 
then identify the eluted proteins, using standard methods. 
 
 
 
 
74 
 
4.2.4 Saturation Transfer Difference (STD) of Hemoglobin with Peptide 
Fragments Present 
 STD NMR studies were recorded at 298 K with 1 mM N-terminal peptide and 
100 µM hemoglobin, and using the Varian cyclenoe pulse sequence.  1D-1H NMR 
spectra were taken in advance, for both protein and peptide, to select the proper 
frequency for irradiation.  During the STD experiment, alternating on-resonance 
irradiation of the protein methyl region (around -2.5 ppm), and off-resonance irradiation 
at a region far from any protein or peptide signals (-10 ppm) was used.  The spacing and 
pattern values were set to 20 and 5, while cycle was set to y and tau to 100 ms, with the 
saturation power at -10 dB.  The total irradiation time was set to 4 s, with 512 transients 
collected for each experiment.  All 1D-1H NMR spectra and 1D STD spectra were 
processed using iNMR on a Mac workstation.  Exponential multiplication was used with 
2 Hz line broadening for all spectra.   
 
4.3 Results and Discussion 
4.3.1 Signal Sequence Database Search 
To begin exploring the hypothesis that the 9 N-terminal residues of PMK have a 
functional/signaling role, and to identify which protease might cleave this N-terminal 
peptide, an exhaustive search of signal sequence databases was performed, searching 
only against the peptide sequence in question (i.e. Met1 to just past Arg9). While none of 
these searches yielded a strongly scoring motif hit, one did give a modest scoring 
prediction of cleavage immediately after Arg9: 
PLGGAPR∨LV 
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This site was identified using the ProP 1.0 server, using a neural network model trained 
using literature sequence data.42  While the score for the cleavage site was relatively low 
(0.112; scores in the 0.5-1.0 range are considered high probability), it is the best scoring 
motif hit obtained thus far, and should be interpreted in the context of NMR data that 
indicate cleavage, if it occurs, is expected at exactly this site (after Arg9). The enzyme 
predicted to cleave here is a furin-like protease, which belongs to a family of proteases 
broadly classified as “proprotein convertases.”43-46 Interestingly, there is growing 
evidence in recent years that proprotein convertases affect cholesterol levels and lipid 
metabolism, largely by undefined mechanisms.47, 48  Furthermore, data have indicated 
that inhibiting the proprotein convertase PCSK9 may be an effective means to treat 
hypercholesterolemia and associated cardiovascular disease, as a complement to statin 
treatment,45, 46 based on the observation of synergistic lipid lowering effects.  Many of the 
newly discovered proprotein convertases, including PCSK9, do not have any known 
substrates, and therefore have poorly defined peptide recognition motifs.  As such, we are 
now pursuing studies to identify which, if any, proprotein convertase might cleave the 
disordered PMK N-terminal peptide, and what affect this cleavage might have.  Likewise, 
it is possible that a protein other then a proprotein convertase may recognize this 9 amino 
acid sequence, and our studies endeavor to identify this protein.   
 
4.3.2 Human Liver Proteins Binding to PMK  
 A 15N-1H HSQC 2D NMR spectrum was acquired before human liver protein 
addition and at each time point after.  If any protein binds to or cleaves the N-terminal 
region of PMK, then we should notice chemical shift changes in the N-terminal amino 
76 
acid residues, especially residues 1-9.  As shown in Figure 4.2 there are no chemical shift 
changes in any residues when comparing purified PMK (black) to PMK after the liver 
proteins have been added (red), then after 4 hrs. (green), and after 24 hrs. (blue).  So, 
HSQC data suggest that no liver proteins bind to or cleave PMK.  This could be for any 
of several reasons, the first being that the concentration of the protein that may be doing 
the binding or cleaving is not in high enough concentration to produce any chemical shift 
changes.  The approximate PMK concentration was 250 µM when mixed with liver 
proteins.   To see any chemical shift changes, the protein(s) that bind would have to be 
close to that concentration (at least > 25 µM) to produce any detectable chemical shift 
changes.  Another reason that we may not see binding is due to the additional 20 amino 
acid chain on the N-terminal region of PMK.  This chain contains the histidine tag region 
that was engineered onto PMK to facilitate purification, and this tag may block binding to 
other proteins.  Finally, it is of course possible that no human liver proteins bind to and/or 
cleave this N-terminal sequence.   
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Figure 4.2:  1H-15N HSQC 2D spectra of human PMK (black) and PMK incubated with 
human liver proteins directly after addition (red), 4 hrs. after addition (green), and 24 hrs. 
after addition (blue).   
 
 
4.3.3 Purification of Human Liver Proteins That Bind to the Synthesized N-
terminal Peptide Sequence 
 
Activated CH-Sepharose 4B resin is designed to be specific for reaction with 
primary amino groups.  At lower pH, the NHS (N-hydroxysuccinimide) ester becomes 
available for attack (Figure 4.3) by ligands with active primary amino groups.  As stated 
in the previous section, the disordered N-terminal region starts at Met1 and ends with 
Arg9, so we had this peptide sequence synthesized with those 9 residues with an 
additional 4 residues from the sequence and 7 more amino acids added as a flexible and 
hydrophilic linker, with the two-lysine residues at the C-terminal end to react with the 
NHS ester on the resin: 
Acetyl-MAPLGGAPRLPLLGSGSKSK 
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 These lysine residues (KSK) have the primary amino groups needed to react with the 
resin.  To ensure that the amino group of Met1 does not react with the resin, we had the 
N-terminal residue acetylated.     
 
 
 
 
Figure 4.3: Chemical reaction of activated CH sepharose 4B with the primary amine of 
the amino acid lysine.   
 
 
The column purification and subsequent concentration of the eluent yielded seven 
clear bands on the SDS-PAGE gel (Figure 4.4).  The molecular weights, as determined 
by the measuring Rf values of the bands in the gel, are 13.7, 43.7, 52.4, 61.3, 65.1, 73.3, 
142.8 kDa.  Some of the proteins that correspond to the molecular weights, determined 
by mass spectrometry (MS), are represented in Table 4.1.   
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Figure 4.4: SDS-PAGE gel of eluted human liver proteins from the affinity column with 
covalently attached A) N-terminal PMK peptide and B) scrambled N-terminal PMK 
peptide.  Note: Gel B is much darker due to longer staining time, to make sure that every 
band is resolved.   
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Table 4.1. Human liver proteins with the highest probability of being bound to the N-
terminal region of human PMK.  These proteins were bound to the N-terminal peptide 
that was covalently attached to the affinity column. 
 
 
  
 In this MS anaylsis, protein probability is the likelihood that the peptides that 
were sequenced are for the “identified” protein.  Peptide count is the number of 
sequenced peptides in the sample that are present in the “identified” protein; scan count 
represents the number of times the peptide was identified in the MS-scanning process 
(reflects S/N); percent coverage is the percent of the total protein sequence covered by 
the sequenced peptides, and MWT is the molecular weight of the identified protein.  Of 
all the categories, probably the most important is percent coverage, along with score.  
According to these criteria, the highest rated proteins are hemoglobin subunits α (52.4% 
coverage) and β (37.1% coverage) as well as L-xylulose reductase (25.5% coverage).  
Hemoglobin is a tetramer with two α subunits and two β subunits that are used for 
oxygen transport from the lungs to the rest of the body, where the oxygen is released for 
cell uptake.49  L-xylulose reductase is involved in the uronate cycle of glucose 
metabolism and catalyzes the reduction of xylulose into xylitol.50  Currently, we have no 
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reason to suspect that either of these proteins would interact with PMK, however we are 
testing to determine whether hemoglobin binds the N-terminal peptide fragment (vida 
infra). 
 To make sure that the human liver proteins are not binding non-specifically to 
something else in the column, such as support material, we had another peptide 
synthesized using the same procedure as the first, except the amino acids that comprise 
the PMK signal peptide were scrambled.  We did this by assigning a number to each 
amino acid then used a random number generator to scramble the order of the amino 
acids.  To make sure there were no important amino acids still together in the sequence 
(Arg9 and those residues before and after it) we manually adjusted the sequence, as 
needed.  This led to the following peptide, which was synthesized at MCW: 
Acetyl-LARGPMLGLLAPVGSGSKSK 
We preserved the final 7 amino acids so that they still bind the peptide to the sepharose 
support.  Figure 4.4B shows the concentrated eluent from the scrambled N-terimanl 
region peptide of PMK.  The bands look nearly the same between the two gels, however 
at 15 kDa, there appears to be no band present for the scrambled peptide indicating that 
there was no binding of any protein to affinity column at that molecular weight.  This 
indicates that something does indeed bind to the natural N-terminal region of PMK 
(Figure 4.4A) with the molecular weight of 15 kDa.  This strongly supports the MS data 
(Table 4.1) that hemoglobin (with a molecular weight of approx 15 kDa) could be the 
protein that binds to PMK’s N-terminal disorderd region.   
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3.3.4 Saturation Transfer Difference STD NMR Binding Assay to Determine if 
Hemoglobin Binds to the N-terminal Disordered Region of PMK 
 
Saturation transfer difference (STD) is a relatively new NMR technique in which 
a certain frequency region of the NMR spectra is irradiated; mainly the methyl region and 
difference spectra are measured.  This irradiation of protein methyl protons leads to 
magnetization transfer via spin diffusion from the methyl protons to the rest of the 
protein.51  If a ligand binds to the protein in fast exchange, magnetization is then 
transferred to the ligand, giving rise to a 1-D difference NMR spectrum for that ligand 
(the “NOE difference spectrum”).  As mentioned in methods and materials, a 1-D 1H 
NMR spectrum was taken of both the peptide and the hemoglobin, to determine the best 
spectral region for irradiating (Fig. 4.5).  As shown, there is signal as low as 0.6 ppm for 
the ligand and -2.5 ppm for the protein.  The STD experiment (Figure 4.6B) with 
hemoglobin and peptide, with irradiation of the methyl region at -2.5, gave only a modest 
increase in STD signal at 0.6 ppm, for peptide.  To determine if we are observing 
artifactual STD of just the peptide, a control experiment was run in which only the 
peptide (no hemoglobin) was subjected to an irradiation at -2.5 ppm (Figure 4.6A).   
When the spectra are overlaid on each other using the same noise level as 
reference what is observed is that the STD signal with hemoglobin present is roughly 
twice the signal for the control STD experiment with peptide alone.  This doesn’t 
necessarily mean that peptide binds to hemoglobin, as generally the STD signal is much 
larger. It is possible that STD signal is attenuated because binding is too tight (STD 
signal requires fast exchange binding).  If a ligand binds to tightly, no STD signal will be 
observed, as the ligand won’t be released before the magnetization that was transferred 
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from the protein decays.  More experiments will have to be done to confirm whether the 
N-terminal peptide does in fact bind to hemoglobin.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. 1-D 1H NMR spectra of hemoglobin to determine methyl irradiation for STD 
NMR spectra.  Note: methyl regions extends to -2.4 ppm. 
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Figure 4.6: 1-D STD NMR spectra of A) the N-terminal region peptide and B) the N-
terminal region peptide with 100 µM hemoglobin.  An expanded overlay of the possible 
STD signal in the upper right corner. 
 
 
 
4.3.4 Conclusion 
The N-terminal region of PMK was synthesized and used in NMR and affinity 
column binding experiments to determine if there are proteins in the human liver 
proteome that bind to it and/or cleave it.  We have identified proteins from human liver 
tissue that may bind to the N-terminal peptide of PMK, using tandem mass spectrometry 
(ESI), with hemoglobin being the most likely binding partner.  Hemoglobin was then 
used in NMR STD binding experiments to determine if binding of hemoglobin to peptide 
does actually occur.  However, it is still unclear if such binding does occur.  An 
alternative strategy to verify binding is to have the peptide synthesized with one of the 
amino acids in the sequence labeled with 15N, which will then give a signal in 1H-15N 
HSQC spectra, and which will permit monitoring of binding of the peptide to protein 
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based on chemical shift changes.  The peptide could also be synthesized with a 
fluorescence tag, and we could monitor binding to hemoglobin based on fluorescence 
changes. 
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Chapter V. Solution Structures of Oxidized and Reduced forms of 
Thioredoxin C, and Models to Describe the Intact Thioredoxin System from 
Mycobacterium tuberculosis 
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5.1 Introduction 
 Mycobacterium tuberculosis (M. tb) is the causative agent of the infectious 
disease tuberculosis, and is a devastating pathogen that has affected (new and previously 
occurring infection) nearly 11 million people and a mortality rate of 1.3 million people in 
2008.52  It is also thought that a third of the population is infected, with a latent form of 
the disease, which is not infectious.53  The pathogen resides in the alveolar phagocytes 
and can resist the oxidative killing of the cell however this mechanism is still unclear.54  
The method by which phagocytes kill the invading microbes is by the production of 
reactive oxygen and nitrogen species, including superoxides and hydrogen peroxide, 
which can create free radicals that become toxic to the microbe.55  One method that M. tb 
uses to resist this oxidative killing is by the same process that eukaryotic cells use to 
combat oxidative stress.  In other prokaryotes, this is done by the thioredoxin system, 
which keeps the cell in a reduced state, based on it’s ability to control the redox state of 
cellular thiols/disulfides.56, 57   
 Thioredoxins are well-studied proteins, and found in almost every organism.58  
They share common features such as a similar three-dimensional structure, a conserved 
catalytic motif of WCXXC in the active site of the protein, and a molecular weight of 
about 12 kDa.59  Thioredoxins catalyze thiol-disulfide exchange reactions using redox 
active cysteine thiols to reduce oxidized disulfide cysteines of other essential proteins, 
including metabolically essential enzymes.60, 6162  Oxidized thioredoxins are then reduced 
by thioredoxin reductase in an NADPH dependant reaction, via redox active cysteine 
thiols.63  Disulfide reductions occur via hydride transfer from NADPH to a bound FAD 
cofactor, followed by electron transfer from FADH2 to bound thioredoxin.  The 
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interaction and reaction between the thioredoxin reductase and the thioredoxin substrates 
are essential to keep the cell in a reduced state, and define what is called the thioredoxin 
system.  While the thioredoxin system of E. coli is well characterized, that of M. 
tuberculosis is not.64  If this system were disrupted, the M. tuberculosis pathogen would 
be more vulnerable to the oxidative attacks of our immune cells (neutrophils, 
macrophages).  
 The thioredoxin system in M. tb is comprised of three thioredoxins (TrxA, TrxB, 
and TrxC) and one thioredoxin reductase (TrxR).54, 64, 65 Many organisms have multiple 
genes encoding thioredoxins, which is probably a function that enables coping with the 
amount and perhaps type of oxidative stress in a cell.  It has been shown that TrxB and 
TrxC behave as general disulfide reductases with near equal reduction potential, while 
TrxA is observed to have a weak capacity to act as a disulfide reductase, and was found 
to not be a substrate of TrxR.64  It was also observed that the ability of M. tb to survive 
redox stress isn’t dependant on the expression of one thioredoxin over another, which 
suggests that having multiple thioredoxins may be a “redundant system” to ensure 
survival under oxidative conditions.64   
 It is for these reasons, and the severity of the tuberculosis disease, that make the 
thioredoxin system of M. tb a suitable target for drug inhibition, as long as a drug could 
be designed knock out the whole thioredoxin system (ex. inhibit TrxR binding).66  There 
has been some work done on the inhibition of TrxC signaling.67  The crystal structure of 
TrxC in the oxidized state has been solved to help facilitate those studies.65  Previous 
studies of the different redox states of prokaryotic thioredoxins have shown that there are 
subtle changes in structure in going from oxidized to the reduced state.68-70  Most of the 
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changes are occuring in the active site, around the redox active cysteines, with some 
conformational flexibility observed in the active site loop.68, 71  The secondary structure 
of the whole protein remains the same, as the thioredoxin goes from oxidized to reduced 
state.  Whether this is also true in M. tb is not known, since there is no structure of 
reduced TrxC (or of any TrxA or B).   
 Here we report the NMR solution structures of Mycobacterium tuberculosis 
thioredoxin C in both the oxidized and reduced states, with discussion of structural 
changes that occur in going between redox states.  The NMR solution structure of the 
oxidized TrxC, when compared to the crystal structure, corresponds very closely.  
However, crystal packing may have caused an artifactual shift in the α4 helix in the 
reported crystal structure, compared to the solution structure.  With the previous report of 
the crystal structure of M. tb’s thioredoxin reductase (not bound to a Trx), we have 
modeled the complete thioredoxin system in the mechanism (catalytic cycle) for disulfide 
exchange.  This was based on existing structures of M. tb TrxR and both redox states of 
TrxC (our solution structures), and using the E. coli TrxR/Trx complex as a template for 
model building.72  
 
5.2 Methods and Materials 
 
5.2.1 Protein Expression and Purification 
 
 The plasmid containing the gene Rv3914 (TrxC) in the pET vector pET22b and 
gene Rv3913 (TrxR) in pET vector pET23a was obtained from Tuberculosis Vaccine 
Testing and Research Materials at Colorado State University and Shkhar C. Mande from 
the Center for DNA Fingerprinting and Diagnostics in Hyderabad, India.73  The plasmid 
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containing the expression constructs (with a C-terminal histidine tag) was transformed 
into E. coli BL21-(DE3) Rosetta cells from Novagen and grown overnight at 37° C, 
which was then used to inoculate 2 L of LB (Luria Bertani) media.  The media was 
closely monitored at O.D. 600 nm until the cell density reached an absorbance of 0.7, at 
in which point, the media containing the cells for expression of TrxR were induced with 1 
mM IPTG and the cells containing TrxC, the cells were then spun down at 4000 rcf and 
washed with M9 minimal media salts at pH of 7.0.  The cell pellets were transferred to 
0.5 L of M9 minimal media containing 0.5 grams 15NH4Cl and 2.0 grams of 13C-glucose 
as the only sources of nitrogen and carbon, to yield uniformly labeled protein.74  The cells 
were allowed to acclimate for 1 hour and then induced with 1 mM IPTG for an additional 
4 hours at 37° C, then cells were harvested.  The bacterial pellet was resuspended in 50 
mM Tris base, 300 mM NaCl, 5 mM imidazole, and 10% glycerol at pH of 7.8, and lysed 
using sonication.  The lysate was clarified by centrifugation at 15,000 RPM for 30 
minutes and the supernatant loaded onto 1 mL of nickel-Sepharose (Amersham Scienes) 
resin at 1 mL/minute.  The bound proteins (TrxC/R) were then washed with lysate buffer, 
then with lysate buffer containing 25 mM imidazole, and then eluted using lysate buffer 
containing 300 mM imidazole.  The eluted protein was than dialyzed with 40 mM 
potassium phosphate buffer at pH of 6.3 (NMR structures) and pH of 7.0 (TrxC/R 
binding experiments) and concentrated to 1 mM, with protein concentration determined 
by the absorbance at 280 nm using extinction coefficients of 11,000 and 14,440 L/mol-
cm for TrxC and TrxR respectively by using the resource ProtParam 
(http://expasy.org/tools/protparam.html).  To reduce the disulfide, 5 mM DTT was added 
to the protein samples.   
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5.2.2 NMR Spectroscopy and Structure Calculation 
  
 All NMR experiments were performed on a 600 MHz Varian NMR System at 
599.515 MHz using a triple resonance cryoprobe with z-axis gradients at 25 °C.  
Backbone assignments were obtained using 2D 1H-15N HSQC, and 3D HNCO, 
HN(CA)CO, HNCA, HN(CO)CA, CBCA(CO)NH, and HNCACB spectra (Figure 5.1).  
The side chains were assigned using CC(CO)NH, HBHA(CO)NH, HCC(CO)NH, and 
HCCH-TOCSY spectra.  Distance restraints were obtained from 3-D 15N-NOESY, 13C 
aliphatic NOESY, and 13C aromatic NOESY experiments which were obtained using 150 
ms mixing times.  Structures were calculated using these distance restraints with the 
program CYANA1, 2, in conjunction with backbone phi and psi angle restraints as 
predicted from TALOS3 based on chemical shifts of Cα, Cβ, Hα, Hβ, HN, and CO atoms.  
Initial structures were obtained using the noeassign macro of CYANA2, followed by 
manual refinement using the calibration of peaklists by the CYANA function caliba,75 
with the disulfide bond added as a restraint for the oxidized structure.  A final ensemble 
of 500 structures was calculated, and the 100 conformers with the lowest target function 
were then selected for water refinement using AMBER.   Using implicit solvent (which 
treats the solvent as a high dielectric continuous medium surrounding the protein near its 
van der Waals surface so it can interact with the charges on the low dielectric protein), a 
500 step energy minimization was first performed on the 100 structures (no restraints) 
followed by two cycles of 30 ps simulated annealing from 1000K to 0K, with distance 
and dihedral restraints applied.  After the MD simulated annealing, a 2000 step 
minimization with restraints was applied in implicit solvent and analyzed for distance and 
dihedral penalties and rank ordered by lowest AMBER energy.  The 20 lowest energy  
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  Selected strips from CBCA(CO)NH (left strip of residue) and HNCACB 
(right strip of residue where red peaks are Cβ and black peaks are Cα) spectra of residues 
30-38.  Blue lines indicate peaks used in sequential assignment of backbone residues.   
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structures were then selected for the final ensemble, and were subjected to analysis using 
the PSVS (http://psvs-1_4-dev.nesg.org/) server.  NMR spectra were processed using 
NMRPipe24 and analyzed using NMRView25 and Sparky (T. D. Goddard and D. G. 
Kneller, SPARKY 3, University of California, San Francisco).  In general, processing 
was performed with a cosine bell window function in the direct and indirect dimensions.  
All calculations were done using Pere and Condor submission process (NSF OCI-
0923037). 
 
 
5.2.3 Modeling of M. tb Thioredoxin Oxidoreductase Activity 
 
 The M. tb thioredoxin reductase structure (pdb code 2A87)54 had been solved in 
the oxidized state.  To create a model TrxR of in the reduced state, where the disulfide is 
converted to surface free thiols, available to react with and reduce thioredoxins, the 
coordinates of the E. coli homolog of TrxR bound to a thioredoxin (pdb code 1F6M)72 
were used as template.  The M. tb TrxR (oxidized) structure was superimposed on the E. 
coli TrxR (reduced) structure; but, the reduced E. coli TrxR is known to have a 66° 
domain rotation relative to the oxidized TrxR,54, 72 so this rotation was created in the M. 
tb structure.  To do this, the pdb file of M. tb TrxR was split at amino acids 117 and 241 
so that the FAD and NADPH domains could be separated.  The separated NADPH and 
FAD domain coordinates were then superimposed onto the coordinates of the E. coli 
NADPH and FAD domain using Pymol (The PyMOL Molecular Graphics System, 
Version 1.2r3pre, Schrödinger, LLC.), rejoined and then minimized using AMBER.  To 
model the various oxidation states of the TrxR/TrxC complexes, including the mixed 
disulfide bond between TrxR and TrxC, structures were minimized with a restrained 
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disulfide bond between the cysteines (oxidized) or left with no restraint (reduced).  All 
AMBER minimizations were performed with 2000 steps in implicit solvent.   
5.2.4 Thioredoxin System NMR Binding Experiments  
 Concentrated TrxC and TrxR solutions were buffer exchanged in 50 mM 
potassium phosphate at pH 7.0, to 1 mM each.  TrxC was diluted to 320 µM in the 
absence of DTT, so that it was in the oxidized state.  TrxR was then added to the TrxC 
NMR sample, so that both proteins were at equal concentrations of 250 µM.  NADPH 
was then added to the sample at 1 mM so that TrxR would reduce the disulfide of TrxC.  
As a control to test for binding in the presence of the different redox states of the 
cofactor, NADP+ was added to the sample at 1 mM.   1H-15N HSQC experiments were 
taken after every step, and pH was measured to ensure that it remains at 7.0.  As a control 
for the reduced state, 1H-15N HSQC spectra were acquired of TrxC in the oxidized state, 
and then reduced by DTT at pH 7.0.   
 
5.3 Results and Discussion 
 
5.3.1 NMR Structures of Oxidized and Reduced Thioredoxin C 
 
The solution structures of M. tb Thioredoxin C were solved by NMR, with 2036 
unique NOE derived restraints and 168 angle restraints in the oxidized state and 2114 
NOE restraints in the reduced state with 169 angle restraints.  Statistics describing the 
restraints used in calculation, precision to average coordinates, and quality of the 
structures are summarized in Table 5.1.  The ensemble of structures for oxidized TrxC 
has a backbone RMSD of 0.54 Å, and 0.50 Å for the reduced conformer (Figure 5.2A-D).  
To ensure that the cysteines were reduced, 5 mM DTT was added to the protein sample 
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and chemical shifts were monitored before and after each experiment, using a 1H-15N 
HSQC (Figure 5.3A-B) spectrum, to ensure there was no disulfide reformation.  Further 
confirmation of the reduction of the active site cysteines is provided by the decrease in 
the 13Cβ chemical shift from 44.6 to 26.9 ppm and 35.1 to 27.6 ppm for Cys37 and Cys40 
respectively.  The HSQC spectrum of TrxC shows good dispersion of chemical shifts.  
After addition of DTT, those residues that are affected the most are located along that 
active site loop, including F32, A34, T35, C37, G38, and C40.       
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1.  NMR and structure refinement statistics for the NMR solution structures of 
the oxidized and reduced states of M. tb TrxC, obtained using the program pdbstat. 
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Figure 5.2.  Solution NMR structures of A) the ensemble of oxidized TrxC with a 
backbone RMSD of 0.54 and B) is the median structure for this ensemble with the 
disulfide of C37 and C40 shown.  Panel C shows the ensemble of the reduced state of 
TrxC with a backbone RMSD of 0.50 and D) is the median structure for this ensemble 
with the free thiols shown.   
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Figure 5.3 2D 1H-15N HSQC spectra of A) the oxidized state of TrxC (red) with all the 
backbone N-H chemical shifts assigned, and B) the reduced state of TrxC (black) with 
the large chemical shift changes associated with going from the disulfide to free thiols 
labeled.   
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Analogous to the situation with the solution structures of the E. coli 
thioredoxins,68 the oxidized and reduced forms of TrxC are very similar to each other, 
showing only small differences between oxidized and reduced states, with a pairwise 
RMSD of 0.53 (calculated using Pymol) between ensembles (Figure 5.2A-D).  Compared 
to other thioredoxins, TrxC in both forms has the characteristic folding pattern of 4 α-
helices surrounding a 5 stranded beta sheet core, consisting of three parallel strands and 
two antiparallel.  The redox active cysteine residues C37 and C40 are located in the 
conserved active site loop (C37-G-P-C40) that leads into the α2 helix, which in both states 
is a bent helix.  The active site of TrxC includes a predominately hydrophobic core 
including two Ala (34 and 44), two Pro (39 and 81), an Ile (80), and a Val (43) residue.  
Both Trp (33 and 36) indole rings are all within 6 Å of the two Cys’s, with W36 forming 
the interface with the thioredoxin reductase.  The disulfide in the oxidized state has the 
typical 90° χ1 angle between the C-S-S-C linkage, and keeps roughly the same χ1 angle 
going to the free thiols.  The most drastic change is the distance of the Cys residue 
sidechains, with the S-S distance in the oxidized state of the median structure in the 
ensemble having a distance of 2.0 Å, and 3.5 Å in the reduced state (Figure 5.4). 
Although the α1 helices are nearly identical between the two states, it is 
somewhat of an irregular helix.  It is also present in the crystal structure of M. tb TrxCox65 
as well both E. coli Trx solution structures.  The α4 helix spans residues 101-111 
however it begins to show disorder at L108, while still keeping its secondary structure.  
There is some degree of difference between the two states in the random coil and turn 
region linking the α1 helix to the β3 sheet (22-26), and the α3 helix connecting to the β4 
sheet (75-81).  The latter region closely contacts the active site region.  These regions are 
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probably dynamic in nature, and are also evident in the E. coli solution structures of the 
different redox states, which resemble the M. tb solution structures (Figure 5.5).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.  The overlay of backbones for the median structures from the solution 
structures of TrxC in both redox states (with active site cysteines shown), where blue is 
the oxidized form and wheat is the reduced form.  Thiol and disulfide atoms from 
cysteines 37 and 40 are shown.   
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Figure 5.5.  Overlays of both redox states of solution structures from E. coli Trx and M. 
tb TrxC, where A) is the overlay for the oxidized states, with blue being from M. tb and 
green from E. coli and B) is the overlay for the reduced states, with wheat being from M. 
tb and purple from E. coli.   
 
 
5.3.2 Comparison to M. tb TrxC Crystal Structure 
 The M. tb TrxC crystal structure (pdb code 2i1u)65 was solved in the oxidized 
state, and is nearly identical in secondary structure to our solution structure, with a 
pairwise rmsd of 0.83 Å between the crystal structure and the median structure from the 
ensemble (Figure 5.6).  The major differences and the source of the high RMSD, is the 
orientation of the α4 helix.  It was noted in the crystal structure study that the protein 
crystals packed such that the C-terminal residues (110-114) in the α4 helix rested in the 
active site groove of an adjacent protein in the crystal lattice.  Based on our solution 
structure, this crystal packing seems to have caused the α4 helix to be pushed up 2.7 Å 
towards the β5 strand, and rotated in towards the β4 strand  (Figure 5.6).  Residues 108-
115 in the crystal structure are disordered, perhaps so that those residues can occupy the 
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active site neighboring protein.  However, residues 108-111 still retain helical shape (as 
mentioned above) before becoming disordered at residues 112-115 in our solution 
structure.  
 
Figure 5.6.  Overlay of the median structure of the NMR solution structure of oxidized 
TrxC (blue) and the crystal structure of oxidized TrxC orange with the active site 
disulfides shown.   
 
 
5.3.3. Oxidoreductase Activity of M. tb Thioredoxin Reductase and Thioredoxin C 
 To complete the redox cycle, after having reduced other proteins in the cell, TrxC 
itself must be regenerated to the reduced state.  As previously mentioned, it does this by 
serving as the substrate of thioredoxin reductase.  Figure 5.7 shows our models of 
TrxR/TrxC in different redox states, depicting the complete redox cycle between TrxR 
and TrxC, using the M. tb TrxR crystal structure54 and our TrxC structures (oxidized and 
reduced).  It has long been known that bacterial TrxR’s undergo a large conformational 
domain rearrangement, to place the reactive cysteines in a position so that they are able to 
react with the disulfide on its thioredoxin substrate.  The crystal structure of the M. tb 
α4	   α4	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TrxR is in the oxidized state (FO), with it’s disulfide buried in the protein interior, near 
the isoalloxazine ring of FAD so the reduced state of M. tb TrxR (FR), with the cysteines 
at the surface and the NADPH close to the FAD, was modeled using the E. coli 
thioredoxin reductase structure, which was crystallized in complex with thioredoxin (pdb 
code 1f6m).72  This E. coli structure was used as a template for proper positioning of the 
M. tb TrxR FAD and NADPH domains.  All the steps in the reaction sequence have 
corresponding structures or models (Figure 5.7), and are based on previous kinetic and 
structural studies of the E. coli system.76, 77     
 As shown in Figure 5.7A the catalytic cycle for the M. tb thioredoxin system is 
shown starting out in a conformation described as the “FR” state, so that the active site 
cysteines have just reduced TrxC and there are bound NADP+ and FADH2 cofactors in 
TrxR.  It is called the FR state because of the relative orientation of the NADPH and FAD 
domains such that the NADPH binding site is close to the FAD (and the thiol/disulfide is 
distal).  Assuming M. tb TrxR behaves as the E. coli reductase, it will then undergo a 66° 
rotation around the NADPH binding domain to bring the disulfide bonded cysteines 
(C145 and C148 with a bond length of 2 Å) closer to the isoalloxazine ring of FADH2, 
while the NADPH binding pocket moves away from the FADH2.  This positions the 
isoalloxazine ring within 3.7 Å of the S atom of Cys 148 (now TrxR is in the “FO” state), 
while releasing NADP+.  The FADH2 then reduces the disulfide by electron transfer 
(Figure 5.7B-C), now giving a sulfur inter-atom distance of 3.7 Å between the two 
cysteine thiols, although giving a slightly smaller χ1 angle.  After reduction, a general 
base (thought to be D149 which is 5.3 Å from the thiol of C148) abstracts the proton 
from C148 to produce a thiolate ready for attack to the oxidized cysteines of the 
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thioredoxin.77  NADPH then binds to TrxR, and the NADPH domain undergoes another 
66° rotation to bring the reduced active site cysteines away from the FAD isoallxazine 
ring, and back to the surface (back to the FR state) of the protein in the TrxC binding 
pocket (Figure 5.7D).  At the same time, the NADPH nicotinamide ring is brought to 
within 3.4 Å of the isoallooxazine ring of FAD so that it can reduce the cofactor back to 
FADH2.   The FADH2 can once again reduce the disulfide of TrxR, later in the catalytic 
cycle.   
 The TrxR is now in a conformation that can bind TrxC (Figure 5.7E), where the 
two proteins come together in a complex that is stabilized by hydrophobic interface 
produced by the FR state of TrxR residues F142 and F143 in TrxR, interacting with TrxC 
residues A34, P39, V43, A44, A72, V78, I80, and P81.  Figure 5.8 shows an expanded 
view of this binding interface, between the two proteins, with surface rendering showing 
the hydrophobic pocket.  Notice how Trp36, which is conserved in all thioredoxins, has 
its indole ring situated in the middle of this hydrophobic pocket, with the indole ring 
nitrogen NH hydrogen bonding to the carboxyl group of Asp66, at a distance of 1.9 Å.  
Such interactions with TrxC’s Trp36 are likely to be important for proper positioning of 
the TrxC C37 for reaction with the TrxR thiol/disulfide (C45,C148).  The thiolate of 
C148 in TrxR is 4.9 Å from the disulfide linked cysteine (C37) of TrxC (Figure 5.7E).  
Attack of C37 on C148 (disulfide) produces the mixed disulfide between the two proteins 
(Figure 5.7F), which is analogous to the mixed disulfide structure of E. coli TrxR/Trx 
that was recently reported.  During mixed disulfide formation, a proton is abstracted from 
C146, producing the thiolate that is capable of forming the disulfide with C148, and 
releasing the C37 leaving group of the thioredoxin.  This ultimately leaves TrxC in the 
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thiol reduced state (Figure 5.7G).  The newly reduced TrxC is released from TrxR, which 
is in the same state as panel A, completing the catalytic cycle.   
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Figure 5.7. The complete redox and catalysis cycle of M. tb thioredoxin system of reduced TrxR reducing 
and oxidized TrxC.  FR and FO refer to the reduced or oxidized conformations of TrxR, which are related by 
a 66° domain rotation.  TrxC (ox and red) structures are those reported herein, TrxR (FO) is the previously 
reported crystal structure, while models for the various complexes were constructed based on structural and 
functional data for the E. coli thioredoxin system.  Each modeled complex was minimized with AMBER. 
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Figure 5.8.  Expansion and surface rendering (white) of the hydrophobic interface 
formed when TrxR reduces an oxidized TrxC (from Figure 5.7F).   
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5.3.4 NMR Evidence for Binding Interactions between M. tb TrxC and TrxR  
 It has been proposed that the E. coli TrxR, in solution, exists in a dynamic 
equilibrium between the two conformations (FO and FR),76 no matter what the state of 
oxidation is for the flavin or cysteines.  The hypothesis is that changing redox state or 
binding complex merely shifts the FO/FR equilibrium.  While are studies are not directed 
to testing this hypothesis, NMR binding and chemical shift perturbation measurements 
can be used for various catalytically competent and dead-end complexes, related to those 
shown in Figure 5.7.  This can establish that binding occurs, and can define the 
interaction surface on TrxC.  To determine what oxidation state the proteins (TrxC and 
TrxR) must be in order for binding to occur, a series of 1H-15N HSQC experiments were 
performed so that changes to the state of the proteins in different oxidative states could be 
monitored (Figure 5.9).  Chemical shift changes could be due to binding or to 
conformational/structural changes induced by redox changes.  The TrxC protein was 
partially reduced, so that we could track the changes that occur upon full reduction and 
binding, amongst the different redox states in the experiments.  When oxidized TrxR in 
the absence of NADPH, was added to TrxC (Figure 5.9A), there were no chemical shift 
changes.  Interestingly, the small amount of TrxC that was present in a reduced state was 
converted to a fully oxidized state, shown by the absence of red peaks over the reduced 
black peaks of TrxC.  When the reducing agent (NADPH) for the thioredoxin system was 
added in excess (4-fold), all of the oxidized TrxC is converted to the reduced state 
(Figure 5.9B).  But, there is no chemical shift changes from this reduced state of TrxC, 
and that observed in Figure 5.9C when of fully reduced TrxC is produced by adding the 
reducing agent DTT in 4-fold excess.    
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Figure 5.9.  2D 1H-15N HSQC spectra where the black cross peaks in all panels are for 
oxidized/reduced TrxC and A) TrxR has been added to the sample (red), B) TrxR has 
been added to the sample and the redox activity initiated by addition of with NADPH to 
reduce TrxC (green), and C) DTT is added to the sample to fully reduce TrxC as a control 
experiment (blue).  Protein concentration is 250 µM for both TrxC and TrxR. 
A)	  	  	  	  	  	  	  	  	  	  	  	  	  B)	  	  	  	  	  	  	  	  	  	  	  	  	  C)	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Figure 5.9 continued.  2D 1H-15N HSQC spectra where D) black cross peaks are for 
oxidized/reduced TrxC and TrxR is added to the sample along with the oxidized cofactor 
NADP+. E) The overlay of the DTT reduced sample (blue) and the NADPH reduced 
sample (green), and F) is the same as panel E with the oxidized sample from panel D and 
DTT added to it (orange). 
D)	  
E)	  
F)	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This indicates that while NADPH binds and reduces FAD, and subsequently reduces 
TrxC, that protein products of this reaction do not have high affinity for each other.  In an 
effort to trap a dead-end complex, NADP+ was added.  But, when NADP+ is added to the 
sample of TrxC/R there appears to be no chemical shift changes from the oxidized state 
of TrxR (Figure 5.9D). 
 When the spectra for TrxC that has been reduced using NADPH and DTT are 
overlaid onto each other (Figure 5.9E), there are no distinguishable chemical shift 
changes.  However there are a few residues that broaden indicating an intermediate 
exchange process, perhaps due to binding interactions between TrxC and TrxR.   To see 
whether binding was a function of the oxidation state of the flavin, the sample used in 
Figure 5.9D was reduced with DTT, so that both proteins were reduced, the flavin was 
still oxidized, and the cofactor NADP+ was still bound.  The results from this experiment 
are shown in Figure 5.9F, and are analogous to the results when both proteins were being 
reduced using NADPH, there were no distinguishable chemical shift changes, but some 
residues were exchange broadened.  The residues that were in intermediate exchange in 
the complex with TrxR in Figures 5.9B and 5.9F, were mapped onto the reduced state 
solution structure of TrxC in Figure 5.10.  The majority of the residues that were 
exchange broadened are in the active site region of the protein (F32, A34, T35, W36, 
C37, T67, V78), which is consistent with expectations from the modeling of the 
thioredoxin system in Figure 5.7E and 5.8, where the proteins interacting via a 
hydrophobic interface.  These residues’ are still present in Figure 5.9A (with no 
significant chemical shift change).  The dead-end complex has both proteins in the 
oxidized state, with flavin being oxidized too.  Based on these results, although the 
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protein may be sampling both FO and FR states, TrxC will only be bound to the reduced 
(free thiol) form of TrxR, no matter the state of oxidation of the flavin.  And, the identity 
of the residues that exchange-broaden provide some confirmation of the protein-protein 
interface suggested in the model (Figure 5.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10.  Solution structure of reduced TrxC with those chemical shifts that have 
exchanged broadened upon binding to TrxR mapped on it (blue spheres). 
 
 
 
5.4 Conclusion 
 
 We have determined the solution structures of both redox states of thioredoxin C 
from Mycobacterium tuberculosis using NMR with high-resolution (backbone RMSD of 
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0.54 and 0.50 Å for TrxCox and TrxCred, respectively).  Like the E. coli thioredoxins,68 the 
secondary structure and folding of the different redox states of TrxC are nearly identical, 
with only subtle changes around the active site the protein, and with some dynamic loop 
regions.  In the presence of the thioredoxin reductase from M. tb, it appears that TrxC 
binds to TrxR only when TrxR has a reduced disulfide.  This was demonstrated by the 
disappearance of cross peaks for residues in the active site of TrxC.  Using these data, 
and previous structures of the thioredoxin system from E. coli organism,72 structural 
models depicting the steps of the oxidoreductase catalytic cycle of the thioredoxin system 
was developed to facilitate future mechanistic studies of this system, and perhaps aid in 
design of inhibitors as potential drug leads.   
 Further studies will include more experiments to define the binding interactions of 
TrxC and TrxR, with potential point mutations to trap mixed disulfide intermediates the 
proteins.  This can help to determine whether TrxR really needs to be reduced for the 
proteins to bind to each other.  The NMR solution structures of TrxA and B are also in 
the process of being solved, to provide a complete understanding of the M. tb thioredoxin 
system, and to aid in the drug design process.  Inhibitors of the M. tb thioredoxin system 
may also help us to better understand this pathogen’s ability to survive intracellular redox 
stress. 
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CHAPTER VI. Discovery of Inhibitors of Protein Drug Targets by Automated  
 
Docking: PMK, SDF1, and DUSP-5 
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6.1 Introduction 
 
6.1.1 Docking and Virtual Chemical Libraries  
 
 Docking is the process of positioning a ligand into the binding site of a protein, by 
computationally exploring different translations, orientations, and conformations until a 
lowest energy structure and “pose” orientation is found.  Virtual screening is the process 
of automated docking of a compound library into a known binding site of a protein, with 
the goal of discovering inhibitors with high affinity for the protein.78  This method 
reduces time, cost, and material of high-throughput ligand screening processes such as 
random screening and structure based drug design.79 Virtual screening is used in the early 
phase of drug discovery, since it can substantially reduce the number of compounds to be 
screened, so one can focus on the most relevant compounds which will go on to further 
testing.80 
 
 Chemical libraries are computational databases of chemical structures often 
broken down by specific needs (i.e. small fragments or larger chemical structures) and 
generally there are physical compounds accompanying the library for experimental 
testing.  The first of two chemical libraries used in this study were a database of 2,000 
Thai natural products coming from 7 plants from ChemieBase, which is a molecular 
database of 2D bioactive compounds developed by the Cheminformatic Research Unit at 
Kasetsart University in Bangkok, Thailand.  This database houses approximately 30,000 
compounds in 2D structure format and are grouped by the plants from which they come.  
There were no physical compounds associated with this database but if the virtual 
screening hits were strong enough, compounds similar in structure or the actual 
compound (if available) was purchased for testing.  The second database is an in-house 
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physical collection of 10,590 compounds that contain numerous kinds of compound dyes, 
including sulfonates that had been selected or designed for binding dehydrogenases and 
kinases.   
 Automated docking, on average, takes approximately an hour per compound, 
which becomes very computationally expensive when trying to dock whole 
computational databases.  To increase the speed of virtual screening the databases, we 
use a workload management system called Condor.81, 82  Condor essentially provides a 
job queuing system that distributes jobs to computers, monitors progress, and compiles 
the data sent to those computers to a central location.  Condor was set up on 400 
computers throughout campus that are capable of running 400 jobs simultaneously which 
significantly decreases computational time for virtual screening of the compounds into 
our drug target proteins: phosphomevalonate kinase (PMK), dual specificity phosphotase-
5 (DUSP-5), and stromal cell derived factor 1 (SDF1). 
 
6.1.2 PMK as a Drug Target 
 Phosphomevalonate kinase (PMK) is a good drug target for such a docking study,  
as it relates to cardiovascular disease since it is in the mevalonate biosynthetic pathway.  
This pathway is a mammal’s only route to biosynthesis of steroids and isoprenoids, 
including cholesterol.26, 83  Much work has been done already on the inhibition of this 
pathway using statin drugs, which target the HMG-CoA Reductase enzyme.84  However, 
PMK offers similar advantages to HMG-CoA Reductase inhibitors, in that the active site 
has been characterized and a structure is currently available for it (Figure 6.1).85  In this 
study both chemical libraries were docked into the whole active site of PMK.  Good 
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binding ligands, as predicted by AutoDock calculations,12 were then tested 
experimentally for binding using both NMR and fluorescence-based titrations. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.  Crystal structure of PMK (pdb code 3ch4)85 with natural substrates, ATP and 
M5P, docked into the active site.  Nearby interactions from ligands to residues are shown 
in the black and yellow box, which indicates the site that was docked in to using 
AutoDock. 
 
 
 
6.1.3 DUSP-5 as a Drug Target 
 
 Dual-specificity phosphatase 5 (DUSP-5) is part of a class of proteins that 
dephosphorylate phospho-serine/threonine and phospho-tyrosine substrates (DSPs) on 
proteins called mitogen-activated protein kinases (MAPKs).86  MAPKs are involved in 
the mediation of cell signaling that is directly involved in diseases such as cancer, 
diabetes, and autoimmune disorders.87-89   MAPKs are fully activated when the tyrosine 
and threonine in their active loops are both phosphorylated.  As such DSPs counteract 
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such activity and if over expressed or the activity of DSPs were to increase, the cell 
signaling brought on by MAP would cease.   In effect, the phosphorylation state of 
proteins such as MAPKs acts as an on/off switch for the proteins signaling activity. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.  Crystal structure of the catalytic domain of DUSP-5 (pdb code 2g6z) is 
shown with the active p-loop residues displayed.  The green box indicates the site that 
was docked into by the in house library of compounds. 
 
 
 DUSP -5 specifically dephosphrylates a MAPK called extracellular signal 
regulated kinase (ERK).  It has also been shown that over expression of DUSP-5 
suppresses the growth of several types of human cancer cells, by “shutting off” ERK (i.e. 
dephosphorylation).86  There is also some interest in inhibition of DUSP-5, which would 
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lead to increased levels of phosphorylated ERK2, leading to angiogenesis (growth of 
blood vessels).  Inhibition of DUSP-5 could, for example, be used to treat retinal 
diseases.  Figure 6.2 shows the crystal structure of the catalytic domain of DUSP-5 as 
well as the binding site into which we docked.90  The residues shown are those involved 
in binding the phosphorylated substrates, located in what is called the p-loop (residues 
232, 263-269).91  The in house library was docked into this site and the top binding 
compounds with good clustering information were used by our collaborators; Dr. Ramani 
Ramchandran (Medical College of Wisconsin) in cell-based assays to see whether these 
compounds inhibited or activated ERK.  Of the 10 compounds that were tested, 1 of them 
showed promise as a potent in inhibitor.   
 
 
6.1.4 SDF1 as a Drug Target 
 Stromal cell-derived factor 1 (SDF1) is a cytokine, a small protiein secreted by 
cells to carry signals to and from other neighboring cells, which in adulthood, plays an 
important role in angiogenesis (blood vessel growth).92  Because of this, SDF1 is also 
important in the initial creation of tumor cells and formation of networks of blood 
vessels, which leads to tumor progression.93  Figure 6.3 shows the dimer that SDF1 forms 
to permit signal transduction, with Arg 47 which is important for binding.94, 95  The in-
house chemical library was docked into the active site of SDF1, and then screened by 
NMR to verify the binding of compounds.  Any compounds that were determined to bind 
by this screening assay were then sent to our collaborator on this project, Dr. Brian 
Volkman (Medical College of Wisconsin), to be further tested for binding affinity and 
inhibition.  
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Figure 6.3.  Shows one of the structures in the ensemble of solution structures of SDF1 
(pdb code 2k05)94.  Relevant side chains (Arg 47 and Val 49) are shown and the orange 
box shows the site into which the in-house chemical library was docked. 
 
 
 
6.2 Methods and Materials 
 
6.2.1 Ligand Preparation 
 
Ligands were received as 2D MDL MOL files and were converted to 2D SDF 
MOL files using Babel, as CORINA was not equipped to handle 2D MDL MOL file 
extensions.  The newly converted SDF MOL files were then converted to 3D PDB 
coordinate files by using CORINA (Molecular Networks, Erlangen, Germany), which 
generates low energy 3D structures.  The files were then processed with the python script 
prepare_ligand4.py, which comes with AutoDock12, 96 molecular modeling package.  This 
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script generates a pdbqt file, and adds partial charges to the ligand, sets all torsions in the 
ligand to active (to permit rotation), as well as merging all non-polar hydrogen’s.  
 
 
6.2.2 Docking Protocol 
The protein pdb files and grid maps were all prepared using the AutoDock Tools 
suite.96  Grid maps are used in the energy calculations performed by AutoDock.  The 
protein was treated just as the ligands were (done manually on AutoDock), adding partial 
charges and merging all non-polar hydrogens and saved as a pdbqt file.  The 13 different 
grid maps, one needed for each of the different atoms in the chemical libraries (ex. C, H, 
F, Cl, etc.) were generated using AutoGrid415 with the grid box, the site used to dock the 
ligands, placed over the active sites of the protein (the colored boxes in Figures 6.1-6.3).  
Calculations are then limited to the region defined by the grid box. 
 The docking parameter file (dpf), which contains the parameters that AutoDock 
uses to dock the ligand into the protein, was prepared using the python script 
prepare_dpf4.py, and default docking parameters were used, except that 50 separate 
docking calculations were performed with each calculation consisting of 1,750,000 
energy evaluations and an rmsd tolerance set to 2.0 angstroms (to define entry of 
structure into a given cluster).  The dpf files were then automatically docked using 
MUGrid with Condor submission files and AutoDock4 using the Lamarckian genetic 
algorithm local search method to perform the optimization of docking pose.12  The 
docking results were then clustered on the basis of the root mean square deviation (rmsd) 
between the coordinates of the atoms in a given ligand, and were ranked on the basis of 
calculated free energy of binding.  The docking log files were then analyzed using the 
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python script summarize_results4.py contained in the shell script sumresults_4, which 
rank orders all the dockings, by binding energy.  The results were then analyzed to find 
the best clustered compounds with highest free energy of binding as determined by 
AutoDock. 
 
6.2.3 Sample Preparation and NMR Spectroscopy 
The compounds that were predicted to bind best, based on AutoDock calculations 
of binding energy were located in our chemical library inventory and dissolved initially 
into 25 mM in deuterated DMSO and diluted to 5 mM as the working stock solution for 
experiments other than NMR.  15N-labeled protein (PMK and SDF1) was concentrated to 
300 µM for NMR screening, and titration experiments were performed by monitoring 
chemical shift changes in a 2-D 1H-15N HSQC experiment.  For the titration experiments, 
aliquots of 25 mM of compound were added to the protein in increasing amounts until 
saturation was reached.  For screening experiments, 5 compounds were pooled together 
to a final compound concentration of 1.25 mM for each compound and added to the 
protein.  If there were any chemical shift changes in the screening experiment, each 
compound was then tested individually to identify which compound had bound to the 
protein.  This process allows identification of best-binding compounds, with fewer NMR 
experiments and less protein consumption.   
Dissociation constants were obtained by measuring the chemical shift changes in 
going from free to various bound states, monitoring NMR cross peaks in fast exchange in 
both 1H and 15N dimensions.  These changes were then combined using Equation 2: 
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     Δshiftobs = [(1H shift)2+(15N shift/6.51)2](1/2)                       Eq. 6.1      
                 
The chemical shift change (Δshiftobs) is plotted as a function of the concentration of the 
ligand, then data were fitted to a quadratic equation, to determine the dissociation 
constant Kd: 
 
Δshiftobs = (Δshiftmax/(2[Po]))*{([Lo] + [Po] + Kd) –{([Lo] + [Po] + Kd)2 – 4[Lo][Po]}1/2}      Eq. 6.2 
 
 using Sigmaplot8, where Lo is the total ligand concentration, Po is the total protein 
concentration, and Δshiftmax is the maximum chemical shift change observed for the 
particular peak in question. Fitting to the quadratic equation was required because [Po] > 
Kd. Standard deviations are from the non-linear least squares fitting process.  Note that as 
Kd gets very small relative to [Po], errors will become larger because Kd become less 
well-defined in the fitting process).    
 
6.3 Results and Discussion 
6.3.1 PMK 
 Twenty computationally selected compounds were chosen for testing using NMR 
titration experiments.  Ten were from the in house library and ten from the Thai natural 
product library.  Of those twenty, 4 compounds were found to bind to PMK and these 
were all from the in house library of compounds.  Those compounds are labeled as 
mu_1633, mu_1750, mu_2260, and mu_2419 and shown in Figures 6.4-6.8 and 
summarized in Table 6.1.   
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 Compound mu_1633 is a substituted anthraquinone flanked by two hydroxyls and 
two amino-sulfonate toluene groups and is shown in figure 6.4A.  AutoDock calculations 
predicted mu_1633 to bind in the ATP – γ phosphate site (Figure 6.4B) with 25 poses in 
the lowest binding cluster, and mean calculated binding energy of -10.76 kcal/mol (the 
lowest in the cluster being -11.66 kcal/mol).   Panel C in Figure 6.4 shows all the 
predicted interactions (less than 3.2 Å) between mu_1633 (the lowest energy docked 
pose) and the active site of PMK, including many ionic and hydrogen bonding 
interactions between the sulfonate groups and positively charged residues (R18, K19, 
R73, and R110).  Following the chemical shifts of the residues in panel D of the titration 
experiment of mu_1633 and PMK and fitting the data as a function of concentration of 
ligand, gave a dissociation constant (Kd) of <150 µM (since the concentration of protein 
is so high, accurate Kd determination cannot be made).  Following that up with a 
fluorescence titration (to get more accurate Kd measurement) and monitoring the 
emission of the tryptophan indole ring, gave the corresponding Kd of 127 ± 10 µM.   
 Compound mu_1750 is substituted naphthalene with a diazo linkage to a di-
carboxylic acid substituted phenyl group (Figure 6.5A).  AutoDock found l_cpfm1750 to 
bind in the ATP – γ phosphate site (Figure 6.5B) with the 8 poses in the lowest binding 
energy cluster having a mean binding energy of -9.8 kcal/mol (lowest in the cluster being 
-10.42 kcal/mol).   Panel C in Figure 6.5 shows all the predicted interactions (less than 
3.2 Å) between mu_1750 (the lowest docked pose) and the active site of PMK.  Like the 
previous compound, the sulfonate groups (and one carboxyl group) show hydrogen 
bonding interactions with the basic residues R18, K22, and R73, and hydrogen bonds to 
the amide protons of S20, G21, and K22.  Following the chemical shifts of the residues in 
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panel D in the titration experiment of mu_1750 gave a dissociation constant (Kd) of <40 
µM and following the NMR titration with a fluorescence titration gave the corresponding 
Kd of 3.6 ± 1.0 µM.   
 Compound mu_2419 is naphthalene with a diazo linkage to a phenyl group with a 
single branched carboxylic acid figure 6.6A, which differs from mu_1750 by on 
carboxylic acid group on the phenyl ring.  AutoDock found mu_2419 to bind in the ATP 
– γ phosphate site (Figure 6.6B) with the 2 poses in the lowest binding cluster with a 
mean binding energy of -10.99 kcal/mol and the lowest in the cluster being -11.02 
kcal/mol.   Panel C in Figure 6.7 shows the all the interactions (less than 3.2 Å) between 
mu_419 (the lowest docked pose) and the active site of PMK.  The negatively charged 
sulfonate groups are involved in ionic interactions with R18, K22, and R73, with further 
hydrogen bonding to amide groups of K22 and G16.  Following the chemical shifts of the 
residues in panel D in the titration experiment of mu_2419 gave a dissociation constant 
(Kd) of <800 µM and subsequent fluorescence titration gave a Kd of 48 ± 11 µM.  
 Compound mu_2260 is a tetra-substituted pyrimidine ring with three thio-ether 
linked acetyl groups and a phenyl ring (Figure 6.7A).  AutoDock found mu_2260 to bind 
in the ATP – γ phosphate site (Figure 6.7B) with the 10 poses in the lowest binding 
cluster with a mean binding energy of -9.36 kcal/mol (lowest in the cluster being -10.36 
kcal/mol).   Panel C in Figure 6.7 shows all the predicted interactions (less than 3.2 Å) 
between mu_2260 (the lowest docked pose) and the active site of PMK. Following the 
chemical shifts of the residues in panel D of the titration experiment of mu_2260 gave a 
dissociation constant (Kd) of <20 µM, and subsequent fluorescence titration gave a Kd of 
14.6 ± 4.6 µM.  
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Figure 6.4.  Docking and experimental data where A) summarizes the calculated binding 
energy of the compound and experimental binding affinity (dissociation constants) from 
NMR and fluorescence titrations.  Panels B and C are active site with relevant ionic and 
hydrogen bonding interactions shown, and residues labeled.  Panel D is the overlay of 2D 
1H-15N HSQC spectra for the NMR titration, where black is free PMK and the cross 
peaks going to red are for increasing amounts of compound titrated onto PMK.  The 
chemical shift changes indicate that the compound is binding to the protein, and fitting 
chemical shift values versus compound concentration provide the Kd for binding.   
 
 
 
mu_1633 
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Figure 6.5.  Docking and experimental data where A) summarizes the calculated binding 
energy of the compound and experimental binding affinity (dissociation constants) from 
NMR and fluorescence titrations.  Panels B and C are active site with relevant ionic and 
hydrogen bonding interactions shown, and residues labeled.  Panel D is the overlay of 2D 
1H-15N HSQC spectra for the NMR titration, where black is free PMK and the cross 
peaks going to blue are for increasing amounts of compound titrated onto PMK.  The 
chemical shift changes indicate that the compound is binding to the protein, and fitting 
chemical shift values versus compound concentration provide the Kd for binding. 
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Figure 6.6.  Docking and experimental data where A) summarizes the calculated binding 
energy of the compound and experimental binding affinity (dissociation constants) from 
NMR and fluorescence titrations.  Panels B and C are active site with relevant ionic and 
hydrogen bonding interactions shown, and residues labeled.  Panel D is the overlay of 2D 
1H-15N HSQC spectra for the NMR titration, where black is free PMK and the cross 
peaks going to purple are for increasing amounts of compound titrated onto PMK.  The 
chemical shift changes indicate that the compound is binding to the protein, and fitting 
chemical shift values versus compound concentration provide the Kd for binding. 
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Figure 6.7.  Docking and experimental data where A) summarizes the calculated binding 
energy of the compound and experimental binding affinity (dissociation constants) from 
NMR and fluorescence titrations.  Panels B and C are active site with relevant ionic and 
hydrogen bonding interactions shown, and residues labeled.  Panel D is the overlay of 2D 
1H-15N HSQC spectra for the NMR titration, where black is free PMK and the cross 
peaks going to green are for increasing amounts of compound titrated onto PMK.  The 
chemical shift changes indicate that the compound is binding to the protein, and fitting 
chemical shift values versus compound concentration provide the Kd for binding. 
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 The four compounds that were found to bind to PMK bind with reasonable 
affinity all have similar structural qualities, having aromatic rings substituted with 
negatively charged functional groups. Table 6.1 summarizes the computational and 
experimental results of the virtual screening process.  Compounds l_cpfm1750 and 2260 
are the tightest binding of the four, with low micromolar affinity.  It is curious that 
compound l_cpfm 1750 looks very similar to l_cpfm2419, but l_cfpm1750 binds nearly 
10 times tighter.  This could be attributed to having the negative charged carboxyl group 
on the phenyl ring of l_cpfm1750 instead of two hydroxyls on l_cfpm2419.   These sort 
of compounds are model compounds for binding to PMK since this protein has many 
positively charged amino acids (17 arginines and 6 lysines), with the majority of them in 
the active site,  that can neutralize the negative charge on the compounds.  While these 
inhibitors are of value for in vitro studies of PMK, having too much negative charge on a 
molecule poses problems in vivo such as drug bioavailability, since charged molecules 
will have difficulty crossing the cell membrane.  This will likely represent a significant 
challenge in any drug discovery effort that targets PMK. 
 
 
 
 
 
 
 
 
 
 
Table 6.1.  Summary of virtual and experimental screening of compounds that were 
found to bind to PMK, from our in house library of compounds.  
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6.2.2 SDF1  
 The in house library of compounds was docked into the  Sy-21 site of SDF1 
(specifically, in the vicinity of R47) where the signal peptide (sulfotyrosine 21) is known 
to bind, and mediate dimer formation (Figure 6.3).  The top 50 scoring compounds were 
ranked by calculated binding energy of the lowest energy pose in the docking cluster and 
were then experimentally screened for binding to SDF1 protein in batches of 5 
compounds.   If any of the batches showed any chemical shift changes in NMR 1H-15N 
HSQC then each compound was added individually to SDF1 to identify which compound 
was indeed binding to SDF1.  Since the compounds were dissolved in DMSO and DMSO 
has an effect on the spectra of SDF1, each batch of compounds was compared to a 
spectrum of SDF1 with only DMSO, and any chemical shift changes observed were in 
reference to this spectrum.  Of the 50 compounds tested against SDF1, three were found 
to bind with reasonable affinity, and are shown in Figures 6.8-6.10. 
 The first compound coming from the batch screening process is mu_1452, which 
contains phenol sulfonate substituted napthlene rings, linked through diazo groups.  Since 
this is a rather larger molecule (770 Da) there are a lot of torsional degrees of freedom 
that cause the docking to cluster rather poorly (32 different clusters out of 50 dockings), 
however the lowest energy cluster (-9.70 kcal/mol with lowest energy pose being -10.7 
kcal/mol) is the most populated clustered with 5 poses within an RMSD of 2 Å.  As the 
docking was confined to the Sy-21 binding site95, the negatively charged sulfonate groups 
are interacting with the positively charged arginine group, which is important for binding 
(Figure 6.8A-B).  There are also some hydrogen bonding interactions between the 
hydroxyl groups of the naphthalene and phenol rings and the carbonyl of E15.   The 
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NMR spectra of mu_1452 shows chemical shift changes from green going to red and the 
binding affinity calculated from these chemical shift changes is < 50 µM (Figures 6.8C-
D).   
 
Figure 6.8.  Docking and experimental data for the docking of compound l_cpfm1452 
with SDF1 where panels A) and B) are the lowest energy pose of l_cpfm1452 and 
relevant interactions to SDF1.  Panel C are the curves generated from the chemical shifts 
in panel D) to calculate the binding affinity for of the compound bound to SDF1 which 
was determined to be < 50 µM. Experimental data provided by Josh Ziarek of the 
Volkman lab at the Medical College of Wisconsin.  SDF1 was at 50 µM in pH 6.8 
predeutero MES buffer (25 mM). 
 
 
 
ΔG	  =	  -­‐10.73	  kcal/mol	  
mu_1452 
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 The second compound identified in the batch screening process was mu_1784, 
which has an anthracene core with two amide groups stemming from it connected to a 
trimethyl sulfonate phenyl group.  Although this compound is relatively large, there are 
less torsional degrees of freedom, so 8 clusters out of 50 poses were obtained, with 42 of 
the poses in the top two clusters ( -8.35 kcal/mol and -8.95 kcal/mol for the lowest energy 
pose), where most of the variation is caused by the rotation of the phenyl rings.  This 
compound’s sulfonate groups are also located near R47, with interactions from the 
sulfonate groups to R47, N47, and D22, with some hydrogen bonding from the amide and 
hydroxyl groups of mu_1784 to the carbonyl of E15 (Figure 6.9A-B).  The binding 
affinity, as determined from the chemical shifts (Figure 6.9C-D with chemical shifts 
going from green to red as compound is added) of multiple backbone residues is Kd < 
100 µM.  Based on which cross peaks perturbed, binding seems to be primarily confined 
to the Sy-21 site, as opposed to being at the dimer interface, as in the next case.    
 The last compound that was found to bind to SDF1 is mu_1661, which has 
sulfonate group attached to a pyrazole ring through a diazo linkage, and is connected to a 
dichloro phenyl sulfonate group.  This compound’s docking results had 16 clusters, with 
poor clustering due to significant rotation through the bonds coming from the pyrazole 
ring.  The lowest energy cluster, with a binding energy of -8.62 kcal/mol (-8.92 kcal/mol 
for the lowest energy pose), had 18 of the 50 docking poses clustered into it, making it 
the most probable binding geometry.  Many of the interactions between the lowest energy 
pose (Figure 6.10A-B) are between the sulfonate groups and the positively charged 
gunaido group of R47, as well as the backbone carbonyl and the amide of the sidechain 
of Q48.  The binding affinity of this compound is slightly less than the previous two 
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compounds, with a Kd of ~ 200 µM (6.10C-D), however the chemical shift changes upon 
binding this compound are significantly greater than for the previous two compounds 
tested, with more of the changes being around the dimer interface.  This indicates that 
this compound may cause dimerization of SDF1, which is known to occur upon binding 
ligand. 
 The docking and experimental data provided above suggests that the three 
compounds do indeed bind with reasonable affinity to SDF1.  However, further testing 
will be needed to determine if these compounds do indeed inhibit this protein.  As 
previously suggested that compound mu_1661 appears to induce dimerization based on 
chemical shift changes of 1H-15N HSQC spectra for residues in the dimer interface.  This 
is of importance since dimerization of SDF1 causes the protein to cease cell signaling 
(proliferation of cancer).  Since the docking box used for AutoDock calculations was 
located at this particular binding site, centered on R47, is probably the reason that the 
compounds identified were comprised of sulfonates and other negatively charged groups.  
Since the Sy21 binding site is another reason these compounds are so large, if we were to 
dock in a smaller binding site is quite large, it is not surprising that the compounds 
identified were also large.  It should be noted that during titrations, protein appeared to 
precipitate.  Subsequent SDS PAGE analysis by the Volkman lab indicated that the 
precipitate contained covalently linked SDF1 protein monomers.  It is possible that the 
diazo groups, associated with many of the compounds, will form free radicals in the 
presence of light (when bound to protein active sites) and oligomerize the protein to the 
point in which it eventually precipitates out.  Further work is being done to explore this 
phenomenon.   
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Figure 6.9.  Docking and experimental data for the docking of compound l_cpfm1452 
with SDF1 where panels A) and B) are the lowest energy pose of l_cpfm1452 and 
relevant interactions to SDF1.  Panel C are the curves generated from the chemical shifts 
in panel D) to calculate the binding affinity for of the compound bound to SDF1 which 
was determined to be < 100 µM. Experimental data provided by Josh Ziarek of the 
Volkman lab at the Medical College of Wisconsin.  SDF1 was at 50 µM in pH 6.8 
predeutero MES buffer (25 mM). 
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Figure 6.10.  Docking and experimental data for the docking of compound l_cpfm1452 
with SDF1 where panels A) and B) are the lowest energy pose of l_cpfm1452 and 
relevant interactions to SDF1.  Panel C are the curves generated from the chemical shifts 
in panel D) to calculate the binding affinity for of the compound bound to SDF1 which 
was determined to be ~ 200 µM. Experimental data provided by Josh Ziarek of the 
Volkman lab at the Medical College of Wisconsin.  SDF1 was at 50 µM in pH 6.8 
predeutero MES buffer (25 mM). 
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6.2.3 DUSP-5 
 The in house library was docked into the p-loop active site region of DUSP-5, 
which is the binding site for dephosphorylation of the ERK protein.  The presence of 
arginines 213,214, and 269 in the DUSP-5 active site make this an ideal binding site for 
the many sulfonated compounds that we have identified using docking analysis.91  A 
select set of compounds from the docking (based on binding energy and clustering) was 
given to our collaborators (the Ramchandran group from Medical College of Wisconsin).  
Those compounds were tested directly in cell-based assays, using HUVECS (Human 
Umbilical Venous Endothelial Cells).  Dose response experiments in these cells tests the 
effect of the compounds on a cell at differing levels of compound, by changes in 
phosphorylated ERK monitoring at a certain time after dosage.  The HUVEC cells were 
stimulated by the addition of a compound that binds to the cell surface called VEGF 
receptor, which stimulates growth of blood vessels by stimulating the DUSP-5 catalytic 
reaction (i.e. dephosphorylating phospho-ERK).  The amount of phospho-ERK (pERK) is 
monitored by a Western blot assay, in which antibodies specifically target pERK and 
thereby monitor pERK concentratio, when run on an SDS PAGE gel (concentration of 
pERK is related to intensity of band).  If DUSP-5 has been inhibited in some way, after 
VEGF stimulation, the intensity of the Western blot band (for pERK) should be high.  
This intensity should decrease with time, and in the case of DUSP-5, the time it takes for 
the depletion of pERK is 45 minutes.  But, if DUSP-5 is inhibited, the band will remain 
intense.  In addition to monitoring pERK levels, ERK and DUSP-5 levels were also 
monitored.  All compounds tested were monitored 45 minutes past stimulation by VEGF 
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and if the compounds are inhibitory, the relative concentration of pERK should be similar 
to that observed 2 minutes after VEGF stimulation in the control reaction.   
 The first of the compounds tested was mu_1472, which is comprised of two 
substituted naphthalene rings connected via a diazo group.  Each naphthalene ring has a 
sulfonate and hydroxyl group, with one it with one also having an exocyclic amine.  
Compound mu_1472 has a median calculated binding energy of -8.60 kcal/mol in the 
lowest energy cluster as determined by AutoDock ( -9.22 kcal/mol for the lowest docked 
compound).  Of the 50 poses docked into the active site, 25 poses were clustered in the 
lowest energy cluster with the remaining 25 dispersed amongst 16 other clusters.  As 
mentioned previously, the negative charged sulfonate groups of mu_1472 (Figure 6.11A-
B) are involved in ionic interactions with the positively charged guanido groups of the 
three arginines in the DUSP-5 active site (R213,R214, and R269), with further hydrogen 
bonding interactions to H234 and the carbonyl of D232.  The dose response curve (i.e. 
titrations) shows that compound mu_1472 inhibits DUSP-5 most effectively at 6 µM 
concentration (the amount of phospho-ERK  after 45 minutes is nearly the same 
concentration as at two minutes after stimulation). 
 The second compound found to inhibit DUSP-5 is mu_1693 and was intended to 
be a control compound, since it was predicted to bind poorly according to AutoDock (-
6.52 kcal/mol).  In hindsight, this compound may not have been an appropriate negative 
control since it has many of the same structural features as mu_1472 and it had been 
selected in a previous docking study for another protein with a positively charged active 
site.  This compound is rather large for a drug at 840 Da, consisting of a biphenyl bonded 
to two naphthalene groups through diazo groups.  Each naphthalene ring is substituted 
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with two sulfonate groups as well as a hydroxyl and amine.  Due to the large size of this 
compound and all the possible torsions it has, AutoDock had calculated 41 different 
clusters for this compound.  The lowest energy pose seems to wrap around the outside of 
the active site as shown in Figure 6.12A-B with interactions between the sulfonates of the 
compound and R213 and R214, and hydrogen bonding from the hydroxyl to E231 and 
T235.  According to the dose response curve, compound mu_1693 inhibits DUSP-5 most 
effectively at 3 µM. 
 The last compound that was found to inhibit DUSP-5 was mu_1842.  This 
compound appears to be a nanomolar inhibitor, and an ideal starting point drug lead 
optimization project since it is smaller  (404 Da), and is comprised of a reasonably drug-
like core, a tri-sulfonated carbazole.  Since this compound is rigid with fewer torsions, it 
clustered very well with the majority of the 50 poses clustering into 3 groups, with the 
lowest energy pose being -8.15 kcal/mol with average cluster binding energy of -7.93 
kcal/mol.  Note that calculated binding energies tend to scale with the size of the ligand, 
so given the small size of mu_1842 this is quite good.  The lowest energy pose of the 
lowest energy cluster bound similarly to the previous two compounds with the sulfonate 
groups, interacting with the three arginines in the active site, with other hydrogen 
bonding interactions predicted with the sidechain carbonyl of E264 and backbone 
carbonyl of D232.  The dose response curve in HUVEC cells indicates that at 500 nm, 
there is maximum inhibition of DUSP-5 by mu_1842 with inhibition all the way down to 
10 nm.  These studies need to be repeated at concentrations of mu_1842 < 10 nm, since 
pERK levels were still high at 10nm (Figure 6.13C).  Interestingly, there appears to be 
two inflections in the dose response curve with mu_1842, especially based on panel D of 
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Figure 6.13.  Furthermore, all compounds seem to show a loss of potency at higher 
concentrations, perhaps due to aggregations.  These effects will need to be further 
characterized (ex. aggregation can be determined using nephelometry).   
 
Figure 6.11.  Computational and experimental results for the docking of compound 
mu_1472 into DUSP-5.  The lowest energy pose for the docking of compound mu_1472 
to DUSP-5 is shown in panels A and B, with relevant residues interactions labeled.  Panel 
C is the dose response results for the compound incubated into HUVEC cells of the 
specified concentrations with relevant control experimental results shown.  Specifically, 
NS is no VEGF stimulation, while 2 and 45 minutes after VEGF stimulation.  Compound 
was incubated at 0, 0.5,…25 µ, and pERK or total ERK measured at 45 minutes.  Panel D 
is the western blot of pERK and total ERK in all experiments, and corresponds to the data 
shown in Panel C.  Experimental results provided by Indranil Sinha from the 
Ramchandran group at the Medical College of Wisconsin. 
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Figure 6.12.  Computational and experimental results for the docking of compound 
mu_1693 into DUSP-5.  The lowest energy pose for the docking of compound mu_1693 
to DUSP-5 is shown in panels A and B, with relevant residues interactions labeled.  Panel 
C is the dose response results for the compound incubated into HUVEC cells of the 
specified concentrations with relevant control experimental results shown.  Specifically, 
NS is no VEGF stimulation, while 2 and 45 minutes after VEGF stimulation.  Compound 
was incubated at 0, 1,3,…50 µM, and pERK or total ERK measured at 45 minutes.  Panel 
D is the western blot of pERK and total ERK in all experiments, and corresponds to the 
data shown in Panel C.  Experimental results provided by Indranil Sinha from the 
Ramchandran group at the Medical College of Wisconsin. 
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Figure 6.13.  Computational and experimental results for the docking of compound 
mu_1842 into DUSP-5.  The lowest energy pose for the docking of compound mu_1842 
to DUSP-5 is shown in panels A and B, with relevant residues interactions labeled.  Panel 
C is the dose response results for the compound incubated into HUVEC cells of the 
specified concentrations with relevant control experimental results shown.  Specifically, 
NS is no VEGF stimulation, while 2 and 45 minutes after VEGF stimulation.  Compound 
was incubated at 0, 0.01,0.05,…3 µ, and pERK or total ERK measured at 45 minutes.  
Panel D is the western blot of pERK and total ERK in all experiments, and corresponds 
to the data shown in Panel C.  Experimental results provided by Indranil Sinha from the 
Ramchandran group at the Medical College of Wisconsin. 
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 Unlike the other tests performed on compounds docked into SDF1 and PMK, 
these cell-based in-vitro assays cannot actually be used to unambiguously conclude that 
these compounds are binding and inhibiting DUSP-5. Rather these compounds will have 
to be tested with overexpressed and purified DUSP-5 protein, to study inhibition and 
binding.  These cell-based assays do however provide evidence that the introduction of 
the compounds to the HUVECs have the desired cellular effect of preventing 
dephosphorylation of pERK.  Compounds mu_1472 and mu_1963 seem to inhibit DUSP-
5 with modest IC50 values of 6 µM and 3 µM, but are really no comparison to the results 
obtained by compound mu_1872 which has maximum inhibition at 500 nm with potency 
at as low as 10 nm.  These results are very intriguing and will be investigated further not 
only with other various in-vitro assays but also with DUSP-5 protein.   
 
6.4 Conclusion 
 Since the active sites of all the drug targets tested are rich in basic residues it is 
not surprising that most of the compounds identified using docking are rich in sulfonate 
groups.  This poses other kind of problems in developing these molecules as drugs, since 
an excess of the negative charge makes it difficult to cross cell membranes.  This problem 
can sometimes be addressed by masking charges as esters, which are then hydrolyzed in 
the cell.  In the case of HUVEC studies, we know the compounds can make it into the 
cells.  The next logical step in developing these compounds as drug leads is to try and 
optimize the binding of these ligands to the drug targets by changing and adding various 
functional groups to the compounds until binding potency is in the < 100nm range.97, 98  
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Of all the compounds tested the most promising is compound l_cpfm1842 and its 
inhibition of DUSP-5.  The fact this compound seems to have potency as low as 10 nm is 
an exciting find and could potentially be very lucrative as a drug lead. From the results 
provided, virtual screening is an effective to way to find drug leads as we are getting a 
10% hit ratio of compounds that bind to the drug targets that have been screened.  The 
use of Condor and the resources of MUGrid have made it possible to virtual screen many 
compounds (ex. > 10,000) in a reasonable amount of time.  The optimization of the 
virtual screening and experimental verification can lead this project down the road of 
offering this as a service to those groups (ex. collaborators) who wish find inhibitors and 
drug leads to their own drug targets.   
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CHAPTER VII. 15N-Carboxamide NAD(H) Probes to Determine Conformational 
Binding Dynamics
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7.1 Introduction 
7.1.1 Rationale for Design of Conformational Dynamics Ligand Probe  
 Methods for charactering protein dynamics are becoming increasingly well 
developed, however dynamics from the ligand perspective has not been adequately 
explored.  This is in part because such studies rely on the use 13C or 15N labels, and it has 
become routine to isotopically label proteins, but not ligands.  Dynamic characterization 
of protein-ligand complexes using NMR has focused mostly on dynamics changes to the 
protein using a generalized order parameter which measures dynamics on the psec-nsec 
timescale (local backbone and sidechain dynamics) and relaxation dispersion which 
measures dynamics on the µsec-msec timescale (protein domain movement).8, 99-101  In 
the unbound state, the ligand has a large amount of conformational entropy, which is lost 
upon binding to a protein, with enthalpic gains offsetting these entropic penalties.   In 
certain proteins however, ligands can retain some flexibility in the bound state such as the 
matrix metalloproteinase 1 (MMP-1).102, 103  It has been shown that tightly bound ligands 
of MMP-1 exist in multiple conformations that exchange slowly on the chemical shift 
timescale in which two sets of signals arise for the bound ligand.97   
 In an attempt to characterize dynamics changes from the ligand perspective, we 
have designed a 15N-carboxamide ([15N-CA])-labeled NAD(P)+ and NAD(P)H cofactor 
(Figure 7.1) to be used as a probe in such studies.  NAD(P)H are cofactors that are 
involved in redox reactions, which participate in hydride transfer to adjacently bound 
substrates.104  Oxidoreductases (or dehydrogenases) are the class of enzymes that are 
responsible for this kind of reaction and are the class proteins of interest in this study.  
Previous bioinformatic studies from the Sem lab and others have indicated that genomes 
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are 2-5% oxidoreductases, so probes to study these enzymes could be broadly useful.105, 
106  Of particular interest to us for our initial studies is the protein ornithine 
monoxygenase (OMO) from Aspergillus fumigates,107 which is an NADP(H) and FAD 
dependant enzyme that uses NADPH as an electron source and molecular oxygen to 
hydroxylate the sidechain amine of L-ornithine (Figure 7.2), an amino acid derivative of 
arginine that plays a role in the urea cycle to dispose of excess nitrogen.   
 Such dynamics studies are important for studying the mechanism of OMO in that 
cofactor immobilization/movement is a necessary part of catalysis, to permit electron 
transfer.  Since a number of crystal structures show the nicotinamide displaced from that 
active site, sometimes showing no electron density for the nicotinamide ring, it is inferred 
that some domain movement and subsequent binding interactions are needed to bring the 
nicotinamide ring of the NAD(P)H cofactor into the right position for hydride transfer.72, 
108, 109  Since this process is generally occurring on the µsec-msec timescale, the most 
useful NMR experiment will be the relaxation dispersion experiment, using the Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence.32, 99, 101, 110  This pulse sequence relies on 
the measurement of the transverse relaxation rate by measuring the decay of the NMR 
resonance signal during the CPMG sequence.  These NMR relaxation dispersion 
experiments have been used to study protein folding, protein-ligand interactions, and 
enzyme function, which makes them ideal experiments to study the conformational 
dynamics changes that the NAD(P)(H) cofactor appears to undergo upon binding to 
proteins, such as ornithine monooxygenase (OMO).   
 Besides studies of cofactor dynamics, the labeled NAD(P)(H) probes being 
developed can be used to address a structural questions related to oxidoreductase 
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function.  The conformation of the carboxamide of the NAD(P)(H) cofactor when bound 
to proteins is sometimes ambiguous when determining protein structure with x-ray 
crystallography, since the nitrogen and oxygen of amides is not easily distinguished at 
typically achieved resolutions.105  This was a problem that was recently recognized by the 
Richardson lab, with regard to carboxamides of asparagine and glutamine sidechains.  
Based on data compiled form crystal structures, the Sem lab has found that ~90% of the 
time the carboxamides are oriented so that the carbonyl is in the direction of hydride 
transfer (Figure 7.5B) with the remaining 10% of structures having the carboxamide in 
the opposite direction (Figure 7.5C).  Since it is difficult to distinguish the orientation of 
the carboxamide, the question becomes, is the 90% number accurate?   Could it be 50% 
or is it closer to 100%?  If it is 100%, why is this geometry preferred?  Using this NMR 
probe we can determine the orientation of the carboxamide when bound to proteins using 
simple 15N-filtered NOE measurements.  Besides addressing basic mechanistic questions 
about the role of the carboxamide in oxidoreductase function, such studies can also 
facilitate drug design efforts where inhibitors are rationally designed to bind cofactor 
binding sites.  A detailed understanding of positioning and role of hydrogen bond donors 
and acceptors is needed to design inhibitors.  
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Figure 7.1.  Cofactors NADH and NADPH, as well as their oxidized states.  NAD(P)+ 
and NAD(P)H shown with the 15N-labeled carboxamide shown in red. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2.  Catalytic reaction of ornithine monooxygenase (OMO) in which molecular 
oxygen is used to hydroxylate the sidechain amine of L-ornithine. 
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7.2 Materials and Methods 
7.2.1 Synthesis of [15N-CA]-nicotinamide 
 In an ice bath, 4.0 g NaOH and 60 mL deionized water was added to a 250 mL 
round bottom flask with a magnetic stirrer. When the NaOH dissolved, 1.0 g 15N-NH4Cl 
was added. To this solution, 3.9 g of nicotinic acid chloride was added over 20 minutes.  
The reaction was kept on an ice bath for another 20 minutes, and immediately frozen and 
water removed by lyophilizing.  The product nicotinamide was extracted with hot 
benzene.  Sample purity was tested by TLC using equal parts of DMF/Chloroform as the 
separating solvent.  Product was 0.50 g, with a yield of 14.3%.  
 
7.2.2 Synthesis of [15N-CA]-NAD+111-116 
 80 mg of [15N-CA]-nicotinamide was dissolved in 10 mL of 40 mM potassium 
phosphate and brought to a pH of 7.0.  200 mg of NAD+ was dissolved in 15 mL of 40 
mM potassium phosphate buffer and brought to a pH of 7.0.  In the same solution, 500-
700 mg of the acetone dried powered form of porcine brain NADase (purchased from 
Sigma Aldrich) was added and pH brought to 7.0.  For control experiments, 1 mL of 
NAD+ solution and 1 mL of NAD+/NADase solution were added to eppendorf tubes.  
Both solutions, [15N-CA]-nicotinamide and NAD+/NADase, were added together were 
incubated at 37°C, as were control reactions.  The reaction mixture was tested 
periodically using the cyanide method, where 20 µL of reaction was added to 980 µL of a 
1 M KCN solution and monitored spectrophotometrically at 326 nm with the same molar 
extinction coefficient as NADH (6220 L/mol-cm), to determine if the NADase has 
exchanged all the unlabeled for labeled nicotinamide rings of NAD+, to produce [15N-
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CA]-NAD+.  In the assay, CN- attacks NAD+ to produce an adduct that absorbs at 326 
nm.  In the control reaction that has no nicotinamide, the NADase enzyme simply 
hydrolyzes the nicotinamide of NAD, rather than swapping the ring, (so absorbance at 
326 nm decreases).  After the reaction was complete (the control reaction lacking free 
dropped to base line levels, while the test reaction maintained similar absorbance levels 
as the NAD+ control reaction), the reaction mixture was heated up to 70°C for 2 min to 
precipitate the protein, and spun down for 10 minutes at 4000 RPM.   
 The [15N-CA]-NAD+ was purified by using a BioGel P2 size exclusion column 
(100 ml bed volume) and washed with water to separate the [15N-CA]-NAD+ from all the 
free nicotinamide.  Fractions were tested using TLC, and the same separation solvent as 
before and the fractions containing only [15N-CA]-NAD+ were pooled together. [15N-
CA]-NAD+ concentration was determined in an enzymatic endpoint assay.  An aliquot of 
this solution was mixed 20 mM of ethanol and 20 mM semicarbazide and 100 units of 
yeast alcohol dehyrogenase at pH 7.3.  Absorbance increase was monitored at 340 nm, 
with the molar extinction coefficient of 6220 L/mol-cm.  If [15N-CA]-NAD+ was the 
desired product, the solution was then flash frozen and lyophilized overnight.  A 2D 1H-
15N HSQC spectrum was acquired to confirm the 15N labeling of the cofactor. 
 
7.2.3 Synthesis of [15N-CA]-NADH 
 [15N-CA]-NADH was prepared by reduction of [15N-CA]-NAD+ using yeast 
alcohol dehydrogenase (ADH) and ethanol (Figure 7.3). The reaction was run at room 
temperature in the presence of excess alcohol (20 mM) in pH 7.3, 100 mM phosphate 
(KPi) buffer and monitored at 340 nm until reaction was complete. After the reaction was 
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done the ADH enzyme was denatured by heating at 70°C for two minutes, and then 
removed by filtration using an Amicon Ultra filtration device (Millipore, cutoff 10 kDa).  
The solution was then flash frozen in liquid nitrogen and lyophilized over night. 
 
7.2.4 NMR Study of [15N-CA]-NAD+ in Complex with Ornithine Monooxygenase 
 OMO was obtained from the DuBois lab at Purdue University and concentrated to 
600 µM in 200 mM KCl and 100 mM KPi buffer at pH 7.8.  To this, 500 µM of [15N-
CA]-NAD+ was added, and pH measured to be 7.5.  To determine the orientation of the 
carboxamide on the nicotinamide ring, a 2D 15N-filtered [1H-1H] NOESY experiment, 
was run with a mixing time of 150 ms. To determine possible conformational exchange, 
CPMG measurements were taken with 10 measurements, with a total delay of 30 µsec.  
The intensities of the NH protons were measured using the VNMRJ program, and fitted to 
Eq. 7.1, to obtain R2 = 1/T2, where I is intensity of a given measurement, Io is the control 
intensity and τcp is the delay that surrounds the 180° pulse in the CPMG sequence.  R2 and τcp 
was fit using GraphPad Prism to the fast exchange equation (Eq. 7.2)99, 
 
I = Io*e(-τcp/T2)                                              Eq. 7.1 
 
R2 = R20 + Rex*(1-2tanh(kex*τcp/2)/(kex*τcp)), Rex = p1p2Δω2/kex                                             Eq. 7.2 
 
Rex = (p1p2*Δω)/kex         Eq. 7.3 
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where p1 and p2 are the relative site populations (concentration) of the two states that are 
in exchange, Δω is the chemical shift difference between the two states (s-1), and kex is 
the exchange rate constant for the two states.  R2o represents the transfer relaxation rate, 
in the absence of exchange between states.   
  
7.3 Results and Discussion 
7.3.1 Preparation and Analysis of [15N-CA]-NAD(H) 
 [15N-CA]-NAD(H) was synthesized according to Figure 7.3 and characterized 
with UV-Vis spectroscopy to determine concentration and viability as a cofactor with the 
ADH enzymatic endpoint assay, and NMR to ensure 15N labeling.  Two crosspeaks are 
observed at 5°C in a 2D 1H-15N HSQC experiment, one for each proton on the 
carboxamide of NAD+ (Figure 7.4).  Analysis of a 1D slice 1H-15N HSQC experiment 
reveals that the crosspeak at 8.6 ppm (anti N-H) has 2/3 of the intensity of the crosspeak 
at 7.8 ppm (syn N-H), and previous studies showed that at higher temperature and pH, the 
crosspeak at 8.6 ppm significantly line broadens due to exchange with water because of 
the relatively higher acidity of this anti NH proton (however binding to a protein 
decreases the exchange, and permits the anti N-H to be observable).  For this reason it 
was necessary to run all the experiments at 5°C and at neutral or slightly acidic pH, to 
decrease proton exchange with water, while keeping the necessary buffer requirements of 
the protein in mind.   
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Figure 7.3.  Synthetic scheme for preparation 15N-nicotinamide and [15N-CA]-NAD(H).  
ADH is alcohol dehydrogenase from yeast.    
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Figure 7.4.  2D 1H-15N HSQC spectrum of [15N-CA]-NAD+ with 1D slice taken at the 
15N chemical shift indicated, showing the relative intensity of Ha (downfield) and He 
(upfield) protons.  Spectrum was take at pH 7.0 and 5°C.   
 
 
 
7.3.2 15N-edited NOESY studies of [15N-CA]-NAD+  
 A useful application of the [15N-CA]-NAD+ probe is that it can be used to 
determine the orientation of the carboxamide group when binding to protein. The 
carboxamide, in the unbound state, should be able to rotate around the bond connecting to 
the pyridine ring of the nicotinamide group to sample two states (Figure 7.5).  But, when 
bound to the protein, the amide protons are probably involved in hydrogen bonding to 
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amino acids in the active site, to stabilize the cofactor and permit hydride transfer.   Since 
the 15N isotope is on the amide group, the orientation of the amide can be determined 
with the 15N-edited NOESY experiment, where NOEs are observed within 5 Å of the 
proton(s) stemming from the 15N.  NOE intensity is much greater, the closer two atoms 
are to each other, with intensity decreasing as 1/(distance)6.  So if the amide is oriented 
like Figure 7.5B then we should see an NOE around 9.3 ppm corresponding to the proton 
H2, however if its oriented like Figure 7.5C the NOE should be around 9.0 ppm, 
corresponding to proton H4.117  The 15N-[1H-1H] NOESY experiment of [15N-CA]-NAD+ 
bound to OMO shows the two characteristic diagonal cross peaks of the carboxamide 
protons of the cofactor at ~7.8 ppm (NH syn) and ~8.65 ppm (NH anti)with NOEs to 
each other.  The strong peaks at approximately 4.9 ppm are due to magentization transfer 
with water, as this sample had to be in water (vs. D2O) so the amide protons would be 
visible.  At the bottom of the spectra there are NOE cross peaks correlating the amide 
protons (7.8, 8.6 ppm) with the H2 protons at 9.26 ppm, indicating the carboxamide 
protons of [15N-CA]-NAD+ close to the H2 proton of the nicotinamide ring.  This 
information suggest the structure in Figure 7.5B is the relevant structure of [15N-CA]-
NAD+ when bound to OMO.  This chemical probe and NMR experiment provides a 
relatively simple test to verify the correct carboxamide geometry of any NAD(P)(H) 
cofactor when bound to an oxidoreductase.  Further work will entail testing the cofactors 
with other oxidoreductases in literature and to confirm or disprove the reported geometry 
of the carboxamide in the crystal structure of cofactor/protein complexes.  
 
 
156 
 
 
Figure 7.5.  A) 2D 15N-filtered [1H-1H}NOESY spectrum of [15N-CA]-NAD+ bound to 
OMO, and B) the two possible orientations of the carboxamide group of [15N-CA]-NAD+ 
The carboxamide could be oriented with the protons closer to the H2 proton (B) or to H4 
proton (C).  The NOE data indicates NAD+ binds OMO in the orientation shown in panel 
B. 
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7.3.3 Relaxation Dispersion Study to Determine Conformational Exchange of 
Bound [15N-CA]-NAD+ Cofactor 
 Conformational exchange is a phenomenon in which nuclei sample multiple 
conformations/environments, and is measured by the rate term Rex, which is associated 
with transverse relaxation effects (T2).  Biological processes of proteins that undergo 
conformational exchange include protein folding, substrate binding, and catalysis, which 
often occur on the µsec-msec time-scale.  One way to measure such motional processes is 
with NMR spectroscopy using relaxation dispersion experiments with the CPMG pulse 
sequence.  These experiments measure the transverse relaxation rates while partially or 
fully suppressing the relaxation rate due to exchange Rex, by a series of 180° refocusing 
pulses (or spin-echo’s) known as CPMG.20, 99, 118  The intensity of the peaks (i.e. the NH 
protons) are measured to get the transverse relaxation rates (R2 = 1/T2) using Eq.1, and 
are then plotted as a function of the delay (τcp) between successive spin-echo’s and fit to 
Eq.2 to get Rex.  If there are Rex contributions, the curve will demonstrate exponential 
decay in which the asymptote is the transverse relaxation rate (R2).  If there are no Rex 
contributions, then only a flat line is observed.   
 Since OMO utilizes the cofactor FAD for electron transfer to its substrate, with 
NAD(P)H transferring a hydride ion to FAD, NAD+ had to be used in place of NADH to 
avoid catalytic turnover.  To study the conformational exchange effects of binding 
cofactor, relaxation dispersion profiles were acquired for unbound [15N-CA]-NAD+ and 
bound to OMO protein (in a 3:4 ratio so that all [15N-CA]-NAD+ was bound to OMO).  
The same relaxation dispersion experiments were used with both samples, except that the 
TROSY (Transverse Relaxation Optimized Spectroscopy)119, 120 version of HSQC spectra 
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was acquired for OMO to sharpen the signals.  Since the [15N-CA]-NAD+ is bound to a 
large protein OMO is (55 kDa), the slow rotation of the bound [15N-CA]-NAD+  would 
cause the signals to broaden, and TROSY compensates for this effect.  For each 
experiment, a control experiment was run to determine the amide proton intensity (Io) in 
the absence of delay (no CPMG) and was used in Eq.1 to determine R2 and plotted 
against 1/τcp and fit to Eq.2, with fitted curve shown in Figure 7.6. 
 
 
 
 
 
 
 
 
 
 
Figure 7.6. Relaxation dispersion plot for unbound [15N-CA]-NAD+ and [15N-CA]-NAD+ 
bound to OMO.  Spectra were taken at pH 7.8 and 5°C with 500 µM [15N-CA]-NAD+.  
R2 is the transverse relaxation rate for the amide protons, and τcp is the delay used in the 
CPFM pulse sequence. 
 
 
 
 The dispersion profile for unbound [15N-CA]-NAD+  in Figure 7.6 shows no 
conformational exchange occurs in this state, indicated by the flat line with an apparent 
transverse relaxation rate (R2o) of 9 s-1.  Upon binding to OMO the dispersion profile 
shows the exponential decay associated with conformational exchange due to binding 
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with a Rex value of 67 ± 6 s-1, an exchange rate constant (kex) of 922 ± 104 s-1, and an R2o 
of 88 s-1.  The significant increase in R2o (9 to 88 s-1) from unbound to bound states is 
most likely due to the slow tumbling of the bound labeled cofactor, which would lead to 
significant transverse relaxation.  In effect, signal that is observed is like that of a large 
molecule (protein), even though we are still only observing the [15N-CA]-NAD+ amide 
protons.  Since we also observe a transverse relaxation rate due to conformational 
exchange (Rex) in the bound state of the cofactor, this is likely indicative of adopting 
multiple conformations in the bound state, perhaps due to domain motion for OMO to 
bind its other substrate (ornithine).  If ornithine were bound to OMO in the presence of 
the [15N-CA]-NAD+, we would assume that the cofactor would then be locked down 
rigidly, for catalysis to occur, and would suppress most, if not all, of the Rex contribution 
to R2. 
 
7.4 Conclusion 
 The 15N-labeled cofactor NAD+ probes, and their application described herein, are 
a useful tool for studies of NAD(P)(H) binding proteins, since they can be used to explore 
effects of complex formation and protein binding.  We have shown that these probes can 
be used to determine carboxamide geometry (which crystallography often cannot) using 
the 15N-filtered NOESY experiment.  They can also be used to study cofactor binding 
dynamics, using CPMG-based relaxation dynamics methods.  The synthesis of these 
probes is relatively straightforward and can be easily extended to the phosphorylated 
cofactor, since NAD+ can be converted to NADP+ using the protein NAD+ kinase.117  
There are many ways that this probe can be used, for future experiments of binding [15N-
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CA]-NADP+ to M. tb thioredoxin reductase.   For example, it can be used to monitor the 
NADPH domain rotation (FO and FR states) in absence and presence of protein substrate 
thioredoxin C.  This can be done with reduced and oxidized states of the cofactor 
(NADPH vs. NADP+), of thioredoxin C, and of thioredoxin reductase.   
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APPENDIX  
 
Scripts and Procedure for NMR Structure Calculation 
 
A) The files necessary to begin structure calculation coming from experimental data. 
 
1) Protein sequence file (the exact sequence of the protein expressed, even if residues 
could not be assigned) called nameofprotein.seq with the format; 
 
 
MET 1  
THR 2 
ASP 3 
SER 4 
GLU 5 
LYS 6 
SER 7 
ALA 8 
THR 9 
ILE 10 
LYS 11 
VAL 12 
THR 13 
ASP 14 
ALA 15 
SER 16 
PHE 17 
ALA 18 
THR 19 
ASP 20 
VAL 21 
LEU 22  
SER 23 
SER 24 
ASN 25 
LYS 26 
PRO 27 
VAL 28 
LEU 29 
VAL 30 
ASP 31 
PHE 32 
TRP 33 
ALA 34 
THR 35 
TRP 36 
CYSS 37 
GLY 38 
PRO 39 
CYSS 40 
LYS 41 
MET 42 
VAL 43 
ALA 44 
PRO 45 
VAL 46 
LEU 47 
GLU 48 
GLU 49 
ILE 50 
ALA 51 
THR 52 
GLU 53 
ARG 54 
ALA 55 
 
THR 56 
ASP 57 
LEU 58 
THR 59 
VAL 60 
ALA 61 
LYS 62 
LEU 63 
ASP 64 
VAL 65 
ASP 66 
THR 67 
ASN 68 
PRO 69 
GLU 70 
THR 71 
ALA 72 
ARG 73 
ASN 74 
PHE 75 
GLN 76 
VAL 77 
VAL 78 
SER 79 
ILE 80 
PRO 81  
THR 82 
LEU 83 
ILE 84 
LEU 85 
PHE 86 
LYS 87 
ASP 88 
GLY 89 
GLN 90 
PRO 91 
VAL 92 
LYS 93 
ARG 94 
ILE 95 
VAL 96 
GLY 97 
ALA 98 
LYS 99 
GLY 100 
LYS 101 
ALA 102 
ALA 103 
LEU 104  
LEU 105 
ARG 106 
GLU 107 
LEU 108 
SER 109 
ASP 110 
 
In which cysteines involved in disulfides have the name CYSS, and prolines in the cis 
conformation have the cPRO.  This file is created manually. 
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2) The chemical shift list called nameofprotein.prot is every assignment that could be 
made from all backbone and sidechain spectra, and is written using the xe command in 
sparky.  (note: every time a prot file is written, sparky should be closed and re-opened as 
sparky retains all chemical shift information and this can cause problems later on)  This 
file will have the format; 
 
1   55.063  0.000     CA 3 
   2   41.232  0.000     CB 3 
   3    4.698  0.000     HA 3 
   4    2.627  0.000    HB2 3 
   5    2.760  0.000    HB3 3 
   6   58.682  0.000     CA 4 
   7   63.603  0.196     CB 4 
   8    8.414  0.001      H 4 
   9    4.393  0.007     HA 4 
  10    3.847  0.008    HB2 4 
  11    4.023  0.004    HB3 4 
  12  116.388  0.014      N 4 
  13   56.626  0.011     CA 5 
  14   29.908  0.144     CB 5 
  15   36.218  0.031     CG 5 
  16    8.394  0.010      H 5 
  17    4.271  0.009     HA 5 
  18    1.937  0.012    HB2 5 
  19    2.038  0.007    HB3 5 
  20    2.225  0.010    HG2 5 
  21    2.267  0.006    HG3 5 
  22  122.604  0.079      N 5 
  23   56.050  0.000     CA 6 
  24   33.182  0.087     CB 6 
  25   29.023  0.000     CD 6 
  26   42.302  0.000     CE 6 
  27   24.474  0.000     CG 6 
  28    8.241  0.011      H 6 
  29    4.341  0.002     HA 6 
  30    1.727  0.005    HB2 6 
  31    1.808  0.014    HB3 6 
  32  122.518  0.029      N 6 
  33    1.394  0.003     QD 6 
  34    2.982  0.000     QE 6 
  35    1.672  0.000     QG 6 
  36   57.132  0.180     CA 7 
  37   64.338  0.000     CB 7 
  38    8.260  0.001      H 7 
  39    4.551  0.006     HA 7 
  40    3.896  0.005    HB2 7 
  41    3.652  0.002    HB3 7 
  42  117.134  0.030      N 7 
  43   52.590  0.033     CA 8 
  44   20.124  0.000     CB 8 
  45    9.691  0.006      H 8 
  46    4.454  0.001     HA 8 
  47  129.351  0.089      N 8 
  48    1.378  0.013     QB 8 
  49   61.020  0.047     CA 9 
  50   70.889  0.050     CB 9 
  51   21.194  0.072    CG2 9 
  52    8.335  0.006      H 9 
  53    4.531  0.004     HA 9 
  54    3.843  0.010     HB 9 
  55  111.119  0.009      N 9 
  56    0.863  0.008    QG2 9 
  57   59.562  0.042     CA 10 
  58   40.114  0.000     CB 10 
  59   13.430  0.064    CD1 10 
  60   26.463  0.000    CG1 10 
  61   17.374  0.000    CG2 10 
  62    8.695  0.005      H 10 
  63    4.651  0.002     HA 10 
  64    1.800  0.010     HB 10 
  65  116.239  0.135      N 10 
  66    0.642  0.010    QD1 10 
  67    1.311  0.007    QG1 10 
  68    0.843  0.007    QG2 10 
  69   56.240  0.001     CA 11 
  70   33.245  0.000     CB 11 
  71   29.625  0.000     CD 11 
  72   42.143  0.000     CE 11 
  73   25.259  0.020     CG 11 
  74    8.643  0.004      H 11 
  75    4.735  0.006     HA 11 
  76  126.201  0.107      N 11 
  77    1.790  0.005     QB 11 
  78    1.618  0.004     QD 11 
  79    3.014  0.000     QE 11 
  80    1.226  0.010     QG 11 
  81   59.077  0.082     CA 12 
82   35.040  0.055     CB 12 
  83   22.622  0.074    CG1 12 
  84   20.256  0.000    CG2 12 
  85    8.576  0.002      H 12 
  86    4.687  0.009     HA 12 
  87    1.969  0.010     HB 12 
  88  120.675  0.056      N 12 
  89    0.820  0.009    QG1 12 
  90    0.748  0.007    QG2 12 
  91   58.711  0.004     CA 13 
  92   73.893  0.000     CB 13 
  93    8.135  0.002      H 13 
  94    4.778  0.006     HA 13 
  95    4.777  0.004     HB 13 
  96  110.422  0.032      N 13 
  97    1.205  0.005    QG2 13 
  98   58.096  0.059     CA 14 
  99   40.722  0.128     CB 14 
 100    9.093  0.007      H 14 
 101    4.328  0.004     HA 14 
 102    2.705  0.007    HB2 14 
 103    2.814  0.015    HB3 14 
 104  120.389  0.011      N 14 
 105   54.086  0.014     CA 15 
 106   18.715  0.079     CB 15 
 107    8.225  0.005      H 15 
 108    4.310  0.009     HA 15 
 109  119.446  0.028      N 15 
 110    1.450  0.007     QB 15 
 111   58.955  0.002     CA 16 
 112   65.303  0.030     CB 16 
 113    8.132  0.003      H 16 
 114    4.701  0.009     HA 16 
 115    4.360  0.006    HB2 16 
 116    3.619  0.008    HB3 16 
 117  115.620  0.070      N 16 
 118   64.042  0.038     CA 17 
 119   39.999  0.048     CB 17 
 120  131.972  0.114    CD1 17 
 121  130.748  0.071    CE1 17 
 122  128.638  0.082     CZ 17 
 123    8.172  0.005      H 17 
 124    3.603  0.004     HA 17 
 125    3.541  0.014    HB2 17 
 126    3.038  0.005    HB3 17 
 127    6.444  0.006     HZ 17 
 128  126.834  0.083      N 17 
 129    6.926  0.003     QD 17 
 130    6.675  0.009     QE 17 
 131   55.676  0.034     CA 18 
 132   17.528  0.016     CB 18 
 133    9.142  0.005      H 18 
 134    3.937  0.010     HA 18 
 135  120.418  0.027      N 18 
 136    1.558  0.007     QB 18 
 137   65.254  0.001     CA 19 
 138   69.205  0.032     CB 19 
 139   21.777  0.027    CG2 19 
 140    7.864  0.005      H 19 
 141    3.911  0.003     HA 19 
 142    4.076  0.004     HB 19 
 143  113.363  0.032      N 19 
 144    1.192  0.007    QG2 19 
 145   56.648  0.049     CA 20 
 146   42.156  0.042     CB 20 
 147    8.576  0.006      H 20 
 148    4.274  0.007     HA 20 
 149  119.229  0.025      N 20 
 150    2.271  0.009     QB 20 
 151   63.365  0.023     CA 21 
 152   32.031  0.010     CB 21 
 153   20.602  0.040    CG1 21 
 154   20.830  0.000    CG2 21 
 155    7.640  0.004      H 21 
 156    3.843  0.008     HA 21 
 157    0.581  0.001     HB 21 
 158  113.358  0.015      N 21 
 159   -0.438  0.007    QG1 21 
 160    0.001  0.007    QG2 21 
 161   58.022  0.031     CA 22 
 162   39.425  0.048     CB 22 
163   22.621  0.050    CD2 22 
 164   25.294  0.006     CG 22 
 165    7.149  0.002      H 22 
 166    3.738  0.010     HA 22 
 167    2.312  0.012    HB2 22 
 168    1.608  0.008    HB3 22 
 169    1.205  0.005     HG 22 
 170  115.492  0.037      N 22 
 171    0.741  0.010    QD2 22 
 172   58.077  0.159     CA 23 
 173   63.339  0.051     CB 23 
 174    7.068  0.002      H 23 
175    4.551  0.007     HA 23 
 176    4.043  0.015    HB2 23 
 177    4.059  0.010    HB3 23 
 178  109.764  0.014      N 23 
 179   57.924  0.035     CA 24 
 180   63.904  0.010     CB 24 
 181    6.552  0.005      H 24 
 182    4.270  0.006     HA 24 
 183    3.693  0.005    HB2 24 
 184    3.787  0.003    HB3 24 
 185  112.853  0.044      N 24 
 186   54.597  0.000     CA 25 
 187   38.476  0.001     CB 25 
 188    8.943  0.002      H 25 
 189    4.787  0.002     HA 25 
 190    2.893  0.013    HB2 25 
 191    2.920  0.005    HB3 25 
 192  127.681  0.019      N 25 
 193   53.783  0.000     CA 26 
 194   33.680  0.000     CB 26 
 195   29.604  0.000     CD 26 
 196   41.790  0.056     CE 26 
 197   24.239  0.000     CG 26 
 198    7.820  0.006      H 26 
 199    4.790  0.003     HA 26 
 200    1.652  0.009    HB2 26 
 201    1.544  0.012    HB3 26 
 202    1.443  0.002    HD2 26 
 203    1.559  0.009    HD3 26 
 204  120.623  0.133      N 26 
 205    2.793  0.008     QE 26 
 206    1.416  0.013     QG 26 
 207   63.912  0.034     CA 27 
 208   32.082  0.054     CB 27 
 209   50.983  0.016     CD 27 
 210   28.689  0.000     CG 27 
 211    4.867  0.006     HA 27 
 212    1.966  0.018    HB2 27 
 213    2.132  0.011    HB3 27 
 214    3.962  0.006     QD 27 
 215    2.361  0.002     QG 27 
 216   60.187  3.187     CA 28 
 217   35.213  0.039     CB 28 
 218   22.495  0.193    CG1 28 
 219   20.783  0.112    CG2 28 
 220    8.638  0.010      H 28 
 221    5.016  0.016     HA 28 
 222    1.910  0.010     HB 28 
 223  120.208  0.065      N 28 
 224    0.637  0.009    QG1 28 
 225    1.064  0.009    QG2 28 
 226   53.023  0.003     CA 29 
 227   44.474  0.001     CB 29 
 228   23.741  0.064    CD1 29 
 229   26.249  0.009    CD2 29 
 230   26.967  0.000     CG 29 
 231    9.398  0.006      H 29 
 232    4.932  0.006     HA 29 
 233    2.126  0.011    HB2 29 
 234    1.167  0.008    HB3 29 
 235    1.407  0.014     HG 29 
 236  130.791  0.011      N 29 
 237    0.784  0.012    QD1 29 
 238    0.811  0.012    QD2 29 
 239   61.461  0.053     CA 30 
 240   33.043  0.034     CB 30 
 241   22.307  0.029    CG1 30 
 242   24.538  0.000    CG2 30 
 243    9.595  0.004      H 30 
244    4.587  0.006     HA 30 
 245    2.337  0.008     HB 30 
 246  127.755  0.045      N 30 
 247    0.217  0.012    QG1 30 
 248    0.914  0.010    QG2 30 
 249   52.327  0.012     CA 31 
 250   40.487  0.127     CB 31 
 251    9.169  0.007      H 31 
 252    5.024  0.013     HA 31 
 253    2.226  0.004    HB2 31 
 254    2.929  0.006    HB3 31 
 255  125.859  0.036      N 31 
 256   58.094  0.056     CA 32 
 257   38.298  0.121     CB 32 
 258  132.812  0.116    CD1 32 
 259  127.776  0.072     CZ 32 
260    9.266  0.007      H 32 
 261    5.292  0.006     HA 32 
 262    3.626  0.009    HB2 32 
 263    2.647  0.011    HB3 32 
 264    6.865  0.006     HZ 32 
 265  128.566  0.030      N 32 
 266    7.374  0.007     QD 32 
 267    7.001  0.002     QE 32 
 268   54.545  0.046     CA 33 
 269   32.813  0.000     CB 33 
 270  126.151  0.092    CD1 33 
 271  124.582  0.074    CH2 33 
 272  114.248  0.051    CZ2 33 
 273  121.359  0.117    CZ3 33 
 274    8.604  0.008      H 33 
 275    5.192  0.007     HA 33 
 276    3.061  0.003    HB2 33 
 277    3.404  0.004    HB3 33 
 278    7.232  0.008    HD1 33 
 279   10.368  0.005    HE1 33 
 280    7.125  0.010    HH2 33 
 281    7.484  0.003    HZ2 33 
 282    6.863  0.005    HZ3 33 
 283  122.476  0.055      N 33 
 284  129.830  0.012    NE1 33 
 285   51.299  0.000     CA 34 
 286   22.663  0.003     CB 34 
 287    7.032  0.003      H 34 
 288    3.728  0.013     HA 34 
 289  116.614  0.023      N 34 
 290    0.348  0.007     QB 34 
 291   21.858  0.046    CG2 35 
 292    9.334  0.003      H 35 
 293    4.232  0.005     HA 35 
 294    3.972  0.009     HB 35 
 295  115.455  0.052      N 35 
 296    1.314  0.009    QG2 35 
 297   54.193  0.098     CA 36 
 298   29.479  0.000     CB 36 
 299  129.058  0.066    CD1 36 
1015  121.133  0.022    CE3 36 
 300  115.188  0.094    CZ2 36 
 301  121.116  0.000    CZ3 36 
 302    6.564  0.006      H 36 
 303    4.564  0.015     HA 36 
 304    3.692  0.007    HB2 36 
 305    3.167  0.009    HB3 36 
 306    7.390  0.004    HD1 36 
1016    7.385  0.002    HE3 36 
 307    7.165  0.000    HH2 36 
 308    7.360  0.002    HZ2 36 
 309    7.384  0.000    HZ3 36 
 310  114.739  0.018      N 36 
 311   58.287  0.069     CA 37 
 312   26.869  0.003     CB 37 
 313    6.521  0.009      H 37 
 314    4.629  0.011     HA 37 
 315    1.550  0.010    HB2 37 
 316    2.468  0.004    HB3 37 
 317  122.120  0.018      N 37 
 318   49.232  0.026     CA 38 
 319    4.012  0.006    HA2 38 
 320    4.307  0.010    HA3 38 
 321   65.819  0.000     CA 39 
 322   32.618  0.000     CB 39 
323   51.759  0.044     CD 39 
 324   28.036  0.107     CG 39 
 325    4.423  0.004     HA 39 
 326    2.515  0.009    HB2 39 
 327    1.779  0.008    HB3 39 
 328    4.553  0.008    HD2 39 
 329    3.770  0.007    HD3 39 
 330    2.056  0.007    HG2 39 
 331    2.276  0.009    HG3 39 
 332   64.025  0.037     CA 40 
 333   27.621  0.003     CB 40 
 334    7.875  0.003      H 40 
 335    4.121  0.011     HA 40 
 336    3.410  0.002    HB2 40 
 337    3.607  0.013    HB3 40 
 338  114.401  0.029      N 40 
 339   58.954  0.093     CA 41 
 340   32.060  0.000     CB 41 
 341   29.237  0.000     CD 41  
342   42.167  0.124     CE 41 
 343   25.469  0.000     CG 41 
 344    8.116  0.005      H 41 
 345    4.121  0.010     HA 41 
 346    1.980  0.004    HB2 41 
 347    2.034  0.009    HB3 41 
 348    1.780  0.008    HD2 41 
 349    1.741  0.000    HD3 41 
 350    1.512  0.002    HG2 41 
 351    1.642  0.000    HG3 41 
 352  119.964  0.081      N 41 
 353    3.052  0.006     QE 41 
 354   57.324  0.001     CA 42 
 355   32.204  0.000     CB 42 
 356   32.115  0.007     CG 42 
 357    7.397  0.004      H 42 
 358    4.328  0.005     HA 42 
 359    2.571  0.005    HG2 42 
 360    2.674  0.011    HG3 42 
 361  116.264  0.045      N 42 
 362    2.195  0.007     QB 42 
 363   62.943  0.007     CA 43 
 364   33.395  0.167     CB 43 
 365   20.769  0.000    CG1 43 
 366   22.306  0.095    CG2 43 
 367    7.236  0.007      H 43 
 368    4.143  0.007     HA 43 
 369    2.098  0.011     HB 43 
 370  115.791  0.029      N 43 
 371    0.998  0.010    QG1 43 
 372    1.158  0.013    QG2 43 
 373   57.560  0.031     CA 44 
 374   15.381  0.031     CB 44 
 375    7.369  0.008      H 44 
 376    3.916  0.006     HA 44 
 377  123.443  0.010      N 44 
 378    1.368  0.007     QB 44 
 379   65.892  0.062     CA 45 
 380   30.930  0.055     CB 45 
 381   50.571  0.052     CD 45 
 382   28.218  0.085     CG 45 
 383    4.323  0.005     HA 45 
 384    1.933  0.005    HB2 45 
 385    2.315  0.008    HB3 45 
 386    3.734  0.011    HD2 45 
 387    3.625  0.007    HD3 45 
 388    2.053  0.010    HG2 45 
 389    2.028  0.010    HG3 45 
 390   65.533  0.058     CA 46 
 391   31.690  0.004     CB 46 
 392   21.243  0.070    CG1 46 
 393   22.201  0.027    CG2 46 
 394    6.742  0.002      H 46 
 395    3.731  0.004     HA 46 
 396    2.363  0.011     HB 46 
 397  118.790  0.011      N 46 
 398    0.854  0.011    QG1 46 
 399    1.157  0.008    QG2 46 
 400   57.447  0.044     CA 47 
 401   40.806  0.059     CB 47 
 402   22.211  0.000    CD1 47 
773    2.981  0.003    HB3 88 
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403   26.583  0.064    CD2 47 
 404   26.558  0.000     CG 47 
 405    7.722  0.005      H 47 
 406    3.841  0.010     HA 47 
 407    1.212  0.010    HB2 47 
 408    1.886  0.008    HB3 47 
 409    1.720  0.011     HG 47 
 410  117.775  0.050      N 47 
 411    0.634  0.009    QD1 47 
 412    0.697  0.010    QD2 47 
 413   58.952  0.001     CA 48 
 414   28.890  0.004     CB 48 
 415   34.875  0.000     CG 48 
 416    7.573  0.002      H 48 
 417    3.864  0.005     HA 48 
 418    2.135  0.006    HB2 48 
 419    2.044  0.013    HB3 48 
 420  117.254  0.049      N 48 
 421    2.315  0.007     QG 48 
 422   59.829  0.030     CA 49 
 423   29.693  0.039     CB 49 
 424   36.677  0.004     CG 49 
 425    7.498  0.003      H 49 
 426    4.059  0.004     HA 49 
 427    2.029  0.009    HB2 49 
 428    2.182  0.010    HB3 49 
 429    2.533  0.006    HG2 49 
 430    2.121  0.004    HG3 49 
 431  118.949  0.035      N 49 
 432   66.070  0.039     CA 50 
 433   38.343  0.000     CB 50 
  434   29.625  0.093    CG1 50 
 435   16.530  0.040    CG2 50 
 436    8.169  0.009      H 50 
 437    3.491  0.007     HA 50 
 438    1.686  0.008     HB 50 
 439  118.486  0.023      N 50 
 440    0.816  0.021    QD1 50 
 441    1.858  0.007    QG1 50 
 442    0.627  0.011    QG2 50 
 443   54.679  0.052     CA 51 
 444   19.160  0.026     CB 51 
 445    8.497  0.003      H 51 
 446    3.832  0.010     HA 51 
 447  119.695  0.025      N 51 
 448    1.332  0.011     QB 51 
 449   65.423  0.074     CA 52 
 450   69.350  0.014     CB 52 
 451   21.510  0.068    CG2 52 
 452    7.563  0.006      H 52 
 453    4.060  0.003     HA 52 
 454    4.265  0.010     HB 52 
 455  110.660  0.035      N 52 
 456    1.279  0.007    QG2 52 
 457   59.040  0.109     CA 53 
 458   30.696  0.003     CB 53 
 459   36.682  0.029     CG 53 
 460    8.578  0.005      H 53 
 461    4.097  0.007     HA 53 
 462    2.100  0.009    HB2 53 
 463    1.996  0.005    HB3 53 
 464    2.274  0.005    HG2 53 
 465    2.492  0.008    HG3 53 
 466  121.274  0.039      N 53 
 467   52.424  0.000     CA 54 
 468   27.725  0.043     CB 54 
 469   42.008  0.011     CD 54 
 470   26.283  0.049     CG 54 
 471    8.328  0.002      H 54 
 472    4.943  0.007     HA 54 
 473    1.804  0.008    HB2 54 
 474    2.185  0.007    HB3 54 
 475    3.197  0.007    HD2 54 
 476    3.127  0.010    HD3 54 
 477    1.478  0.007    HG2 54 
 478    1.621  0.004    HG3 54 
 479  114.925  0.019      N 54 
 480   55.476  0.000     CA 55 
 481   19.174  0.003     CB 55 
 482    6.758  0.003      H 55 
 483    4.366  0.006     HA 55 
 484  122.065  0.036      N 55 
 485    1.610  0.011     QB 55 
 486   69.088  0.000     CB 56 
 487   22.027  0.018    CG2 56 
 488    8.201  0.002      H 56 
 489    4.165  0.000     HA 56 
 490    4.014  0.002     HB 56 
 491  107.259  0.023      N 56 
 492    1.225  0.003    QG2 56 
 493   55.276  0.000     CA 57 
 494   44.260  0.000     CB 57 
 495    7.772  0.002      H 57 
 496    4.746  0.008     HA 57 
 497    2.459  0.004    HB2 57 
 498    2.573  0.005    HB3 57 
 499  118.403  0.103      N 57 
 500   54.675  0.076     CA 58 
 501   45.758  0.001     CB 58 
 502   26.361  0.000     CG 58 
 503    7.960  0.003      H 58 
 504    4.764  0.013     HA 58 
 505    1.621  0.006    HB2 58 
 506    1.269  0.005    HB3 58 
 507    1.417  0.007     HG 58 
 508  117.425  0.053      N 58 
 509    0.654  0.011    QD1 58 
 510   61.446  0.215     CA 59 
 511   70.758  0.000     CB 59 
 512   22.454  0.000    CG2 59 
 513    8.510  0.002      H 59 
 514    4.396  0.008     HA 59 
 515    3.906  0.007     HB 59 
 516  122.451  0.031      N 59 
 517    1.188  0.012    QG2 59 
 518   61.309  0.004     CA 60 
 519   33.159  0.003     CB 60 
 520   22.000  0.000    CG1 60 
 521   20.865  0.050    CG2 60 
 522    9.452  0.008      H 60 
 523    4.925  0.011     HA 60 
 524    1.827  0.004     HB 60 
 525  128.019  0.125      N 60 
 526    0.824  0.008    QG1 60 
 527    0.797  0.009    QG2 60 
 528   48.742  0.038     CA 61 
 529   24.366  0.022     CB 61 
 530    9.321  0.006      H 61 
 531    5.487  0.006     HA 61 
 532  129.933  0.022      N 61 
 533    0.974  0.007     QB 61 
 534   55.192  0.043     CA 62 
 535   34.618  0.049     CB 62 
 536   28.643  0.011     CD 62 
 537   24.481  0.160     CG 62 
 538    8.960  0.007      H 62 
 539    4.970  0.008     HA 62 
 540  119.181  0.029      N 62 
 541    1.733  0.003     QB 62 
 542    1.326  0.006     QD 62 
 543    1.162  0.011     QG 62 
 544   53.557  0.018     CA 63 
 545   44.364  0.000     CB 63 
 546   25.451  0.055    CD2 63 
 547   28.071  0.006     CG 63 
 548    9.000  0.004      H 63 
 549    4.716  0.010     HA 63 
 550    1.251  0.013    HB2 63 
 551    0.783  0.008    HB3 63 
 552    1.310  0.012     HG 63 
 553  126.402  0.087      N 63 
 554    0.718  0.010    QD1 63 
 555    0.850  0.013    QD2 63 
 556   52.420  0.026     CA 64 
 557   40.566  0.041     CB 64 
 558    8.532  0.006      H 64 
 559    3.861  0.011     HA 64 
 560    2.357  0.012    HB2 64 
 561    2.487  0.007    HB3 64 
 562  126.637  0.058      N 64 
 563   64.463  0.030     CA 65 
 564   31.372  0.000     CB 65 
 565   18.710  0.024    CG1 65 
 566   23.428  0.000    CG2 65 
 567    9.014  0.004      H 65 
 568    3.816  0.008     HA 65 
 569    2.227  0.009     HB 65 
 570  123.712  0.066      N 65 
 571    0.932  0.010    QG1 65 
 572    1.204  0.008    QG2 65 
 573   57.094  0.150     CA 66 
 574   40.647  0.111     CB 66 
 575    8.045  0.002      H 66 
 576    4.553  0.009     HA 66 
 577    2.702  0.005    HB2 66 
 578    2.904  0.011    HB3 66 
 579  119.681  0.036      N 66 
 580   61.223  0.208     CA 67 
 581   69.637  0.009     CB 67 
 582   22.766  0.029    CG2 67 
 583    6.870  0.002      H 67 
 584    4.403  0.012     HA 67 
 585    4.315  0.007     HB 67 
 586  106.834  0.058      N 67 
 587    1.224  0.005    QG2 67 
 588   40.448  0.077     CB 68 
589    7.113  0.004      H 68 
 590    2.227  0.006    HB2 68 
 591  119.223  0.106      N 68 
 592   64.195  0.000     CA 69 
 593   32.587  0.018     CB 69 
 594   50.379  0.033     CD 69 
 595   27.275  0.018     CG 69 
 596    4.440  0.008     HA 69 
 597    1.958  0.005    HB2 69 
 598    2.370  0.002    HB3 69 
 599    3.764  0.006    HD2 69 
 600    3.237  0.004    HD3 69 
 601    2.065  0.004     QG 69 
 602   59.716  0.127     CA 70 
 603   28.650  0.000     CB 70 
 604   36.101  0.000     CG 70 
 605    9.240  0.003      H 70 
 606    4.019  0.007     HA 70 
 607    2.187  0.002    HG2 70 
 608    2.321  0.009    HG3 70 
 609  121.728  0.023      N 70 
 610    1.885  0.005     QB 70 
 611   67.925  0.040     CA 71 
 612   67.953  0.030     CB 71 
 613   20.512  0.024    CG2 71 
 614    9.444  0.004      H 71 
 615    3.774  0.009     HA 71 
 616    3.717  0.004     HB 71 
 617  119.177  0.012      N 71 
 618    0.432  0.006    QG2 71 
 619   55.707  0.021     CA 72 
 620   17.895  0.006     CB 72 
 621    6.925  0.004      H 72 
 622    3.932  0.019     HA 72 
 623  120.366  0.015      N 72 
 624    1.511  0.008     QB 72 
 625   59.163  0.080     CA 73 
 626   30.012  0.000     CB 73 
 627   43.370  0.078     CD 73 
 628   27.412  0.003     CG 73 
 629    7.849  0.010      H 73 
 630    4.105  0.006     HA 73 
 631    1.728  0.006    HG2 73 
 632    1.555  0.005    HG3 73 
 633  117.280  0.016      N 73 
 634    1.917  0.004     QB 73 
 635    3.210  0.004     QD 73 
 636   55.601  0.001     CA 74 
 637   38.168  0.133     CB 74 
 638    8.618  0.004      H 74 
 639    4.216  0.003     HA 74 
 640    2.208  0.010    HB2 74 
 641    2.656  0.008    HB3 74 
 642  120.076  0.045      N 74 
 643   58.431  0.000     CA 75 
 644   38.105  0.000     CB 75 
 645  131.856  0.050    CD1 75 
 646  131.891  0.050    CE1 75 
 647  129.886  0.022     CZ 75 
 648    7.218  0.003      H 75 
 649    4.650  0.001     HA 75 
 650    2.273  0.007    HB2 75 
 651    3.319  0.002    HB3 75 
 652    7.628  0.007     HZ 75 
 653  113.044  0.031      N 75 
 654    7.501  0.012     QD 75 
 655    7.448  0.011     QE 75 
 656   56.756  0.000     CA 76 
 657   25.873  0.001     CB 76 
 658   34.265  0.000     CG 76 
 659    7.819  0.002      H 76 
 660    3.854  0.004     HA 76 
 661    2.076  0.006    HB2 76 
 662    2.196  0.003    HB3 76 
 663    2.195  0.004    HG2 76 
 664    2.310  0.002    HG3 76 
 665  116.553  0.066      N 76 
 666    8.390  0.012      H 77 
 667    3.830  0.000     HA 77 
 668    1.703  0.013     HB 77 
 669  120.482  0.064      N 77 
 670   -0.046  0.009    QG2 77 
 671   61.669  0.174     CA 78 
 672   33.349  0.036     CB 78 
 673   18.675  0.066    CG1 78 
 674    8.033  0.011      H 78 
 675    4.391  0.009     HA 78 
 676    2.228  0.004     HB 78 
 677  121.955  0.042      N 78 
 678    0.815  0.011    QQG 78 
 679   56.994  0.126     CA 79 
  680   64.785  0.013     CB 79 
 681    7.879  0.008      H 79 
 682    4.706  0.009     HA 79 
 683  117.284  0.044      N 79 
 684    3.698  0.006     QB 79 
 685   56.994  0.129     CA 80 
 686   40.133  0.049     CB 80 
 687   14.042  0.000    CD1 80 
 688   18.610  0.000    CG2 80 
 689    8.468  0.006      H 80 
 690    4.702  0.003     HA 80 
 691    1.883  0.003     HB 80 
 692  120.767  0.036      N 80 
 693    0.451  0.008    QD1 80 
 694    0.796  0.007    QG2 80 
 695   63.334  0.003     CA 81 
 696   35.033  0.041     CB 81 
 697   24.909  0.065     CG 81 
 698    5.113  0.007     HA 81 
 699    1.989  0.011    HB2 81 
 700    2.791  0.003    HB3 81 
 701    1.513  0.014    HG2 81 
 702    1.783  0.010    HG3 81 
 703    3.615  0.013     QD 81 
 704   63.911  0.017     CA 82 
 705   73.148  0.075     CB 82 
 706   21.417  0.107    CG2 82 
 707    5.022  0.010     HA 82 
 708    3.918  0.005     HB 82 
 709    1.087  0.012    QG2 82 
 710   53.091  0.000     CA 83 
 711   42.011  0.000     CB 83 
 712   26.431  0.024     CG 83 
 713    9.680  0.005      H 83 
 714    6.089  0.002     HA 83 
 715    1.351  0.007    HB2 83 
 716    1.823  0.006    HB3 83 
 717    0.881  0.004     HG 83 
 718  127.551  0.082      N 83 
 719   60.201  0.010     CA 84 
 720   41.735  0.000     CB 84 
 721   17.709  0.041    CD1 84 
 722   28.237  0.000    CG1 84 
 723   13.350  0.056    CG2 84 
 724    9.136  0.005      H 84 
 725    5.039  0.008     HA 84 
 726    1.760  0.022     HB 84 
 727  120.368  0.048      N 84 
 728    0.148  0.005    QD1 84 
 729    0.800  0.013    QG1 84 
 730    0.637  0.012    QG2 84 
 731   52.736  0.001     CA 85 
 732   44.058  0.000     CB 85 
 733   23.718  0.064    CD1 85 
 734   27.658  0.000     CG 85 
 735    8.719  0.008      H 85 
 736    5.183  0.008     HA 85 
 737    1.871  0.011    HB2 85 
 738    1.052  0.004    HB3 85 
 739    1.423  0.007     HG 85 
 740  129.362  0.051      N 85 
 741    0.786  0.011    QD1 85 
 742   57.087  0.042     CA 86 
 743   41.684  0.063     CB 86 
 744  132.073  0.098    CD1 86 
 745  130.815  0.155    CE1 86 
 746  128.598  0.110     CZ 86 
 747    9.859  0.006      H 86 
 748    5.187  0.004     HA 86 
 749    2.792  0.013    HB2 86 
 750    2.734  0.011    HB3 86 
 751    5.790  0.005     HZ 86 
 752  128.109  0.081      N 86 
 753    6.825  0.008     QD 86 
 754    6.945  0.014     QE 86 
 755   56.019  0.000     CA 87 
 756   36.456  0.000     CB 87 
 757   29.668  0.000     CD 87 
 758   42.172  0.080     CE 87 
 759   25.193  0.107     CG 87 
 760    8.736  0.003      H 87 
 761    4.618  0.006     HA 87 
 762    1.460  0.006    HB2 87 
 763    1.784  0.010    HB3 87 
 764  119.947  0.075      N 87 
 765    1.675  0.006     QD 87 
 766    3.049  0.005     QE 87 
 767    1.377  0.005     QG 87 
 768   55.688  0.143     CA 88 
769   39.709  0.024     CB 88 
 770    9.444  0.007      H 88 
 771    4.534  0.001     HA 88 
 772    2.750  0.003    HB2 88 
774  127.788  0.081      N 88 
 775   46.187  0.029     CA 89 
 776    9.156  0.004      H 89 
 777    4.367  0.008    HA2 89 
 778    3.855  0.005    HA3 89 
 779  103.729  0.023      N 89 
 780   52.038  0.050     CA 90 
 781   30.836  0.064     CB 90 
 782   32.783  0.018     CG 90 
 783    7.861  0.002      H 90 
 784    5.197  0.006     HA 90 
 785    1.929  0.008    HB2 90 
 786    2.157  0.008    HB3 90 
 787  117.288  0.013      N 90 
 788    2.435  0.008     QG 90 
 789   61.840  0.055     CA 91 
 790   30.886  0.040     CB 91 
 791   50.447  0.017     CD 91 
 792   27.680  0.042     CG 91 
 793    3.878  0.012     HA 91 
 794    1.259  0.006    HB2 91 
 795    1.697  0.012    HB3 91 
 796    2.450  0.007    HG2 91 
 797    2.148  0.008    HG3 91 
 798    3.983  0.008     QD 91 
 799   62.061  0.103     CA 92 
 800   33.332  0.036     CB 92 
 801   21.979  0.000    CG1 92 
 802   20.481  0.035    CG2 92 
 803    8.982  0.004      H 92 
 804    4.394  0.004     HA 92 
 805    2.224  0.004     HB 92 
 806  119.911  0.054      N 92 
 807    0.991  0.005    QG1 92 
 808    0.836  0.010    QG2 92 
 809   55.782  0.141     CA 93 
 810   36.090  0.098     CB 93 
 811   42.059  0.113     CE 93 
 812   25.019  0.000     CG 93 
 813    7.194  0.002      H 93 
 814    4.538  0.006     HA 93 
 815    1.558  0.004    HB2 93 
 816    1.810  0.007    HB3 93 
 817  118.773  0.011      N 93 
 818    3.065  0.012     QE 93 
 819    1.356  0.011     QG 93 
 820   54.972  0.009     CA 94 
 821   33.173  0.002     CB 94 
 822   43.369  0.067     CD 94 
 823   28.070  0.002     CG 94 
 824    8.828  0.006      H 94 
 825    5.076  0.005     HA 94 
 826    1.653  0.006    HB2 94 
 827    1.690  0.005    HB3 94 
 828    1.303  0.009    HG2 94 
 829    1.379  0.014    HG3 94 
 830  126.303  0.048      N 94 
 831    3.200  0.005     QD 94 
 832   60.780  0.007     CA 95 
 833   40.922  0.000     CB 95 
 834   14.432  0.133    CD1 95 
 835   27.475  0.000    CG1 95 
 836   17.847  0.000    CG2 95 
 837    9.593  0.001      H 95 
 838    4.347  0.008     HA 95 
 839    1.826  0.005     HB 95 
 840  127.824  0.028      N 95 
 841    0.681  0.012    QD1 95 
 842    1.053  0.009    QG1 95 
 843    0.839  0.010    QG2 95 
 844   62.070  0.068     CA 96 
 845   33.415  0.003     CB 96 
 846   20.586  0.000    CG1 96 
 847   21.321  0.000    CG2 96 
 848    8.898  0.002      H 96 
 849    4.533  0.004     HA 96 
 850    2.013  0.005     HB 96 
 851  127.788  0.013      N 96 
 852    0.949  0.014    QG1 96 
 853    0.932  0.007    QG2 96 
 854   43.717  0.038     CA 97 
 855    8.013  0.003      H 97 
 856    3.589  0.004    HA2 97 
 857    4.394  0.013    HA3 97 
 858  113.977  0.022      N 97 
 859   52.512  0.023     CA 98 
 860   19.273  0.004     CB 98 
 861    8.359  0.003      H 98 
 862    4.065  0.006     HA 98 
863  120.317  0.032      N 98 
 864    1.299  0.010     QB 98 
 865   54.282  0.035     CA 99 
 866   36.401  0.014     CB 99 
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867   28.825  0.049     CD 99 
 868   42.328  0.000     CE 99 
 869   24.548  0.000     CG 99 
 870    7.285  0.003      H 99 
 871    4.546  0.008     HA 99 
 872    1.516  0.006    HB2 99 
 873    1.823  0.007    HB3 99 
 874    1.431  0.001    HD2 99 
 875    1.590  0.002    HD3 99 
 876    2.788  0.003    HE2 99 
 877    2.867  0.001    HE3 99 
 878    1.261  0.002    HG2 99 
 879    1.358  0.000    HG3 99 
 880  120.852  0.017      N 99 
 881   43.980  0.027     CA 100 
 882    8.231  0.003      H 100 
 883    3.863  0.004    HA2 100 
 884    4.171  0.010    HA3 100 
 885  105.881  0.021      N 100 
 886   61.261  0.060     CA 101 
 887   33.361  0.079     CB 101 
 888   30.102  0.035     CD 101 
 889   41.807  0.039     CE 101 
 890   25.219  0.119     CG 101 
 891    8.658  0.003      H 101 
 892    3.549  0.010     HA 101 
 893    1.820  0.007    HB2 101 
 894    1.906  0.005    HB3 101 
 895    1.678  0.005    HD2 101 
 896    1.761  0.007    HD3 101 
 897    2.685  0.005    HE2 101 
 898    2.893  0.008    HE3 101 
 899    1.343  0.012    HG2 101 
 900    1.148  0.009    HG3 101 
 901  119.193  0.069      N 101 
 902   55.381  0.010     CA 102 
 903   17.648  0.037     CB 102 
 904    8.484  0.002      H 102 
 905    4.012  0.005     HA 102 
 906  118.726  0.045      N 102 
 907    1.411  0.010     QB 102 
 908   54.750  0.047     CA 103 
 909   18.703  0.083     CB 103 
 910    8.022  0.007      H 103 
 911    4.050  0.012     HA 103 
 912  120.668  0.024      N 103 
 913    1.442  0.006     QB 103 
 914   58.304  0.004     CA 104 
 915   41.804  0.000     CB 104 
 916   24.901  0.000    CD1 
104 
 917    8.426  0.007      H 104 
 918    3.868  0.008     HA 104 
 919    1.422  0.004    HB2 104 
 920    1.613  0.006    HB3 104 
 921    1.498  0.001     HG 104 
 922  119.833  0.023      N 104 
 923    0.692  0.014    QD1 104 
 924    0.700  0.014    QD2 104 
 925   58.225  0.000     CA 105 
 926   40.868  0.047     CB 105 
 927   22.510  0.000    CD1 
105 
 928    8.421  0.001      H 105 
 929    3.836  0.010     HA 105 
 930    1.891  0.003    HB2 105 
 931    1.390  0.010    HB3 105 
 932  117.284  0.040      N 105 
 933    0.782  0.008    QD1 105 
 934    0.862  0.005    QD2 105 
 935   59.670  0.126     CA 106 
 936   29.892  0.000     CB 106 
 937   43.311  0.052     CD 106 
 938   27.418  0.000     CG 106 
 939    7.899  0.004      H 106 
 940    4.021  0.010     HA 106 
 941    1.724  0.021    HG2 106 
 942    1.600  0.010    HG3 106 
 943  119.038  0.106      N 106 
 944    1.955  0.004     QB 106 
 945    3.211  0.003     QD 106 
 946   58.984  0.081     CA 107 
 947   29.632  0.044     CB 107 
 948   36.165  0.001     CG 107 
 949    7.899  0.002      H 107 
 950    4.126  0.007     HA 107 
 951    2.131  0.007    HB2 107 
 952    2.044  0.004    HB3 107 
 953    2.357  0.008    HG2 107 
 954    2.278  0.007    HG3 107 
 955  119.217  0.109      N 107 
 956   55.545  0.008     CA 108  
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The first value in the list is the atom number associated with the chemical shift which is 
the second value with the standard deviation of chemical shifts assigned to that particular 
atom of a residue which is the fourth and fifth lines.  The chemical shift list that will be 
used for structure calculation can only consist of assignments made on the NOESY 
peaklists (more on this later).  This is done so that there is less inconsistency in chemical 
shifts. 
 
3) Peaklists, the ones which are needed for structure calculation come from the three 
NOESY spectra (c13no.peaks, c13ar.peaks, and n15no.peaks).  The protocol for 
generating these peaklists goes as follows. 
 
-Open all sidechain spectra in Sparky (CBCA(CO)NH, CC(CO)NH, HBHA(CO)NH, 
HCC(CO)NH) as well as the HCCH-TOCSY if you made any assignments using it.   
 
-Write the chemical shift list (.prot) in xeasy format using the command xe.   
 
-Need to convert this chemical shift list into peaks that correspond to the HCCH-TOCSY.  
This is done so that we can easily assign and pick peaks in the c13 aliphatic NOESY.  
This is done on the Mac workstation in room 530 using the program called GARANT.  
The terminal command is: 
 
garant genPeaks HCCH24 sequence_file_name prot_file_name new_peak list 
 
-This peak can then be read on the HCCH-TOCSY peaklist by using the command cg/cy 
in Sparky.  One should then go through and fix any peaks that are not on the actual peak. 
 
-This peaklist should be saved in sparky format so that it can be read onto the 13C 
aliphatic NOESY.   
 
-Once this peaklist is read onto the 13C aliphatic NOESY, one should then go through all 
the planes and pick each peak that isn’t already picked.  Its best to do this using strips in 
Sparky with the command sp and click all assigned peaks which generate stripts 
according to residue number.  This should give strips in a format so that w1 is the x-
dimension (1H), w2 is the y-dimension (1H), and w3 in the z-dimension (13C).  This 
should yield around 2000-4000 peaks depending on the size of the protein.   
 
-The 15N-NOESY should also be hand picked with the only assignments being from the 
1H-15N HSQC.  This should yield around 1500-3000 peaks.   
 
-The 13C aromatic NOESY can be assigned using either the 2D experiments, which 
correlate Hδ or Hη to the Cβ (cbcgcdhd/cbcgcdcehe experiments) or by actually 
assigning them based on the Hδ protons or observed in the aliphatic 13C NOESY and 
working through the aromatic ring.  The rest of the peak should be manually assigned. 
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After all the peaks are assigned and picked in the NOESY experiments, the peaklists are 
written using the command xe and should have the following format. 
 
# Number of dimensions 3 
#CYANAFORMAT HhC 
   1  4.508  3.615 59.401  1 U  1.35e+05        0 e 0    0    0    0  
   2  0.627  3.323 13.364  1 U   1.8e+04        0 e 0    0    0    0  
   3  0.787  5.201 20.846  1 U  1.05e+04        0 e 0    0    0    0  
   4  0.711  1.823 23.030  1 U   1.5e+05        0 e 0    0    0    0  
   5  1.772  3.057 42.102  1 U   1.6e+05        0 e 0    0    0    0  
   6  4.102  1.282 59.019  1 U  4.73e+04        0 e 0    0    0    0  
   7  1.384  4.484 40.852  1 U     1e+04        0 e 0    0    0    0  
   8  0.710  0.462 24.901  1 U  1.54e+05        0 e 0    0    0    0  
   9  0.828  0.449 22.000  1 U  3.59e+04        0 e 0    0    0    0  
  10  4.626  3.747 58.214  1 U  9.56e+03        0 e 0    0    0    0  
  11  6.312  3.208 42.066  1 U  1.66e+03        0 e 0    0    0    0  
  12  0.941  4.782 22.385  1 U   2.4e+04        0 e 0    0    0    0  
  13  1.511  0.688 17.899  1 U  9.06e+04        0 e 0    0    0    0  
  14  1.508  1.360 17.958  1 U  2.62e+05        0 e 0    0    0    0  
  15  0.937  3.727 22.385  1 U  3.66e+04        0 e 0    0    0    0  
  16  0.937  3.603 22.385  1 U  2.51e+04        0 e 0    0    0    0  
  17  1.511  1.676 17.890  1 U  1.79e+05        0 e 0    0    0    0  
  18  0.933  2.392 22.385  1 U   2.5e+04        0 e 0    0    0    0  
  19  4.497  3.734 64.083  1 U  1.32e+04        0 e 0    0    0    0  
  20  4.499  3.573 64.083  1 U  2.01e+04        0 e 0    0    0    0  
  21  1.938  3.983 30.931  1 U   2.7e+04        0 e 0    0    0    0  
  22  4.499  1.718 64.083  1 U  1.13e+04        0 e 0    0    0    0  
  23  2.330  3.715 32.285  1 U   4.3e+04        0 e 0    0    0    0  
  24  4.130  2.801 64.123  1 U  1.07e+04        0 e 0    0    0    0  
  25  4.139  3.871 64.011  1 U   5.3e+04        0 e 0    0    0    0  
 
3811  0.923  2.081 22.112  1 U  4.76e+05        0 e 0  985  983  979  
3812  0.923  0.923 22.112  1 U  1.03e+07        0 e 0  985  985  979  
3813  0.930  0.930 22.385  1 U  8.72e+06        0 e 0  985  985  979  
3814  0.925  0.917 21.740  1 U  1.04e+07        0 e 0  985  985  979  
3815  0.925  0.930 21.740  1 U  1.04e+07        0 e 0  985  985  979  
3816  0.930  0.917 22.385  1 U  8.72e+06        0 e 0  985  985  979  
3817  0.923  0.893 22.112  1 U  1.03e+07        0 e 0  985  986  979  
3818  0.904  1.807 20.824  1 U  1.23e+05        0 e 0  986  814  980  
3819  0.899  3.062 20.868  1 U  6.08e+04        0 e 0  986  816  980  
3820  0.889  4.169 20.765  1 U  8.14e+04        0 e 0  986  959  980  
3821  0.893  4.398 20.765  1 U  1.31e+05        0 e 0  986  982  980  
3822  0.893  2.081 20.765  1 U  2.73e+05        0 e 0  986  983  980  
3823  0.893  0.923 20.765  1 U   7.8e+06        0 e 0  986  985  980  
3824  0.893  0.893 20.765  1 U   7.8e+06        0 e 0  986  986  980  
3825  0.868  0.868 21.120  1 U  6.48e+06        0 e 0  986  986  980  
3826  4.502  0.765 59.401  1 U  2.55e+04        0 e 0  992  438  987  
3827  4.504  0.672 59.401  1 U  1.07e+04        0 e 0  992  964  987  
3828  4.503  4.524 59.401  1 U  5.18e+05        0 e 0  992  992  987  
3829  4.503  2.090 59.401  1 U  4.92e+04        0 e 0  992  993  987  
3830  4.503  0.917 59.401  1 U  2.34e+05        0 e 0  992  995  987  
3831  4.503  0.930 59.401  1 U  2.34e+05        0 e 0  992  995  987  
3832  4.503  0.917 59.401  1 U  2.34e+05        0 e 0  992  996  987  
3833  4.503  0.930 59.401  1 U  2.34e+05        0 e 0  992  996  987  
3834  4.504  1.959 59.401  1 U     4e+04        0 e 0  992 1003  987  
3835  2.102  1.680 32.124  1 U   6.4e+04        0 e 0  993  436  988  
3836  2.089  4.156 32.124  1 U  3.16e+04        0 e 0  993  959  988  
3837  2.114  0.694 32.124  1 U  3.78e+04        0 e 0  993  964  988  
 
 
The top two lines are needed so that CYANA can properly interpret the peaklists 
(#CYANAFORMAT HhN for the 15N NOESY) and are added manually.  The lines are 
the chemical shifts of the peaks with the inensity/volume of the peak.  If the peaks are 
assigned (as in the right panel), the numbers correspond to the atoms from the chemical 
shift list.  These peaklists should be saved with a name that tells the nature of the 
experiment (i.e. c13no.peaks, n15no.peaks, c13ar.peaks). 
 
4) Dihedral restraints are generated using Talos+, which come from the chemical shifts of 
the Cα, Cβ, Hα, Hβ, CO, and HN atoms from the sidechain, HNCO, and 1H-15N HSQC 
experiments.  To generate the dihedral constraints go to the Mac workstation and in the 
terimanl type; 
 
-cyana 
-read prot name.prot 
-taloslist newname.tab 
 
which creates the input needed for Talos called newname.tab.  Dihedral constraints are 
generated by typing; 
 
-talos+ -in newname.tab 
 
You can look at the constraint values by typing;  
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-rama+ -in newname.tab 
 
To generate the file that can be read by Cyana type, copy the file talos+2aco into the file 
and type; 
 
-talos+2aco pred.tab > name.aco 
 
This file has the format; 
 
 
3 ASP   PHI     -76.7   -45.1 
   3 ASP   PSI     -63.5     0.5 
   4 SER   PHI     -96.1   -44.3 
   4 SER   PSI     -50.0   -16.4 
   7 SER   PHI    -126.5   -60.4 
   7 SER   PSI     107.7   161.9 
   8 ALA   PHI    -105.7   -74.2 
   8 ALA   PSI     109.1   153.7 
   9 THR   PHI    -141.5   -89.7 
   9 THR   PSI     152.4   178.3 
  10 ILE   PHI    -183.6   -59.7 
  10 ILE   PSI     125.1   154.6 
  11 LYS   PHI    -135.5   -83.7 
  11 LYS   PSI     108.4   145.0 
  12 VAL   PHI    -139.4  -106.8 
  12 VAL   PSI     151.0   171.0 
  13 THR   PHI    -123.0   -82.8 
  13 THR   PSI     153.8   173.8 
  14 ASP   PHI     -71.6   -51.6 
  14 ASP   PSI     -50.7   -28.2 
  15 ALA   PHI     -84.2   -59.6 
  15 ALA   PSI     -53.6   -13.9 
  17 PHE   PHI     -64.5   -44.5 
  17 PHE   PSI     -62.2   -42.2 
  18 ALA   PHI     -69.8   -49.8 
  18 ALA   PSI     -52.8   -32.8 
  19 THR   PHI     -79.0   -59.0 
#  19 THR   PSI     -51.9   -31.9 
#  20 ASP   PHI     -77.3   -55.6 
  20 ASP   PSI     -53.6   -33.1 
  21 VAL   PHI     -78.7   -58.7 
  21 VAL   PSI     -51.0   -24.0 
  22 LEU   PHI     -73.3   -53.3 
  22 LEU   PSI     -47.5   -13.6 
  23 SER   PHI    -104.4   -62.8 
  23 SER   PSI     -32.7   -11.3 
  24 SER   PHI    -139.4   -59.8 
  24 SER   PSI      84.7   150.4 
  26 LYS   PHI    -141.9   -90.7 
  26 LYS   PSI     102.5   166.1 
  27 PRO   PSI     139.1   157.4 
  28 VAL   PHI    -135.6  -105.7 
  28 VAL   PSI     110.9   140.6 
  29 LEU   PHI    -125.5   -93.7 
  29 LEU   PSI     114.3   134.3 
  30 VAL   PHI    -119.4   -99.4 
  30 VAL   PSI     115.7   144.4 
  31 ASP   PHI    -106.7   -84.4 
  31 ASP   PSI     110.0   130.0 
  32 PHE   PHI    -100.3   -69.2 
  32 PHE   PSI     109.5   139.0 
  33 TRP   PHI    -133.9  -110.4 
  33 TRP   PSI     148.2   172.5 
  34 ALA   PHI    -169.2  -107.3 
  34 ALA   PSI     135.3   168.5 
  37 CYS   PHI    -136.5   -33.6 
  37 CYS   PSI      83.9   196.8 
  38 GLY   PHI    -109.4    61.9 
  38 GLY   PSI    -210.7  -123.7 
  39 PRO   PSI     -42.4   -23.5 
  40 CYS   PHI     -73.4   -53.4 
40 CYS   PSI     -48.6   -28.6 
  41 LYS   PHI     -71.2   -51.2 
  41 LYS   PSI     -49.9   -29.9 
  42 MET   PHI     -75.1   -55.1 
  42 MET   PSI     -50.1   -30.1 
  43 VAL   PHI     -93.6   -68.5 
  43 VAL   PSI     -39.5   -17.0 
  44 ALA   PHI     -61.3   -41.3 
  44 ALA   PSI     -60.9   -40.9 
  45 PRO   PSI     -42.1   -27.4 
  46 VAL   PHI     -74.9   -54.9 
  46 VAL   PSI     -51.2   -31.2 
  47 LEU   PHI     -72.6   -52.6 
  47 LEU   PSI     -49.3   -29.3 
  48 GLU   PHI     -71.6   -51.6 
  48 GLU   PSI     -50.5   -30.5 
  49 GLU   PHI     -75.1   -55.1 
  49 GLU   PSI     -55.2   -35.2 
  50 ILE   PHI     -74.1   -54.1 
  50 ILE   PSI     -53.4   -33.4 
  51 ALA   PHI     -70.2   -50.2 
  51 ALA   PSI     -49.9   -29.9 
  52 THR   PHI     -75.4   -55.4 
  52 THR   PSI     -48.8   -28.8 
  53 GLU   PHI     -77.6   -57.6 
  53 GLU   PSI     -46.8   -21.9 
  54 ARG   PHI    -128.3   -82.1 
  54 ARG   PSI      -5.9    35.5 
  55 ALA   PHI     -71.1   -51.1 
  55 ALA   PSI     -49.9   -28.5 
  56 THR   PHI     -84.0   -64.0 
  56 THR   PSI     -46.2   -20.1 
  57 ASP   PHI    -116.9   -85.5 
  57 ASP   PSI     -39.1    -4.3 
  58 LEU   PHI    -163.5  -130.0 
  58 LEU   PSI     128.7   148.7 
  59 THR   PHI    -136.7  -109.2 
  59 THR   PSI     114.9   138.1 
  60 VAL   PHI    -128.5   -99.7 
  60 VAL   PSI     118.0   138.0 
  61 ALA   PHI    -143.2  -110.6 
  61 ALA   PSI     137.1   165.4 
  62 LYS   PHI    -130.5  -104.6 
  62 LYS   PSI     115.8   135.8 
  63 LEU   PHI    -134.4   -88.5 
  63 LEU   PSI     117.3   143.5 
  64 ASP   PHI    -115.4   -81.9 
  64 ASP   PSI      84.7   127.6 
  65 VAL   PHI     -70.6   -50.6 
  65 VAL   PSI     -38.0   -17.1 
  66 ASP   PHI     -78.5   -58.5 
  66 ASP   PSI     -50.1   -19.9 
  67 THR   PHI    -118.5   -93.0 
  67 THR   PSI     -17.9    15.6 
  68 ASN   PHI    -123.0   -63.7 
  68 ASN   PSI      78.0   141.4 
  70 GLU   PHI     -77.0   -57.0 
  70 GLU   PSI     -46.1   -26.1 
  71 THR   PHI     -76.6   -56.6 
  71 THR   PSI     -50.7   -30.7 
  72 ALA   PHI     -72.7   -52.7 
72 ALA   PSI     -52.6   -32.6 
  73 ARG   PHI     -77.3   -57.3 
  73 ARG   PSI     -49.1   -23.0 
  74 ASN   PHI     -76.2   -54.0 
  74 ASN   PSI     -44.2   -23.6 
  75 PHE   PHI     -96.5   -76.3 
  75 PHE   PSI     -14.2     9.7 
  77 VAL   PHI    -139.0   -23.8 
  77 VAL   PSI      84.2   149.5 
  78 VAL   PHI    -147.3   -80.1 
#  78 VAL   PSI     125.1   174.6 
#  79 SER   PHI    -128.6   -84.7 
  79 SER   PSI     136.3   166.8 
#  80 ILE   PHI    -144.8  -101.2 
  80 ILE   PSI      76.2   146.5 
  81 PRO   PSI     142.4   161.6 
  82 THR   PHI    -135.1  -109.7 
  82 THR   PSI     121.6   146.9 
  83 LEU   PHI    -120.4   -96.8 
83 LEU   PSI     119.7   139.8 
  84 ILE   PHI    -136.4  -116.4 
  84 ILE   PSI     122.4   154.9 
  85 LEU   PHI    -123.2   -92.7 
  85 LEU   PSI     106.8   132.8 
  86 PHE   PHI    -122.7   -97.2 
  86 PHE   PSI     130.0   156.5 
  87 LYS   PHI    -154.0  -100.5 
  87 LYS   PSI     111.9   137.0 
  89 GLY   PHI      68.0    88.0 
  89 GLY   PSI      -6.5    15.6 
  90 GLN   PHI    -125.9   -95.3 
  90 GLN   PSI     108.6   151.8 
  91 PRO   PSI     140.4   156.7 
  93 LYS   PHI    -163.1  -142.3 
  93 LYS   PSI     132.6   152.6 
  94 ARG   PHI    -128.4   -91.8 
  94 ARG   PSI     112.8   141.4 
  95 ILE   PHI    -129.3  -108.0 
  95 ILE   PSI     122.9   145.1 
  96 VAL   PHI    -133.2  -101.8 
  96 VAL   PSI     115.5   143.8 
  97 GLY   PHI    -203.8   -73.5 
  97 GLY   PSI     150.2   181.8 
  98 ALA   PHI    -119.5   -59.3 
  98 ALA   PSI     102.6   158.0 
  99 LYS   PHI    -130.0  -109.0 
  99 LYS   PSI     131.6   175.8 
 100 GLY   PHI    -146.2   -20.2 
 100 GLY   PSI     157.0   177.0 
 101 LYS   PHI     -65.2   -45.1 
 101 LYS   PSI     -54.3   -34.3 
 102 ALA   PHI     -70.9   -50.9 
 102 ALA   PSI     -53.1   -33.1 
 103 ALA   PHI     -75.2   -55.2 
 103 ALA   PSI     -50.7   -30.7 
 104 LEU   PHI     -74.5   -54.5 
 104 LEU   PSI     -55.0   -35.0 
 105 LEU   PHI     -75.5   -53.9 
 105 LEU   PSI     -45.6   -25.6 
 106 ARG   PHI     -74.0   -54.0 
 106 ARG   PSI     -53.7   -33.7 
107 GLU   PHI     -74.6   -54.6 
 107 GLU   PSI     -47.5   -27.5 
 108 LEU   PHI     -97.8   -62.4 
 108 LEU   PSI     -45.1    -9.4 
 109 SER   PHI     -74.5   -54.5 
 109 SER   PSI     -46.6   -26.6 
 110 ASP   PHI     -82.8   -60.2 
 110 ASP   PSI     -44.9   -22.8 
 111 VAL   PHI    -123.8   -89.2 
 111 VAL   PSI     -16.4    11.5 
 112 VAL   PHI    -138.3   -82.2 
 112 VAL   PSI      67.3   122.7 
 114 ASN   PHI     -96.8   -50.1 
 114 ASN   PSI     -50.0    -0.8 
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 The files needed for Cyana have now been generated (n15no.peaks, c13no.peaks, 
c13ar.peaks, nameofprot.seq, and nameofprot.prot).   
 
B) To start structure calculation one has to perform the automatic assignment of the 
peaklists using the noeassign macro of Cyana. 
 
1) Cyana is ran using the Condor submission system of Pere.  So one has to log into Pere 
and transfer the files from above to a new directory in Pere. 
 
2) Transfer files from the shared folder (NMR_STRUCTURE_INFO) in the Mac 
workstation to that directory. 
 -init.cya 
 -autorun.cya 
 -autorun.sub 
 
3) The file init.cya is the initialization script for Cyana  
 
 
 
 
 
 
 
 
Input the name of the protein as well as the rmsd range used to determine rmsd as well as 
the name of the sequence file.  This script is immediately called up when typing starting 
the Cyana program.   
 
4) The file autorun.cya is the script that reads in the files that Cyana uses for automatic 
assignment (all those that were prepared previously). 
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Input the name of your peaklists (peaks), chemical shift list (prot), and any additional 
constraints (dihedral, hbonds, or ssbonds).  The rmsd range should be the same as the init 
file.  The very last line of autorun.cya is the the noeassign macro and the flags needed to 
run automatic assignment (autoaco is optional to allow temporary angle restraints to favor 
Ramachandran plot).   
 
5) To submit this to Condor on Pere to run noeassign of Cyana, one has to use 
autorun.sub. 
 
 
 
 
 
 
 
 
Type condor_submit autorun.sub 
 
6) The output of noeassign is 7 cycles of refinement with one final refinement.  After 
every cycle a pdb file is written with an overview (.ovw) file summarizing the structural 
violations, target function, and rmsd.  With cycle 7, assigned peaklists and new prot file 
are generated (name-cycle7.peaks and name-final.prot). The command cyanatable 
(shown below) summarizes the cycles.   
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As long as the initial target function is under 300 and rmsd is under 3, as well as having a 
cycle 7 target function under 10, the cycle 7 structure and assignments are suitable to go 
onto manual refinement.  If any of these is violated, one can look at the ovw file from 
cycle 7 and look for any really violated distance or dihedral restraints and delete those 
and run again.  Generally deleting the dihedral constraints is good enough to decrease the 
target function.  Automatic peak picking of NOESY peaklists can lead to a lot of peaks 
being thrown out because they aren’t real which leads very high target functions.  This is 
why manual peak picking is preferred.  The upper distance limits is the number of NOEs 
used in the automatic assignments. 
 
C) Manual refinement involves assigning the peaks that noeassign missed. 
 
1) In a new directory copy the files cycle7.pdb, all name-cycle7.peaks, name-final.prot, 
*.aco, *.seq, stereofound.cya, and init.cya.   
 
2) (optional) Delete the ambiguous restraints the Cyana gave some peaks (if it wasn’t 
sure it assigned more than one assignment to a peak) with the command; 
 
- grep –v ‘0 e 0’ name.peaks > newname.peaks  
 
3) In sparky bring up the clean (no peaks) NOESY spectra and put the peaklists that 
noeassign from Cyana assigned onto them from step 2 by using the command cy/cg 
 
4) As in Step 1-3 generate strips of the particular NOESY spectra and go through each 
strip and make as many assignments as possible (using the cycle7.pdb as guide for close 
residues, since they have to at least be within 5 Å).  Go through about 10 residues and 
and run through manual Cyana structure calculation. 
 
5)  Copy from the shared folder (NMR_STRUCTURE_INFO) in the Mac workstation the 
scripts to run manual refinement. 
- man_calc.cya 
- calc.cya 
- calc.sub 
 
Where man_calc.cya is the script to calibrate the peaklists and run the structure 
refinement in the initial process.   
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Where the macro caliba is used to calibrate the peaklists.  At the end of caliba  post script 
file is generated called noesyname.ps.  The values must be altered until the post script file 
looks like this.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The line must be just barely above the dots for it to be calibrated properly.  You get a ps 
file for each peaklist with backbone class, sidechain class, and methyl class, all of which 
must look like the figure above.  If not calibrated properly the target function will go way 
up.   
 
After the peaklists are calibrated properly, look at the overview file and delete any 
severely violated distance restraints and run again…repeat until all the bad restraints are 
gone and decent target functions remains.  Copy these peaklists to the NOESY spectra 
using cy/cg command and repeat this process until all the spectra have gone through and 
many more assignments have been made.  
 
In the case of the 15N-NOESY look for NOEs that define secondary structure such as 
alpha helix peakse and beta sheets.  For alpha helices the NH NOEs can be seen from i to 
i+4 residue.   
 
6) Every now and again, its worth it to upload all the peaklists and prot files to another 
directory and run autoassignment again.  This may make the structure look a little better.  
Treat the autoassigned peaklists like earlier and quickly go through the strips you have 
already gone through and make sure those peaks are still assigned.   
 
7) When you are all done making assignments replace the man_calc.cya for calc.cya. 
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8) Calc.cya is only the structure calculation script from man_calc.cya.  This script is used 
to get your final structure and throw out NOEs to lower your target function to an 
acceptable value. 
 
9) After you have gone through all your strips and added as many NOEs as possible you 
have to replace man_calc.cya with this script and change calc.sub so that it matches 
calc.cya. 
 
10) Run this script but pay attention to the last two lines in this script; 
 
Structures violate significant=15 delete=100 
Write upl filter.upl 
 
Structures violate will delete NOEs automatically that were violated upon structure 
calculation from the upl file generated.  Upl file is just the list of upper distance limits 
(NOEs).  This will not delete from the peaklist.   Significant is the number of models in 
which an NOE is violated.  So if an NOE is violated in 15 of the 20 structures it is 
considered significant.  Delete is the percentage of NOEs that are significantly violated 
that are deleted.  In this case any NOE that is violated in 15 or more structures it is 
deleted from the upl file and the new upl file is written to filter.upl.   (significant should 
start at 20 and move to 15) 
 
11) Change the name of filter.upl to found-c.upl.    
 
mv filter.upl found-c.upl 
 
12) Repeat until target function is between 0-3. 
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13) Once this is achieved, change calc.cya; 
 
So that 500 structures are calculated and the 99 best structures are written out. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D) This last structure of 99 conformers is then put through water refinement using 
simulated annealing and the AMBER molecular force field. 
 
In the same directory as before, copy the files; 
 
-mdin 
-mdin_rst 
-amber_anneal.sub 
-amber_min1.sub 
-amber_min2.sub 
-anneal.in 
-generate.inp 
-refine.inp 
-final_min.inp 
 
 
1) generate.inp splits the 99 structures into individual files and performs and initial 
minimization on the structure in implicit solvent using the script mdin and submitted to 
Condor using amber_min1.sub. 
(type ./generate.inp to run) 
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generate.inp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mdin 
 
 
 
 
amber_min1.sub 
 
 
 
 
 
183 
This initial minimization takes about 5-10 minutes to complete.  
 
2)  The output from the initial minimization (model_min.x) is fed into the simulated 
annealing refinement with the script refine.inp which calls the annealing script anneal.in 
and is submitted to Condor using amber_anneal.sub.   
(type ./refine.inp to run) 
refine.inp 
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The first part of refine.inp changes the atom names of some of the atoms in the upl file so 
that AMBER can convert this to restraints it can use.    The second part converts the 
restraint files so that AMBER can use them and applies force constants to the restraints 
which can be altered.  The last part is condor submission. 
 
anneal.in 
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This script defines the temperatures and step values used.  This particular file heats up to 
1000K and goes through 2 cycles of 30 ps simulated annealing sessions.  Restraints are 
used with this. 
 
amber_anneal.sub 
 
 
 
 
 
 
 
 
This portion of water refinement takes about 4 hours to complete. 
If for some reason this fails, one can try and decrease the temperature and if that still fails 
look at the trajectory file and see where its failing.   
 
3) The output from this file (model.ann.x) is fed into the last portion of water refinement, 
which is a final minimization using restraints in implicit solvent, which is uses the scripts 
final_min.inp which calls up mdin_rst and submits to condor using amber_min2.sub. 
(./final_min.inp is how to run this) 
final_min.inp  
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mdin_rst 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
amber_min2.sub 
 
 
 
 
 
 
 
This portion takes about 15-20 minutes to complete.  
 
3) Once all of AMBER water refinement is completed, the statistics are written out using 
the script make_collect.inp (./make_collect.inp on command line).  This script turns the 
output from the last minimization into a pdb file, statistics using the command for each 
model are written using sviol (sviol2) and are merged together and sorted by lowest 
AMBER energy.   
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make_collect.inp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All 99 pdb files are written into one called ensemble.pdb. 
 
The sorted liste (averages.txt); 
 
 
 
 
 
 
 
 
 
 
Where the first line is the rank, the second line is the model number, the fourth line is the 
amber energy, the fifth line is total penalty energy, and ninth and tenth lines are distance 
and torsion penalty.  
 
4) In the second line of averages.txt is the model number, which corresponds to the files 
in the directory.  The top 20 AMBER energy structures should be copied to a new 
directory along with make_collect.inp. 
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make_collect.inp should be ran again to get the top 20 structures into one file called 
ensemble.pdb.   
 
5) To get statistics on this new file, run the program called pdbstat (type pdbstat on 
command line), and follow the directions on start up.   
 
- rea coo pdb ensemble.pdb 
- all 
- rmsd  
- coo 
- backbone (or heavy) 
- range of protein residues (ex 7-110) 
- average 
- new file name 
- write 
- new file name.pdb 
- coo 
- all 
- all 
- pdb 
- exit 
 
6) This can write the coordinates so that they are on top of each other as when 
concatenating the proteins right after AMBER causes them to be of center.   
 
7) pdbstat can also give other statistics about number NOEs and dihedral restraints used.  
(consult this website for more details 
http://www.nmr2.buffalo.edu/nesg.wiki/Main_Page) 
 
Other program such as molmol can do similar features. 
 
E)  The new structures must be validated to make sure they are acceptable for pdb 
submission.  Since we don’t have procheck or whatcheck installed on any computers we 
can use an online resource called Protein Structure Validation Software suite (PSVS) 
from http://psvs-1_4-dev.nesg.org/, which also uses pdbstat to qualify the structure.  Just 
submit the ensemble written from pdbstat and selecy dyana or cyana and any other 
features you want and hit submit.  This takes about 5 minutes to get feedback.   In general 
one wants the protein to have Z scores > -3 for both Procheck G and Molprobity 
Clashscore.   
 
F)  The website http://www.nmr2.buffalo.edu/nesg.wiki/Main_Page offers good details 
on how to submit info to PDB and BMRB.  	  
